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With meiosis spanning from embryonic development to the end of reproductive life 
in females, scientists have faced considerable limitations in studying female meiosis 
and the effects of toxicants on the developing oocyte. Over the last half century, 
various culture methods have been developed with the aim of studying the 
mechanisms of early ovary development, as well as for use in reproductive 
toxicology. However, very few of the established embryonic ovary culture systems 
have been used to investigate potential reproductive toxicants on the embryonic 
ovary, in particular when compared with the vast number of in vitro reproductive 
toxicity studies on the post-natal ovary. Here, a novel test compound, a 
topoisomerase II inhibitor: AstraZeneca Test Compound (AZTC), was used to 
investigate the efficacy and validity of ovarian culture methods when compared with 
in vivo reprotoxicity studies. AZTC was selected due to preliminary in vivo studies 
demonstrating its detrimental effects on spermatogenesis in male rats. AZTC targets 
bacterial type II topoisomerases that might have mammalian homologues involved in 
meiosis.  
 
Topoisomerase-II α was expressed within the female germ cells pre-natally, but 
became localised to the granulosa and stroma cells post-natally. This occurred both 
in vivo and in vitro. Ovaries from female rats exposed pre-natally to AZTC in vivo 
were analysed histologically and a significant increase in the number of primordial 
follicles was observed within the ovaries, as well as an increase in the number of 
unhealthy follicles.  
 
A novel mouse embryonic ovary culture system was developed by adapting, 
improving and bridging existing available culture techniques. The culture system 
supported growth of pre-meiotic mouse germ cells through prophase I of meiosis, the 
formation of primordial follicles and initiation of follicle growth. Cultured ovaries 
contained follicles at stages in comparable ratios to those in vivo and appeared 
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morphologically normal and healthy. The culture also supported meiotic progression 
of oocytes to the pachytene stage, albeit with a slight delay.  
 
AZTC was used to validate the novel embryonic ovary culture by comparing the 
results with those from the in vivo study, where AZTC exposure had also occurred 
during embryonic development. Similar results were consistently observed between 
the in vivo and in vitro studies. In vitro effects of AZTC on the post-natal mouse 
ovary were also investigated, where neonatal mouse ovaries cultured with AZTC had 
fewer primordial follicles and more unhealthy follicles than did control ovaries. 
AZTC therefore demonstrated different effects when exposure occurred pre-natally 
vs. post-natally. The embryonic ovary culture was then used to examine the effects of 
another topoisomerase II inhibitor, etoposide, on the pre-natal ovary. Etoposide is a 
chemotherapy agent and has previously been prescribed to pregnant women. A 
significant reduction in the size of the follicle pool was observed in exposed cultured 
embryonic ovaries, where primordial and transitional follicles were targeted. 
Overall, establishment of post-natal culture systems have become a useful addition to 
in vivo reproductive toxicology studies. The embryonic ovary culture system 
developed here could become a valuable and powerful tool to screen potential 
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Female germ cells, or oocytes, undergo an extended process of meiosis, which begins 
before birth and in some cases, is not completed until the end of the female's 
reproductive lifespan. Oocytes become arrested in prophase I of meiosis before 
becoming enclosed in primordial follicles so that by birth, the ovary contains a pool 
of resting primordial follicles. This primordial follicle pool plays a crucial role in 
determining the future fertility of the female, as it is from this pool of follicles that all 
future oocytes will be ovulated. The pool will become gradually depleted as oocytes 
exit the resting pool and begin to grow and develop toward the pre-ovulatory stage. 
Meiosis is not resumed until the oocyte is ovulated and this stop-and-start process of 
meiosis makes assessment of any external compounds on the ovary difficult, yet that 
much more crucial. If the primordial follicle pool is affected, this can result in 
premature ovarian ageing and potentially premature menopause. However, many of 
the factors and processes involved in the regulation of early oocyte development and 
follicle formation are not fully understood.  
 
The rodent ovary is an excellent model for in vitro studies, partly due to its relatively 
short time-course. Various culture techniques in mice have been developed that span 
various stages of ovary and follicle development, including an embryonic ovary 
culture system and a newborn ovary culture system. Combining these two culture 
systems to generate a culture system that would span from meiotic entry of oogonia, 
through germ cell nest breakdown, follicle formation and initiation of follicle growth, 
would not only be a valuable tool in the study of the dynamics and regulation of 
ovary development, but also a useful model to screen potential toxicants on the pre-
natal ovary.  
 
Current reproductive toxicity testing of pharmaceuticals on the pre-natal ovary 
involves assessing the reproductive performance of females that have been exposed 
in utero. Although this study design will detect any immediate reproductive 
problems, it does not detect any subtle effects the compound may have on the 
primordial follicle pool which could potentially affect long term fertility. For 
example, there are a number of antibiotics that act by targeting bacterial 
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topoisomerases. Many of these will have mammalian homologues involved in 
meiosis, and could therefore affect spermatogenesis or early ovary development, 
potentially resulting in an irrevocably diminished pool of oocytes.  
 
The aim of this PhD was therefore to bridge, adapt and improve existing culture 
methods available in Edinburgh, namely, the embryonic and neonatal ovary culture 
systems, to generate a culture system spanning early ovary development, from 
meiotic entry through to follicle formation and growth. The second aim of the PhD 
was to investigate the potential effects of a novel pharmaceutical test agent, a 
topoisomerase II inhibitor: 'AstraZeneca Test Compound' (AZTC) provided by 
AstraZeneca, on the embryonic ovary culture system.  
 
1.1. The ovary 
The ovary is central to female reproductive function, the site within which germ cells 
form follicles; functional unit of the ovary. Germ cells are responsible for carrying 
genetic material from one generation to the next, and they do this by generating 
haploid cells via a unique type of cell division: meiosis. In female mammals, oocytes 
develop from primordial germ cells (PGCs) during gestation (Baillet and Mandon-
Pepin, 2012). Following the proliferative stage of primordial germ cells, the PGCs 
enter a pre-meiotic state of DNA replication before entering prophase I of meiosis. 
They then progress through the initial stages of meiosis, before undergoing a state of 
meiotic arrest, around the time of follicle formation (Anderson and Hirshfield, 1992, 
Adams and McLaren, 2002). The oocytes remain in this meiotically arrested state 
throughout the phase of follicular development.  In the post-natal ovary, as an oocyte 
grows and matures, its follicle undergoes changes due to proliferation of the 
granulosa cells and formation of the fluid filled antral cavity, resulting in a dramatic 
increase in follicle size.  Once the pre-ovulatory, Graafian follicle has reached full 
maturation, it expels its oocyte during ovulation, at which point the oocyte exits 




The ovary is not only responsible for producing oocytes, but is also an important 
endocrine gland, the source of sex steroids which link reproductive and non-
reproductive organs to the timing of the ovarian cycle. It is in the growing follicle 
that the majority of estrogens in the body are produced and once the oocyte has been 
ovulated, the remainder of the follicle becomes a corpus luteum (CL), a temporary 
endocrine structure secreting the progesterone critical for the establishment and 
initial maintenance of pregnancy. The ovary is responsive to hormones secreted from 
the anterior pituitary, in turn controlled by the hypothalamus, with which it is locked 
into a complex cyclical pattern of communication and feedback that underpins 
successful female reproduction.  
 
There is a certain amount of disparity involving folliculogenesis, follicle growth and 
other reproductive factors between different species. Research using animal models 
for investigating human ovarian function must therefore be carried out with care, 
providing a hypothetical basis for study. Three commonly used animal models used 
in reproductive biology are the mouse, sheep and bovine models, with each model 
differing slightly from the human in different ways. For example, while the mouse, 
bovine and human all undergo menstrual/estrous cycles all year around, the ewe is a 
seasonal breeder. Follicle formation also occurs at slightly different time-points 
depending on the species. In human, ewe and bovine ovaries, follicles first begin to 
form during pre-natal ovary development. This occurs around weeks 16-20 of human 
gestation, around days 70-90 of bovine gestation and around day 170 of bovine 
gestation (Hartshorne et al., 2009, Aerts and Bols, 2010, McNatty et al., 1995, Smith 
et al., 2014). In the mouse ovary on the other hand, the first follicles do not form 
until around birth (Sarraj and Drummond, 2012) . Furthermore, while the bovine and 
ewe are mono-ovular, like the human, the mouse model is poly-ovular. Although a 
large  majority of available information on the ovary and female reproduction comes 
from studies carried out on these three animal models, this thesis will concentrate on 
the mouse model because all the culture work presented in this thesis was carried out 
on the mouse model. From this point onwards I will therefore refer to the mouse 




1.1.1. Pre-natal ovary development 
1.1.1.1. The formation and migration of female germ cells 
The formation of female gametes, oocytes, begins in the developing fetus with the 
formation of PGCs. Pluripotent cells in the epiblast of the developing mouse embryo 
differentiate into PGCs around embryonic day 6.5 (E6.5), with E0.5 being the 
morning a vaginal plug is found, approximately half a day after conception  (Ohinata 
et al., 2005). The PGCs enter a proliferative phase, during which they migrate to the 
developing genital ridges which will later become the ovaries in female embryos. It 
has been suggested that PGC migration occurs in response to an attractant, such as 
stromal cell-derived factor 1 (SDF1) or kit ligand (KL), also known as stem cell 
factor (SCF), originating in the genital ridges (Farini et al., 2007). The PGCs invade 
the developing ovary around embryonic day 10.5 (E10.5), or week 7 of human 
gestation. From this point onwards they become known as oogonia (Anderson and 
Hirshfield, 1992). Once in the ovary, the oogonia continue to proliferate, forming 
germ cell nests or germline cysts due to a series of incomplete cell divisions, 
resulting in the formation of clusters of connected cells (Pepling and Spradling, 
1998). The proliferating oogonia then begin to receive signals from the somatic cells 
of the ovary, which subsequently makes their development become more directed 
(Hajkova et al., 2008, Hajkova et al., 2002). The oogonia stop proliferating and enter 
a pre-meiotic state around E12.5, or between the 8th and the 13th week of human 
gestation (Oktem and Urman, 2010). 
 
1.1.1.2. Female Meiosis 
Meiosis is a central event in the generation of germ cells of both sexes. It reduces the 
complement of chromosomes to form haploid gametes containing only one copy of 
each chromosome. However, while meiotic progression in male gametes is 
continuous, with spermatogenesis occurring at a constant rate, in females of most 
species (including humans and rodents), it contains two constitutive arrest phases. 
 
Meiotic initiation is asynchronous in both rodent and human ovaries, and variation in 
meiotic stage is not uncommon between neighbouring oocytes of the mouse ovary 
(Gondos, 1987, Hartshorne et al., 2009). Meiosis begins in the developing ovary of 
6 
 
the female mouse embryo around E13.5, following the proliferative phase of 
oogonia. From this point onwards, the germ cells are termed oocytes. In human fetal 
development, germ cells enter meiosis in the 3rd month of gestation, but in contrast 
to the mouse ovary which has a smaller window of meiotic entry, some human germ 
cells continue to proliferate for a long time after the first germ cells enter meiosis. 
There is, therefore, a long a time-frame for oocytes entering meiosis in the human 
ovary, whereas the time-span for meiotic entry in the mouse is much smaller (Baker, 
1963, Bendsen et al., 2006, Fulton et al., 2005, Anderson et al., 2007, Childs et al., 
2012).  
 
Prior to meiotic entry, primordial germ cells enter a transient pre-meiotic state of 
DNA replication, the S-phase of interphase, before entering prophase I of meiosis 
(Anderson and Hirshfield, 1992). Prophase I of meiosis consists of five stages: 
leptotene (chromosome condensation), zygotene (beginning of synapsis), pachytene 
(complete synapsis and crossover), diplotene (separation of homologous 
chromosomes, remaining attached at chiasmata) and diakinesis (separation of 
chromosomes, except for at the terminal chiasmata) (Fig. 1.1). Oocytes arrest at the 
diplotene stage and remain in this meiotically arrested state until ovulation. They are 
therefore in this dormant state of meiotic arrest throughout follicular development.  
 
In rodents, the oogonia that are closest to the mesonephros are first to enter meiosis, 
possibly due to the migration of small diffusible molecule, retinoic acid (RA), that 
originates in the ovary and the mesonephros (Mu et al., 2012, Bowles and Koopman, 
2007a). RA is thought to be one of the critical meiosis-inducing factors in the 
developing ovary, along with the RA-inducible STRA8 protein, and DAZL, which is 
an RNA-binding protein expressed in the germ cells (Hartshorne et al., 2009, Lin et 
al., 2008, Baltus et al., 2006, Bowles and Koopman, 2007b). Although initially, 
mesonephros derived RA was believed to be required for initiating germ cell meiosis 
in the fetal ovary, a recent study has demonstrated how ovary derived RA alone is 
responsible for meiosis initiation (Mu et al., 2013). Various other factors have also 
been identified as being involved in prophase I of meiosis. During the pre-meiotic 
phase, cohesin proteins (REC8, SMC1b, SMC3 and STAG3) are required for the 
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attachment of the new sister chromatid to the older chromatid (Baillet and Mandon-
Pepin, 2012). During leptotene, the synaptonemal complex (SC), consisting of a 
transversal element (SYCP1), an axial element (SYCP2 and SYCP3) and a central 
element (SYCE1, SYCE2 and TEX12), is required for pairing of homologous 
chromosomes (Baillet and Mandon-Pepin, 2012). Recombinase proteins DMX1 and 
RAD51 are required to interact with SYCP3 to induce synapsis of chromosomes 
(Tarsounas et al., 1999). The leptotene stage is also associated with double-strand 
breaks (DSBs), which are required for genetic recombination. DSBs are triggered by 
SPO11 (Romanienko and Camerini-Otero, 2000), and the TEX15 protein assists in 
the localisation of DMC1 and RAD51 to the DSB (Yang et al., 2008a). During 
zygotene, the formation of the SC is dependent on the interaction between TEX11 
and SYCP2 (Yang et al., 2008b). Once the SC is fully formed at pachytene, 
crossovers are initiated (SC formation is further outlined in Section 4.13). Analysis 
of SYCP3 protein expression is found in E12.5 mouse ovaries, but it appears in over 
80% of female germ cells by E13.5. Mouse germ cells are therefore in pre-meiotic 
stage at E12.5 and enter prophase I of meiosis at E13.5 (Shen et al., 2006). 
 
Throughout follicular development, the oocyte slowly gains the competency for 
nuclear and cytoplasmic maturation, but it is only following the luteneizing hormone 
(LH) surge of ovulation that the oocyte goes on to complete the diakinesis stage of 
prophase I (Fig. 1.1) and completes meiosis I. The oocyte then enters the second 
meiotic division and arrests again at metaphase II where it remains arrested until 
fertilization. In contrast to meiosis in spermatogonia, each female meiotic division 
results in the formation of one daughter cell (the oocyte) and two polar bodies. Due 
to an uneven distribution of cytoplasm, the daughter cell receives the majority of the 
cytoplasm, with the polar bodies containing little material other than the expelled 























Figure 1.1. Meiosis in oocytes 
Stages and phases of 
mammalian meiosis, including 
two meiotic arrests during 
Prophase I and Metaphase II. 
The figure demonstrates 
chromosomal behaviour during 
meiotic progression in the 
mouse and human, with the 
time-course of events leading to 
the formation of an arrested 
oocyte within the growing follicle 





1.1.1.3. Germ cell nest breakdown 
The creation of the primordial follicle pool is a tightly regulated and multi-faceted 
developmental process. Pre-natal oogenesis of the human ovary results, initially, in 
the production of around 7 million oogonia, but by birth, these have reduced from 7 
million to between 2 million to 70,000 due to pre-natal germ cell loss (Oktem and 
Urman, 2010). 
 
Oogonia that have invaded the developing ovary are initially arranged in germ cell 
nests, which form due to a series of incomplete synchronous mitotic divisions of the 
oogonia. As they divide, cytokinesis is not completed and therefore the daughter 
cells are all connected by intercellular bridges. Germ cell nests form between meiotic 
entry and follicle formation the human ovary around the 9th week of gestation and 
between E10.5-13.5 in the mouse ovary, just prior to their entry into the meiotic 
prophase (Pepling and Spradling, 2001). It has also been suggested that germ cell 
nests can form due to cell aggregation (Bendel-Stenzel et al., 2000, Mork et al., 
2012). 
 
Germ cell nest breakdown is associated with an estimated loss of around one-third to 
two-thirds of oogonia (Pepling and Spradling, 2001, Bristol-Gould et al., 2006). The 
purpose of this germ cell loss is not well understood, but it has been proposed to be a 
way to eliminate germ cells with chromosomal abnormalities or less functional 
mitochondrial genotypes (Pepling and Spradling, 2001). In the mouse, mitochondria 
enter a rapid phase of division right before germ cell nest breakdown, and 
mitochondria have been detected within the intracellular bridges between oogonia 
(Pepling and Spradling, 2001). This supports the possibility that nurse cells exist 
only to produce and transfer nutrients and organelles to the oocyte once germ cell 
breakdown occurs. Another possibility is that certain germ cells within the nest 
become nurse cells and take on a supporting role to assist the germ cells that will 
later go on to become oocytes (de Cuevas et al., 1997). It is still unknown what 
factors control which oocytes are selected for survival or to undergo apoptosis, but 




Steroid hormones, such as estradiol (E2), have been implicated in the regulation of 
cell death in various tissues (Kyprianou et al., 1991, Perillo et al., 2000, Sawada and 
Shimohama, 2000). In the developing ovary, E2 inhibits germ cell nest breakdown 
and protects oocytes and granulosa cells from programmed cell death (Billig et al., 
1993). High estrogen exposure interferes with germ cell nest breakdown and can, in 
some cases result in multioocyte follicles (MOFs). MOFs are follicles containing two 
or more oocytes within a single follicle, with no basement membrane separating 
them (Tingen et al., 2009). Exposure to estrogenic compounds during the time of 
germ cell nest breakdown has been linked to MOF formation in adult mouse ovaries 
(Iguchi et al., 1990, Cimafranca et al., 2010, Jefferson et al., 2007). Oocytes in MOFs 
have a 30% lower fertilization rate than mono-ovular oocytes (Iguchi et al., 1991), 
demonstrating the importance of germ cell nest breakdown for oocyte quality 
(Tingen et al., 2009).  
 
1.1.1.4. Follicle formation 
As germ cell nests break down, isolated oocytes, which at this point have entered 
meiotic arrest, go on to form primordial follicles. A primordial follicle consists of the 
arrested oocyte (about 15-20 µm in diameter in rodents, and around 30 µm in 
humans) surrounded by flattened somatic cells, called pre-granulosa cell 
(Moniruzzaman and Miyano, 2010). The period of germ cell nest breakdown and 
formation of primordial follicles is a crucial one, as the primordial follicles represent 
the pool of follicles from which all future oocytes will be ovulated. By the time 
primordial follicles have formed oocyte numbers have already vastly decreased. 
From this point onwards, oocyte numbers continue to decrease as the vast majority of 
primordial follicles that enter the growing pool of follicles undergo atresia and die 
(Oktem and Urman, 2010). Primordial follicles usually end up occupying the cortex 
of the ovary, with growing follicles located more centrally.  
 
Several genes are critical for early differentiation of the ovary, many of which are 
members of the β-catenin pathway. These include both extracellular paracrine or 
autocrine factors such as RPSO and WNT4, as well as intracellular transcription 
factors (TF) such as FOXL2 (Crisponi et al., 2001, Parma et al., 2006, Chassot et al., 
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2008, Pailhoux et al., 2001, Liu et al., 2009a). Furthermore, numerous oocyte-
specific genes have been identified whose transcription is important for initiating 
follicle formation. These include TFs Gdf9, Zar1, Ngf, Figla and nobox, which are 
all expressed within oocytes of germ cell clusters and/or primordial follicles 
(McGrath et al., 1995).  
 
The primordial follicle pool is believed to be non-renewable. That is, once all germ 
cells have entered meiosis, with no mitotic oogonia left, then no further oocytes can 
form. However, some recent research has suggested the existence of germline stem 
cells within the ovary, proposing that they are used to replenish the primordial 
follicle pool (Johnson et al., 2004, Zou et al., 2009, White et al., 2012). Their 
location within the ovary is still unknown however, and more studies are needed 
before we can be certain of their existence. 
 
1.1.2. Post-natal ovary development 
Primordial follicles become recruited to grow pre-natally in the human ovary, and 
around or shortly after birth in the mouse. Follicle recruitment continues throughout 
life for most species, whereas in the human ovary it carries on until the primordial 
follicle pool has been depleted, at which point the woman reaches menopause. The 
size of the primordial follicle pool is therefore a key determinant of a woman's 
reproductive life span (Oktem and Urman, 2010).  
 
1.1.2.1. Initiation of follicle growth 
The first step in the growth of the follicle occurs when a follicle from the resting pool 
of primordial follicles, surrounded by flattened granulosa cells, become stimulated to 
grow. Once activated, the granulosa cells of primordial follicles become cuboidal and 
the follicle becomes a primary follicle. Secondary follicles are formed as granulosa 




















Figure 1.2. Follicle growth in a human ovary. 
Proliferating PGCs migrate to, and invade the developing ovary to form germ cell nests. 
They proliferate at a high rate, then enter meiosis and form primordial follicles as the germ 
cell nests break down. Throughout the reproductive lifespan, small cohorts of primordial 
follicles are continually released from dormancy as they enter the growing pool. The vast 
majority of growing follicles are lost to atresia, but beginning at puberty, a few follicles grow 
to the Graafian stage, normally resulting in the release of one oocyte each menstrual cycle. 




Early stages of follicle growth occur independently of gonadotropins. They are 
instead reliant on local factors derived from both somatic (granulosa and theca) and 
germ cells creating an orchestrated multi-directional signalling pathway that drives 
the primordial-to-primary follicle transition. The various factors involved in the 
regulation of follicle recruitment include inhibitory factors as well as stimulatory 
ones (Fig 1.3). 
 
Inhibitory factors are important for maintaining primordial follicles in their dormant 
state. Knock-out mouse models of genes involved in maintaining follicular 
quiescence (such as Pten, p27, Foxl2 and Foxo3a) all result in wholescale premature 
follicle activation and subsequently, early exhaustion of the primordial follicle pool 
(Castrillion et al., 2003, Adhikari et al., 2010). Foxo3a, a member of the FOXO 
subfamily of forkhead TFs, is one of the key regulators of early follicle growth, a 
downstream effector of the PTEN/PI3K/AKT pathway (Liu et al., 2009b). Females 
deficient in Foxo3a exhibit accelerated follicular activation and secondary infertility 
(Castrillion et al., 2003). Furthermore, mutations in the Foxl2 gene in the human 
ovary have been linked to premature ovarian insufficiency, emphasising the 
importance of inhibitory factors for female fertility (De Baere et al., 2003). Anti-
mullerian hormone (AMH), another member of the TGFβ family, has been 
implicated in inhibiting primordial follicle activation. AMH is expressed in granulosa 
cells of growing follicles and, when inhibited, an increase in primordial-to-primary 
transitions is observed (McGee and Hsueh, 2000, Durlinger et al., 2002, Durlinger et 
al., 1999).  
 
Several members of the TGFβ family, such as BMP-4, BMP-7 and GDF-9, play 
crucial roles in primordial follicle activation. GDF-9 is an oocyte derived factor 
whereas BMP-4 and BMP-7 are expressed in theca and stromal cells (Lee et al., 
2001, Nilsson and Skinner, 2003, Carbatos et al., 1998, Vitt et al., 2000). Other 
growth factors implicated include KL and LIF, which stimulate oocyte growth and 
theca cell recruitment (Nilsson and Skinner, 2004). The growth factors involved in 




1.1.2.2 Oocyte-somatic cell interactions (gap junctions, tranzonal projections) 
The ovarian follicle is a highly functional unit in which somatic and germ cells are 
closely associated and co-dependent. The follicle requires appropriate oocyte-
somatic cell interactions for growth. Oocytes drive follicle development by secreting 
TGFβ superfamily members GDF9 and BMP15. These growth factors regulate 
proliferation of granulosa cells in primary follicles as well as promoting theca cell 
differentiation (McGee and Hsueh, 2000, Orisaka et al., 2009). Initiation of 
primordial follicle growth to the primary follicle stage is un-affected in mice with 
mutations in the Gdf9 gene (Dong et al., 1996). However, follicles in these ovaries 
are unable to form secondary follicles, characterized by a failure in the theca cell 
layer formation (Elvin et al., 1999).  Furthermore GDF9 augments androgen 
production in pre-antral follicles. GDF9 is therefore thought to be crucial for pre-
antral follicle growth beyond the primary follicle stage where it might stimulate the 
recruitment, proliferation and differentiation of theca cells (Orisaka et al., 2009). 
GDF9 also suppresses KL expression in granulosa cells of antral follicles (Joyce et 
al., 1999, Joyce et al., 2000). In turn, KL is thought to promote oocyte growth and 
development. It is expressed in the granulosa cells and its receptor, c-kit, is expressed 
within the oocyte and theca cells, which further suggests a strong functional 
relationship between oocytes and granulosa cells (Nilsson and Skinner, 2004, 
Nilsson et al., 2002). However, there is some debate over the role of KL in early 
follicle development. One study (Parrott and Skinner, 1999) suggested that KL 
induces follicle development, whereas a different study suggested that it is involved 
in promoting oocyte survival rather than follicle activation directly, as following KL 
exposure they found no increase in the number of growing follicles, but instead 
reported a higher number of surviving primordial oocytes within the ovaries 
(Moniruzzaman and Miyano, 2010). FSH has also been shown to promote KL 
expression in granulosa cells of pre-antral follicles, but not in antral follicles (Joyce 
et al., 1999). BMP15 is thought to play a similar functional role in early follicular 
development as GDF9, where synergism between GDF9 and BMP15 might be 
required for follicle development, although this varies somewhat between species 
(Eppig, 2001). GDF9 and BMP15 promote granulosa cell proliferation in small antral 
follicles (Hayashi et al., 1999, Vitt et al., 2000, Otsuka et al., 2000), demonstrating 
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the importance of oocyte derived factors to drive granulosa cell proliferation. It is 
clear that the oocyte-granulosa-theca cell regulatory loop is a very complex one, with 
the oocyte playing a very active role in driving follicle growth, and the granulosa and 
theca cells secreting factors that in turn, regulate oocyte development.  
 
Gap junctions are responsible for mediating these oocyte-granulosa cell and 
granulosa-granulosa cell signals, linking the granulosa cells to each other as well as 
to the oocyte (Anderson and Albertini, 1976). Gap junctions between oocytes and 
somatic cells start to form during fetal life and become established in primordial 
follicles of the neonatal mouse ovary (de Felici et al., 1989, Mitchell and Burghardt, 
1986).  
 
Trans-zonal projections (TZPs) are cytoplasmic processes that form within the 
granulosa cells, penetrate through the ZP and terminate at the oocyte plasma 
membrane (Albertini et al., 2001). TZP co-ordinate the bi-directional paracrine 
communication between oocytes and granulosa cells. Their numbers vary according 
to follicle stage, where they are most numerous during peak periods of oocyte growth 




























Figure 1.3. The main factors involved in the dynamics of follicle development. Growth 
initiation of primordial follicles and subsequent development of the follicle through the 
primary, secondary and tertiary stages is finely regulated by several inhibitory and excitatory 
growth factors and/or hormones. Growth of the follicle to the secondary stage is 
gonadotropin independent, whereas further growth to the antral stages of follicle 
development are gonadotropin responsive, requiring the presence of gonadotropins such as 












1.1.2.3. Follicle growth to the antral stage 
As follicles progress through the primary, secondary and early antral stages of 
development, successive layers of granulosa cells form around the oocyte. Antral 
follicles eventually form when the proliferating granulosa cells secrete a viscous 
fluid that builds up, forming a fluid filled antrum. This stage is associated with an 
increase in follicle size and in oocyte diameter, as well as the establishment of basal 
lamina, zona pellucida (ZP) and a theca layer (Knight and Glister, 2006).  
  
Once a follicle transits into the secondary, pre-antral stage, its growth onwards to the 
antral stage becomes gonadotropin responsive, with further growth dependent on 
gonadotropins such as follicle stimulating hormone (FSH) (Craig et al., 2007).  
Although FSH receptors are expressed in follicles prior to this, during pre-antral 
follicle development, FSH does not play an essential role in follicle growth until 
follicles have reached the antral stage of development (Oktay et al., 1997). At this 
point, FSH and LH receptors are further up-regulated and further follicle growth 
becomes dependent on gondadotropins. 
 
1.1.2.4. Ovulation 
Ovulation is a complex and highly specialised process that results in the release of a 
mature, fertilizable oocyte from a pre-ovulatory, Graafian follicle. Normally one 
oocyte is released per ovulatory cycle in humans, whereas litter-bearing animals will 
release more. The whole process involves many different cell types within the ovary, 
including the mural granulosa, cumulus and theca cells of the follicle, as well as 
stromal cells and the cells of the ovarian surface epithelium (Richards et al., 1998). 
Successful ovulation is reliant on efficient communication between the oocyte and its 
surrounding cells, as the follicle microenvironment is crucial for the culminating 
stages of oocyte differentiation, its nuclear and cytoplasmic growth and capacitation 
(Hennet and Combelles, 2012). Furthermore, the basal lamina and antral fluid also 
have a role to play in oocyte differentiation. Antral fluid is a rich fluid derived from 
the bloodstream and from components secreted by the granulosa cells. It contains a 
wide range of molecules such as steroid hormones, electrolytes and enzymes. It plays 
an important role in mediating signals between the different cells types of the follicle 
(Hennet and Combelles, 2012).  
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The hypothalamus, pituitary and ovary are the three main sites of sex hormone 
production in the body. They form a complex, intricate feedback loop to control the 
menstrual cycle in women. The human menstrual cycle can be divided into three 
parts: 1) The follicular phase, during which secondary follicles develop to the 
Graafian stage, 2) Ovulation, when a follicle has reached full maturation and an 
oocyte is released from the ovary and finally 3) the luteal, or post-ovulatory, phase 
which occurs following ovulation when the ruptured follicle transforms into the CL. 
 
During the follicular phase of the ovulatory cycle, the hypothalamus releases pulses 
of gonadotrophin-releasing hormone (GnRH), which stimulates synthesis and 
secretion of two gonadotrophins, LH and FSH from the anterior pituitary. LH binds 
to receptors in theca cells and drives the conversion of cholesterol to androgen, 
which in turn is converted to oestrogens E2 and oestrone (E1) under the influence of 
aromatase in the granulosa cells. The FSH signal drives this conversion of theca-
derived androgens to oestrogens in the granulosa cell (Fig. 1.4) (Craig et al., 2007). 
The increase in progesterone released from the granulosa cells activates the A-kinase 
pathway, inducing the expression of genes needed for ovulation, such as 
prostaglandin endoperoxide synthase-2 (PGS-2) and the progesterone receptor (PR) 
(Park and Mayo, 1991, Espey, 1980, Richards, 1994). The increase in progesterone 
levels also activates the production of prostaglandin E1 (PgE1), a vasoactive 
substance that causes a dilation of capillaries in the theca layers, resulting in a 
degradation of the extracellular matrix of the collagenous connective tissue (Hoyer, 
2010). Rising FSH levels allow the dominant follicle to secrete increasing amounts 
of E2, inhibin and activin, hormones that negatively regulate the synthesis and 
release of FSH from the pituitary, inhibiting the remaining growing follicles which 
become atretic. The rising estrogen production exerts a negative feedback on the 
GnRH production in the hypothalamus. Oestrogen production then peaks just before 
ovulation and the granulosa cells of the dominant follicle also increase their secretion 
of inhibin and progesterone (Fortune, 1994). At this point, the negative feedback 
effect of oestrogen on GnRH earlier in the cycle changes to a positive feedback and 




The cumulus oocyte complex (COC) of the Graafian follicle is made up of the pre-
ovulatory oocyte and the cumulus cells that surround it. The COC is critical for 
ovulation as it produces hyaluronan (HA)-rich extracellular matrix. This HA matrix 
allows the COCs to lose contact with each other and start to move away from the 
oocyte through a process called expansion, an essential part of the release of the 
COCs from the ovary (Chen et al., 1990). The final stages of ovulation involve the 
disintegration and subsequent rupturing of the ovarian surface closest to the apical 
region of the Graafian follicle. As the gap-junctions between the oocyte and the 
adjacent granulosa cells break down, meiotic inhibition is relieved and the oocyte 
goes on to complete meiosis I. It enters meiosis II and arrests at the diplotene stage of 
meiosis II as the oocyte is released into the lumen of the oviduct (Richards et al., 
1998).  
 
Prior to ovulation, the oocyte produces factors that induce the proliferation of mural 
granulosa cells and at the same time prevents their differentiation into luteal cells, in 
a process known as luteinization (Shimasaki et al., 1999, Otsuka et al., 2001, 
Gilchrist et al., 2004). Once the oocyte has been released, the granulosa and theca 
cells of the follicle undergo luteinization and form the CL (Richards, 1994, Richards 
et al., 1998). Luteinization is associated with a rapid loss in cell cycle activators, and 
a corresponding increase in cell cycle inhibitors (Robker and Richards, 1998b, 
Robker and Richards, 1998a). This alteration of their inter-cellular balance is 
believed to stop the proliferation of granulosa cells and induce their terminal 
differentiation into luteal cells (Richards et al., 1998). The CL synthesises 
progesterone, which prepares the uterus for pregnancy. In humans, the CL receives 
signals from the fetus that extend its lifespan, and in turn, it produces the hormones 
necessary to maintain early pregnancy. If pregnancy does not occur it undergoes 























Figure 1.4. Outline of ovarian steroidogenesis.  
Ovarian steroidogenesis requires interactions between theca & granulosa cells. LH signalling 
increases the expression of enzymes required to convert cholesterol to androgens in the 
theca cells. These androgens get converted into oestrogens in the granulosa cells under the 






 1.1.2.5. Follicle atresia 
The vast majority of ovarian follicles will never make it to ovulation, but will instead 
undergo atresia, a process by which follicles degenerate and get re-absorbed. Atresia 
can occur at any point of follicle development, but the period of germ cell nest 
breakdown and the pre-antral to antral follicle transition, are two stages associated 
with particularly high rates of germ cell atresia (Hirshfield, 1991). There are many 
reasons for follicle atresia. It can occur as a result of low gonatrophin support due to 
lack of blood supply, due to inhibitory signals from a pre-ovulatory follicle, a deficit 
in survival factors, or it could be a way of eliminating chromosomally abnormal 
oocytes. 
 
The main mechanism in follicular atresia is apoptosis, or a form of programmed cell 
death (PCD) (Rodriguez et al., 2009). During pre-natal development, apoptosis 
occurs in germ cells, in particular during germ cell nest breakdown (Pepling and 
Spradling, 2001, Hartshorne et al., 2009), whereas during adult life it can be 
localised in oocytes as well as in granulosa and theca cells of growing follicles 
(Hussein, 2005, Rodriguez et al., 2009). Apoptosis is characterised by condensation 
of the chromatin within the nucleus resulting in its pyknotic appearance, cell 
shrinkage, fragmentation of the cell, convolutions of the nucleus, production of 
apoptotic bodies and phagocytosis of these apoptotic bodies. 
  
Apoptosis is driven by various intra-follicular regulators, growth factors, cytokines 
and steroids. Some factors promote oocyte survival, such as igf1, bcl-2 and 
interleukin-1β, and other factors are pro-apoptotic, including TGF- β, androgens, 
bax, p53, TNF, Fas and caspases (Van Nassauw et al., 1999, Tilly et al., 1995, Hu et 
al., 2001, Hussein, 2005). These factors generate an intricate balance necessary to 
either initiate or prevent apoptosis. 
  
There are two main mechanisms by which apoptosis is initiated: death receptor-
mediated events and mitochondria-mediated events. Death receptor-mediated events 
occur when a cell initiates the intracellular apoptotic pathway as a direct result to 
'death receptors' or to other external factors such as stress, heat, membrane damage 
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or nutrient deprivation. Death receptors such as Fas, interferon and tumor necrosis 
factor receptors bind to their ligands and activate apoptotic signals through death 
domains (DD) or caspase recruitment domains (CARD), which in turn, mediate the 
activation of pro-caspases and adaptor proteins. This leads to the activation of 
caspases, triggering apoptosis (Hussein, 2005). Mitochondria-mediated events on the 
other hand, occur as death signals act through intracellular factors such as pro-
apoptotic Bcl-2 proteins, resulting in a release of cytochrome c from the 
mitochondria. Cytochrome-c and apoptotic protease activating factor 1 (Apaf-1) bind 
to caspase 9 and in the presence of adenosine triphosphate (ATP), create an 
'apoptosome' complex. The apoptosome complex results in the recruitment of 
cleaved caspase-3, resulting in apoptosis (Hussein, 2005). Other pro-apoptotic 
factors include Bid, Bad and Noxa (pro-apopotitc BH3-only domain proteins) as well 
as PUMA (p53 regulated modulator of apoptosis) (Tilly et al., 1995, Hussein, 2005, 
Kaipa et al., 1997).  
 
In the pre-natal ovary, other types of PCD have also been suggested, namely, 
autophagy: a lysosomal degradation pathway, and necrosis, consisting of plasma 
membrane breakdown that results in an inflammatory reaction (Tilly, 2001, Edinger 
and Thompson, 2004, de Felici et al., 2008, Qu et al., 2007). It is believed that these 
different mechanisms of PCD create a complex system, that together regulate germ 
cell and somatic cell death in the developing ovary (Rodriguez et al., 2009). 
 
1.1.2.6 Epigenetic & Genomic imprinting 
Epigenetic reprogramming occurs during gamete formation, in a process that induces 
heritable modifications within the gene activity of a cell, without altering the 
nucleotide sequences of the DNA strand. Epigenetic changes include DNA 
methylation, alterations in chromatin structure, nucleosome remodelling and histone 
modifications (Bonasio et al., 2010). Genomic imprinting works by an epigenetic 
mechanism that restricts gene expression to only one of the parental chromosomes, 
but this only occurs in a few hundred of the 25,000 genes in our genome, with the 
rest being expressed equally. Non-imprinted genes are expressed from both parental 
genes, and both the maternal and paternal copies of each gene have therefore equal 
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potential to be active genes. An imprinted gene however expresses only one parental 
copy and silences the other. It does this by modifying or imprinting one of the 
chromosomes which then either repels or attracts TFs or mRNA processing factors, 
altering the expression of the imprinted gene in the process (Barlow and Bartolomei, 
2014). A cis-acting DNA methylation signal present only on one of the parental 
alleles, resulting in a molecular mark that leads to the specific expression of the 
imprinted gene on the marked allele (Jurkowska and Jeltsch, 2013). Genomic 
imprinting is an effect of inheritance, where the same imprinted gene is active on the 
same chromosome, either maternal or paternal, regardless of the sex of the offspring 
(Barlow and Bartolomei, 2014). 
 
During oocyte development, epigenetic reprogramming establishes specific gene 
imprints which are maintained throughout development in all somatic cells 
(Jurkowska and Jeltsch, 2013). When two gametes fuse to form a zygote, the 
epigenetic marks are erased, followed by a period of extensive re-methylation 
(Hajkova et al., 2002). This is crucial for embryonic development as studies in mice 
where the male pro-nucleus was replaced with a female, or vice versa, creating a 
unipaternal cell expressing imprinted genes on both copies of the parental genome 
resulted in embryos that were not viable. This was because of the presence of 
imprinted alleles on both chromosomes, resulting in no expression of the allele at all 
(Surani et al., 1984, Jurkowska and Jeltsch, 2013).  
 
1.2. Toxicology and reproductive function 
A considerable number of both man-made and naturally occurring chemicals are 
considered to be potentially disruptive to the endocrine system for both humans and 
wildlife (Sharpe and Irvine, 2004, Petro et al., 2012, Rhind et al., 2010). These 
include environmental toxicants and pharmaceuticals which come from a broad 
spectrum of chemicals. One group in particular, endocrine disrupting compounds 
(EDCs), constitute a major focus. EDCs have been described by the United States 
Environmental Protection agency (USEPA) as agents that ‘interfere with synthesis, 
secretion, transport, binding or elimination of natural hormones in the body that are 
responsible for maintenance of homeostasis, reproduction, development and/or 
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behaviour’ (Birklett, 2003). Pharmaceutical and chemical companies produce novel 
chemicals in the form of new drugs, which can, in some cases, act as EDCs (Rahman 
et al., 2009). Humans are exposed to thousands of these natural or man-made 
chemicals throughout their lifespan (Sharpe and Irvine, 2004, Propper, 2005, 
Woodruff and Walker, 2008, Rahman et al., 2009). Some are ingested as drugs or 
absorbed through the skin via beauty products such as soaps and perfumes (Rahman 
et al., 2009), whereas others can leach out of plastic or be inhaled from cigarette 
smoke or vehicle exhausts). These chemicals can interfere with endocrine 
mechanisms due to their weak intrinsic hormonal activity, most often by mimicking 
or inhibiting estrogens through binding to nuclear, membrane, neurotransmitter 
and/or orphan receptors.  
 
1.2.1 Female reproductive toxicity 
Ovarian follicles that undergo growth initiation enter a period of continuous 
development until they either undergo atresia or develop to the Graafian stage, 
accompanied by rapid granulosa cell proliferation. That continual growth state, 
accompanied by the meiotic arrest of the oocyte for up to 45 years in humans, makes 
them particularly vulnerable targets for environmental toxicants. The somatic cells 
and the BM of the follicle can be thought of as a protective sheath enclosing the 
oocyte, but this does not necessarily protect it from the effect of mutagens, directly 
or indirectly. The majority of toxic compounds are able to access the ovary via the 
circulation, but if these toxicants are able to pass through the BM, then the oocyte 
can also potentially be affected. Any compound that has a direct effect on the ovary, 
may also be able to alter epigenetic mechanisms in the oocyte, resulting in trans-
generational epigenetic effects (Newbold et al., 2000, Miller et al., 2004, Jefferson et 
al., 2007, Bernal and Jirtle, 2010, Zama and Uzumcu, 2010). Even if such chemicals 







1.2.2. Some examples of mechanisms of action of toxic agents on the ovary 
Pre- and postnatal ovaries contain large numbers of germ cells and follicles at 
various stages of development. Pre-natally, this includes the rapid proliferating PGCs 
and the oocytes undergoing the first meiotic division. The mature ovary contains 
primordial follicles with oocytes in meiotic arrest, dividing granulosa cells and 
maturing oocytes of growing follicles, as well as ovulating oocytes resuming 
meiosis. The ever-changing environment is a major challenge for reproductive 
toxicity studies, as follicles in different stages of growth may well vary in their 
susceptibility to different compounds. A compound might, for example, only target 
growing follicles but have no effect on the primordial follicle pool, or vice versa.  
  
Compounds targeting the primordial pool can have adverse effects on fertility, 
arguably more so than those targeting growing follicles. If the primordial pool of 
follicles is damaged, future follicle growth and ovulation may be affected. At worst, 
a chemical that interferes markedly with the resting pool could result in premature 
ovarian insufficiency (POI) (De Vos et al., 2010). In contrast, if a compound 
specifically targets growing or pre-antral follicles, perhaps by targeting dividing 
granulosa cells, these follicles might undergo atresia which could result in cyclic 
disturbances for the few months following exposure to the compound: however, once 
the compound and its effects are removed, new follicles (from the unaffected resting 
pool) will begin growing and form normal ovulatory follicles, thus restoring fertility 
(Cortvrindt and Smitz, 2002). Sustained effects on growing follicles can, though, 
have long-term consequences: studies into the effects of chemotherapy on the ovary 
are providing growing evidence that repeated damage to growing follicles can have a 
severe effect on the primordial pool, as the loss of growing follicles leads to 
premature activation of primordial follicles and consequently, a depletion of the 
primordial follicle pool (Meirow et al., 2010, Morgan et al., 2012, Kalich-Philosoph 
et al., 2013, Morgan et al., 2013).  
 
There are several other ways in which chemicals could disrupt oocyte development. 
The pre-natal phase of ovary development is considered a particularly vulnerable 
phase, as various chemicals have been shown to affect fertility when exposure occurs 
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during fetal development (Fowler et al., 2008, Bellingham et al., 2012, Matikainen et 
al., 2002, Hunt et al., 2012). During meiotic progression of the oocyte, chromosomes 
utilise a bipolar spindle for their segregation for both meiotic divisions. If disturbed, 
this could lead to impairment in chromosome pairing or spindle formation, resulting 
in non-disjunction (Fragouli et al., 2011). Regulation of progression of the cell cycle 
is tightly controlled by feedback mechanisms that sense disturbances and by 
checkpoint controls that protect the cell from such errors and ensure that aneuploidy 
is prevented (Vogt et al., 2008). Failure during these meiotic checkpoints can result 
in meiotic errors, and the resulting mutations introduced to the genetic material have 
the potential to be passed on to the subsequent generation. Studies have been carried 
out on the possible effect of environmental chemicals on meiotic disturbances (Can 
and Semiz, 2000, Hunt et al., 2003, Hunt et al., 2012) and have illustrated that the 
chemicals interfere with the actions of estrogen receptors (ERs) (Susiarjo et al., 
2007) and cause abnormalities in the alignment of chromosomes and spindle 
formation (Can and Semiz, 2000, Eichenlaub-Ritter et al., 2008, Hunt et al., 2012). 
E2 inhibits germ cell nest breakdown and protects oocytes from programmed cell 
death with binuclear oocytes and multioocyte follicles (MOFs) reported as a result of 
estrogenic compound exposure (Pepling and Spradling, 2001, Kim et al., 2009). 
MOFs are often used as an indicator of an adverse effect, as they are considered a 
likely result of disruption to germ cell nest breakdown (Nagao et al., 2001, Suzuki et 
al., 2002, Jefferson et al., 2007, Kim et al., 2009, Cimafranca et al., 2010, Rivera et 
al., 2011, Karavan and Pepling, 2012). Although the vast majority of oocytes 
affected by chemicals are likely to end up becoming atretic (Rodriguez et al., 2009), 
some might form aneuploid ovulated oocytes, with the consequent potential of an 
aneuploid embryo and likely miscarriage.  
  
Reproductive toxicants might either target the oocyte specifically, or have more 
general effects on the surrounding somatic cells. In either scenario, reproductive 
disorders can occur. The follicle is a complex structure relying on interactions 
between the oocyte and its somatic cells (Eppig, 1979, Gilchrist et al., 2004, Su et al., 
2004, Thomas and Vanderhyden, 2006, Orisaka et al., 2009). Granulosa and theca 
cells are responsible for hormone production within the ovary as well as controlling 
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the release of oocytes throughout the adult reproductive lifespan. This is mainly 
regulated through the expression of autocrine and paracrine factors, creating intricate 
feedback loops within the follicle that are essential for normal follicle development 
and for meiotic competence of the oocyte. This complex communication network 
formed by the oocyte, granulosa cells and theca cells, together drives follicle 
development. Any chemical affecting either the oocyte or the surrounding somatic 
cells can lead to a disruption in the secretion of growth factors, then affecting the 
oocyte-granulosa cell regulatory loop (Su et al., 2004). These chemicals could also 
interfere with the feedback loop between the ovaries and pituitary gland to perturb 
the balance of the hypothalamo-pituitary-gonadal axis. Disruption could not only 
have negative effects on follicle development, oocyte maturation and ovulation, but 
could also significantly affect the production of ovarian hormones from the ovary 
(Canipari, 2000). 
 
1.3. In vitro ovary and follicle culture systems 
The first successful rodent ovary culture was established in 1937 (Martinovitch, 
1938, Martinovitch, 1937), and subsequently, various culture methods have been 
developed with the aim of growing ovaries and follicles from an immature state to 
fully mature, fertilizable oocytes (Blandau et al., 1965, Eppig and Schroeder, 1989, 
Spears et al., 1994, Eppig and O'Brien, 1996, Klinger and Felici, 2002, Obata et al., 
2002, O'Brien et al., 2003, Picton et al., 2003, Xu et al., 2009, Jin et al., 2010). Ovary 
and follicle cultures have now become a widely used tool to study the development 
of follicles in reproductive biology and toxicology and have been successfully 
established in humans, primates, cattle, sheep, pig, mouse, and rat (Roy and Treacy, 
1993, Hirao et al., 1994, Ralph et al., 1995, Telfer et al., 2008, McLaughlin and 
Telfer, 2010, Xuying et al., 2011). 
  
In 1989, the first in vitro pre-antral follicle culture that led to the birth of live mouse 
pups was established (Eppig and Schroeder, 1989). The real challenge, however, has 
been to establish a culture system that allows for the expansion and development of 
the germline progenitor cell right through both meiotic divisions to produce a mature 
fertilizable germ cell that is then capable of producing live offspring. A few studies 
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have managed to create the culture conditions necessary to produce live pups from 
immature cultured follicles (Eppig and Schroeder, 1989, Spears et al., 1994, Eppig 
and O'Brien, 1996, Obata et al., 2002, O'Brien et al., 2003, Jin et al., 2010, Mochida 
et al., 2013) but many were invasive, requiring major manipulation to the follicles. 
For example, Obata et al (2002) used fetal ovaries as starting material, culturing pre-
meiotic female germ cells from E12.5 embryos to antral oocytes, although the culture 
system required transfer of nuclei of the E12.5 germ cells into enucleated grown 
oocytes from adult mice following 28 days in culture. This allowed the oocytes to 
resume and complete meiosis in vitro, and following in vitro fertilization they 
successfully developed into blastocysts, with living pups obtained following embryo 
transfer (Obata et al., 2002). 
  
1.3.1. In vitro ovary culture in reproductive toxicity testing 
Exposure of reproductive toxicants can occur in the form of individual chemicals or 
as chemical mixtures and it has proven difficult to establish which situation causes 
more harm to reproductive function, in particular because the effects might not 
become evident until years later (Sharpe and Irvine, 2004). Furthermore, different 
periods of vulnerability to exposed compounds mean that a fetus might not be 
affected by a chemical in the same way as an adult would, making the testing of such 
chemicals on reproductive function difficult, yet that much more crucial.  
  
Many in vivo reprotoxicity studies, in particular those carried out on the reproductive 
effects of pharmaceuticals, use end-points such as pregnancy, implantation and 
number of offspring, parameters that do not identify any potential effects on the 
primordial follicle pool. Consequently, in vivo study designs used at present might 
not pick up long-term effects on the primordial follicle pool since it may not affect 
immediate ovulation rates and subsequent pregnancies, but might have longer term 
consequences on reproductive lifespan. On the other hand it is also possible that an 
effect seen in the neonatal ovary may, in fact, correct itself in later life (Bristol-




In vitro ovary and follicle culture models allow for the possibility of varying culture 
parameters in a highly controlled manner, and thus have the potential to allow a more 
thorough evaluation of early-ovary development and for reproductive toxicity 
studies, than do in vivo studies alone. In vitro cultures used in reproductive toxicity 
studies allow for a thorough investigation of the mechanism of action of toxicants 
and how they contribute to oocyte or somatic cell damage. They also allow for a 
detailed analysis of oocyte quality, effects on the establishment of the primordial 
follicle pool, and paracrine interactions (Sun et al., 2004). Culture systems have the 
potential to reveal whether the ovary is directly targeted by the toxicants, with effects 
observed in vivo but not in vitro presumably being indirect. The cultures can also 
reveal if compounds target follicles at specific stages of development and can give 
deeper insight into the way toxicants might affect the chromosomal integrity of the 
oocyte, or if they have the ability to alter hormonal signalling within and/or between 
follicles.   
 
Testing of chemicals in vivo is time consuming and costly. To date, in vitro models 
have been used primarily as a preliminary or secondary screening protocol for 
toxicity testing. The lack of an alternative test system to available in vivo study 
designs has been commented on (Davila et al., 1998, Jackson, 1998, Cortvrindt and 
Smitz, 2002), leading to an increased demand for adequate in vitro models that may 
be used to gain an insight into the mechanisms of chemical exposure and pinpoint 
potentially hazardous products on reproductive function. In vitro studies might 
provide a good way forward to investigate the direct effects of certain chemicals on 
primordial germ cell reservoir in the ovary. 
 
1.4. Topoisomerase-II 
Type II topoisomerases (Topo II) are large homodimeric nuclear enzymes that play a 
role in the chromosome condensation and in the separation of sister chromatin during 
mitosis.  Due to the double stranded nature of DNA, topological problems can arise 
during transcription and replication when a DNA strand needs to be unwound, as  
this can result in overwinding, or supercoiling, of other areas of the DNA molecule. 
Topo II regulates the topology of DNA during mitotic divisions by creating transient 
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double (type II) DSBs in the DNA, and thereby relieving the torsional stress created 
by supercoiled DNA strands with superhelical turns (Fig. 1.5) (Roca, 2009, Nitiss, 
2009). They are also thought to be required for prophase I of meiosis, during the 
untangling of sister chromatids following recombination, as well as for the 
segregation of replicated chromosomes (Nitiss, 2009, Russell et al., 2000, Li et al., 
2013). Furthermore, supercoiled areas are associated with an increase in 
recombinational events due to genetic instability (Baguley and Ferguson, 1998) and 
this may generate duplications, deletions, insertions, inversions or substitutions 
within a DNA sequence. Therefore, topoisomerases are also believed to play a role in 
reducing these recombination rates by relieving the torsional stress (Baguley and 
Ferguson, 1998).  
  
Topo II acts by breaking one DNA strand with each subunit, passing the unbroken 
strand through the break and then resealing it. Mammals express two types of Topo 
II paralogues: Topo IIα and Topo IIβ, and although they share 70% amino acid 
similarity and have near identical catalytic activity (Li et al., 2013), they have 
different functions and expression patterns (Kimura et al., 1994). Topo IIα 
expression peaks at the G2/M stage of the cell cycle whereas Topo IIβ expression is 
not regulated by the cell cycle (Woessner et al., 1991, Capranico et al., 1992). In the 
mouse ovary, Topo IIβ is expressed in oocytes at all developmental stages. Its 
expression is low in granulosa cells of primordial follicles but becomes more 
pronounced in the granulosa cells of primary and secondary follicles, whilst it 
becomes abundant in the granulosa cells of pre-ovulatory follicles (Zhang et al., 
2013). Within the germ cells nucleus, Topo II is localised within the germinal vesicle 
(GV) prior to meiotic entry, but once GV breakdown (GVBD) has occurred, it 
becomes localized on the chromosomes, adjacent to the centromeres and along the 
chromosome arms (Li et al., 2013). The expression pattern of Topo IIα within the 




















Figure 1.5. Action of Topo II. A DNA strand is in its 'relaxed' state (I). During replication, unwinding of parts of the DNA strand increases 
the twist strain on other areas of the strand, resulting in over-winding (II). If further topological strain is applied, the double helix crosses over 
on itself, resulting in a supercoiled strand (III). Topo II creates breaks in both DNA strands (IV) so that the unbroken strand can pass 
through, relieving the topological stress (V). Topo II then religates the broken strand (VI).  
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1.4.1 Topoisomerase-II knockout models 
Akimitsu et al (2003) demonstrated the importance for Topo IIα in development with 
the generation of a Topo IIα knockout (-/-) mouse, whose embryos were unable to 
progress beyond the 4-8 cell stage (Akamitsu et al., 2003). Conditional knock-out 
models have therefore been adapted to study any loss-of-function effects associated 
with Topo IIα but none investigated the effect of Topo IIα on fertility (Johnson et al., 
2009, Carpenter and Porter, 2004). Topo IIβ knockout (-/-) mice however, are not 
embryonic lethal but instead develop defects in motor axons and in the stratification 
of the cerebral cortex (Lyu and Wang, 2003, Yang et al., 2000). Zhang et al (2013) 
generated a conditional Topo IIβ knockout model where Topo IIβ was deleted in 
granulosa cells. This resulted in a rise in granulosa cell DNA damage, leading to 
increased follicle atresia in these ovaries. Therefore they concluded that the Topo IIβ 
enzyme plays an essential role in granulosa cells where it prevents the accumulation 
of DNA damage and apoptosis (Zhang et al., 2013).  
 
1.4.2 Topoisomerase-II inhibitors  
Due to its role in cell division, inhibiting Topo II has been a popular method for 
targeting tumour cells during cancer treatments. Doxorubicin, ICRF-193, teniposide 
and etoposide (VP-16) are all Topo II poisons that act by inhibiting Topo II from 
religating DNA molecules by interfering with DNA processing. Most Topo II 
inhibitors inhibit the enzymatic activities of both Topo IIα and Topo IIβ (Li et al., 
2013). Topo II inhibition generates high numbers of DSBs, activates DNA damage 
checkpoints and can result in chromosomal abnormalities leading to fragmentation of 
DNA and results in tumour cell death (Roca et al., 1994, Damelin and Bestor, 2007, 
Montecucco and Biamonti, 2007). However, due to the highly toxic nature of these 
drugs, they can also result in adverse side-effects on fertility (Anderson and Berger, 
1994, Soleimani et al., 2011, Ben-Aharon et al., 2010). Inhibition of Topo II during 
mitosis and meiosis can result in an incomplete separation of chromatids and 
chromosomes, and consequently, genomic mutations can occur (Baguley and 
Ferguson, 1998). In male mice, etoposide interferes with the early stages of prophase 
I, specifically between leptotene and diakinesis (Russell et al., 2000). Etoposide 
inhibits the religation of the DNA strand following the cut made by Topo II, and 
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exposure of mouse spermatocytes during early to mid pachytene results in locus 
deletions and a reduction in crossovers. Interestingly, spermatocytes undergoing 
meiosis II are much less sensitive to Topo II inhibition than they are whilst during 
meiosis I (Russell et al., 2000, Kallio and Lahdetie, 1996). Similar effects have been 
reported in the female mouse, where oocytes from dictyate to diakinesis were 
affected by Topo II inhibitors, although unlike in the male, they were also highly 
sensitive to Topo II inhibition during the second meiotic division (Tateno and 
Kamiguchi, 2001a). One of the reasons for this difference in susceptibility between 
male and female germ cells could be that Topo II inhibitors have increased 
accessibility to the DNA in oocyte due to the diffuse state of chromosomes at meiotic 
arrest, compared with the more condensed chromosomes in male germ cells 
(Baguley and Ferguson, 1998). 
 
1.4.2.1 AZTC 
The majority of the work carried during the PhD concentrated on one type of 
compound, an antibacterial agent that was under pharmaceutical development at 
AstraZeneca: 'Astrazeneca Test Compound' (AZTC). AZTC is a Topo II inhibitor 
that targets bacterial Topo II, which has mammalian homologues possibly involved 
with meiosis. Previously it was noted in male rats exposed to this compound that 
there were effects on spermatogenesis, namely, testicular degeneration, abnormal 
sperm morphology and lowered sperm counts (unpublished data, AstraZeneca). The 
testicular damage caused is likely reversible in the testis and would potentially be 
manageable and recoverable in the clinic, however if a female fetus were to be 
exposed in utero, this could potentially irrevocably damage the pool of surviving 
oocytes. AZTC was therefore selected to investigate the efficacy and validity of 
ovarian culture methods.  
 
1.5. Aims of PhD 
In the past 50 years, various culture methods have been developed with the aim of 
growing ovarian follicles in vitro. These culture systems have become a widely used 
tool in reproductive biology and toxicology, but the real challenge has been to 
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establish a culture system whereby mouse germ cells can be cultured from a pre-
meiotic stage to a mature oocyte. The pre-natal period of oocyte development is an 
important one, as it results in the formation of the primordial follicle pool. A 
woman's reproductive span is dependent on the size of the primordial follicle pool, 
which is determined during fetal development, when the germ cell pool undergoes 
proliferation and enters prophase I of meiosis.  Furthermore, in the pharmaceutical 
industry, the majority of reproductive toxicity testing is carried out in vivo to assess 
the effects of a compound for inclusion of women of childbearing potential in 
clinical trials. This involves using immediate end-points such as ovulation, 
pregnancy, implantation and number of offspring, parameters that do not identify any 
potential effects on the primordial follicle pool. Consequently, in vivo study designs 
used at present might not pick up long-term effects of chemicals the primordial 
follicle pool since it may not affect immediate ovulation rates and subsequent 
pregnancies, but could have longer term consequences on reproductive lifespan. This 
has led to an increased demand for adequate in vitro models that may be used 
alongside in vivo methods, to study the biology of the pre-natal ovary and to gain an 
insight into the mechanisms of pre-natal ovarian toxicants.  
 
The aims of this PhD were to:  
1. Bridge, adapt and improve existing culture methods to generate a culture system 
that would span meiotic entry to meiotic arrest, germ cell nest break-down, follicle 
formation and initiation of follicle growth. 
2. Investigate the effects of a novel Topo II inhibitor developed by AstraZeneca, 
AZTC, on the pre-natal and post-natal ovary. The aim was then to compare the in 
vitro effects of exposure to the Topo II inhibitor pre-natally, in part, using the 



















2.1 Neonatal ovary culture 
2.1.1. Dissection medium  
The dissection medium consisted of Liebovitz (L-15) medium (Invitrogen, 
11415049). Before use the medium was first adjusted to the osmolarity of 285 
mmosmol using the calculation below, and adding water (Sigma, W1503):  
  Difference/actual x volume = volume of H2O required 
The medium was supplemented with 3 mg/ml BSA (Sigma, A3311) and once 
dissolved, it was filter sterilised using Becton-Dickson syringes and Iwaki filters 
(Iwaki, 2032-13 or 2052-025). 1-2 ml of the prepared dissection media was placed in 
embryo dishes (VWR, 720-0579) and warmed to 37˚C before dissected ovaries were 
placed into the dishes.  
 
2.1.2. Culture medium (simple medium) 
The culture medium was α-MEM (Invitrogen, 22571020). Before use it was adjusted 
to the osmolarity of 285 mmosmol by adding water using the above calculation 
(section 2.1.1). The medium was supplemented with 3 mg/ml fatty acid free BSA 
(Sigma, A8806) and filter sterilised as above (section 2.1.1). 1 ml of media was 
required per ovary, and media was incubated for a minimum of 30 minutes in plastic 
culture tubes with dual-position caps or in the culture plate, allowing for 
equilibration of media prior to ovary culture.  
 
2.1.3. Plate Preparation 
Flat bottom 24 well culture plates were used for this culture (Greiner, 662960). 1 ml 
of culture medium was placed into each well and a nucleopore polycarbonate 
membrane (Whatman, 110414) was placed on top using sterilised tweezers. The plate 
(without the lid) was placed in a laminar flow hood under UV light for 30 minutes 
for sterilisation prior to culture.  
 
2.1.4 Tissue collection & ovary culture 
Neonatal mouse pups were culled by decapitation and pinned to a corkboard in a 
flow hood. A ventral incision was made and ovaries, with the ovarian bursa attached, 
were dissected under a microscope.  The ovaries were placed in petri dish containing 
the pre-prepared dissection medium (section 2.1.1). Using insulin needles, the 
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ovaries were dissected free of the ovarian bursa and extra tissues under the 
microscope in the flow hood. The ovaries were transferred onto membranes in the 
culture wells using a coated drawn Pasteur pipette. Ovaries were cultured for 6 days. 
The culture medium was changed every other day by exchanging 500 µl of the 
medium for 500 µl of freshly prepared, pre-equilibrated medium using a pipette. This 
culture medium will be referred to as the simple medium for this point onwards.  
 
2.2. Histology 
2.2.1 Ovary fixation and agar embedding 
Following culture, ovaries were washed in 1xPBS for 5 minutes and then fixed either 
in Bouins fixative for 1-2 hours, or in 10% buffered formalin overnight (Sigma, 
HT5014). Ovaries were washed once in 70% ethanol to remove any remaining 
fixative, and then placed in fresh 70% ethanol for storage before processing. 2% agar 
(Sigma, A1296) was made up in ddH20 and ovaries were placed in a drop of agar for 
support and ease of handling. 
 
2.2.2 Wax embedding 
Ovaries (in agar blocks) were placed in tissue processing cassettes and then passed 
through a series of alcohol solutions of increasing concentration (70%, 90%, 100% 
x2), before being immersed in a paraffin wax and xylene solution, allowing the 
ovarian tissue to become penetrated by the molten paraffin wax. They were then 
placed in truncated plastic moulds (Park Scientific), which were subsequently filled 
with wax and allowed to cool.  
 
2.2.3 Sectioning and mounting 
Wax blocks were removed from the moulds and the base trimmed down to create a 
flat surface. A heated chuck was fused to the base of the block and together, and 
placed in water to cool the wax and secure the block onto the chuck. The edges of the 
block were then trimmed around the tissue with a razor blade before being fixed onto 
a microtome. The block was positioned and orientated so that the surface of the block 
is cut at a right angle and the tissue was sectioned at 5 µm. Wax ribbons were floated 
onto a warm water-bath (approx. 42˚C) and carefully placed onto poly-L-lysine 
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coated slides (Fisher), which were placed in a slide-rack and left to dry overnight in a 
37˚C oven. 
 
2.2.4 Haematoxylin and eosin staining 
Slides were placed in a staining rack and placed in xylene for (10 minutes x2) for 
dewaxing before being re-hydrated up through a series of decreasing ethanol 
concentrations (100%, 95%, 90%, 70%), being left for 5 minutes at each 
concentration. If the ovaries had been fixed in bouins, the slides were then placed in 
70% ethanol lithium carbonate for 5 minutes to remove any trace of bouins from the 
tissue. Slides were then washed in tap water for a further 5 minutes and placed in 
freshly filtered haematoxylin for 2-3 minutes to stain the nuclei, before then being 
placed back in the tap water. The intensity of the stain was checked under a 
microscope and if the stain was too dark then the slides were briefly dipped into acid 
alcohol and the stain was checked again. Once the desired intensity of stain was 
achieved, the slides were placed in Scott's tap water solution (STWS) for 3 minutes, 
followed by a 3 minute was in tap water. The slides were then placed in filtered eosin 
stain for 2 minutes, washed in tap water, and then placed in potassium alum for a 
further 2 minutes to fix the stain, followed by a rinse in tap water. The staining was 
then checked under a microscope. If the desired intensity of stain was observed then 
the slides were dehydrated through the ethanol solutions (70%, 90%, 95%, 100%x2), 
but left slightly longer in the ethanol solutions if the stain was too dark. The ovary 
sections were then cleared in xylene for 5 minutes, covered with a xylene-based 
mountant (DPX) and coverslips placed on top, avoiding air bubbles. The slides were 
left overnight in a fume hood and once dry, they were examined and imaged under a 
bright-field microscope (DMLB microscope, DFC480 camera and IM50 software, 
Leica).  
 
2.3 Follicle counts and classification 
2.3.1. Follicle counting 
Following haematoxylin and eosin staining, every 'n'th ovary section of the ovary 
was photographed under bright-field microscopy (described in Section 2.2.4). Each 
figure was converted to a JPEG file using Corel Photo Paint, reducing the size of the 
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file without compromising visual quality. The figure was opened in ImageJ for 
follicle analysis, which was carried out using the cell counter tool in imageJ. Every 
6th ovary section was counted from neonatal (P0 and P4) and embryonic ovary 
cultures (described in Chapter 4), whereas from the in vivo rat study, every 20th was 
counted from the PND 5 ovaries, every 40th from PND 15 ovaries, and finally, every 
50th from the adult rat ovaries (described in Chapter 3). The frequency of sections 
analysed were selected in relation on ovary size, with every 6th section selected for 
the smallest mouse ovaries whereas every 20th-50th were selected for the larger rat 
ovaries, as taking every 6th would requiring an analysis of a very large number of 
sections, whereas counting every 20th, 40th or 50th should give a representative 
sample of follicles in the larger rat ovaries. 
 
2.3.2. Follicle classification 
Follicles counted were categorised into the following follicle types:  Primordial 
follicle (Type 1: PMF), an oocyte with a flattened layer of granulosa cells, 
transitional (Type 2: TRNS), an oocyte with some flattened and some cuboidal 
granulosa cells, primary follicle (Type 3: PRIM), when all the granulosa cells in the 
layer have become cuboidal, Secondary (Type 4: SEC), once a second layer of 
granulosa cells has formed, pre-antral (Type 5; PreA), when the oocyte is surrounded 
by more than two layers of granulosa cells but without an antrum, early Antral (Type 
6: EarlyA), follicles with a small antrum, and finally, Late Antral (Type 7: LateA) 
follicles with a large antral cavity (See Figure  2.1).  Follicle health was recorded 
onto a separate sheet, where oocytes containing a shrunken and pyknotic nucleus or 
granulosa cells, identified by a dark eosin stain, were classified as unhealthy, see 
below.  Only follicles with a visible nucleus were included in the counts to avoid 
double-counting of follicles. The analysis was always carried out blind to the 




















Figure 2.1. Classification of ovarian follicles according to follicle stage and health. 
Ovarian follicles were counted and categorised into their repsective stages of follicle growth: 
primordial (PMF), transitional (TRNS), primary (PRIM), secondary (SEC), early antral (Early-
A) and late antral (Late-A). Follicle health was also measured and follicles with an unhealthy 
oocyte, identified by a darker eosin stain and a pyknotic nucleus, or with unhealthy pyknotic 
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2.3.3. Correction of follicle counts 
The size of an ovarian follicle is larger than the thickness of the sections and this 
increases the chance of the same follicle being double counted in two nearby section. 
This means that when calculating the final estimate over total follicle numbers per 
ovary, the final number will be an over-estimate. Here, in order to get more reliable 
estimates of the total number of follicles within an ovary, the Abercrombie equation 
was used (Abercrombie, 1946). The Abercrombie equation calculates a more 
accurate density of a population of cells by applying a correction factor to the total 
number of counted nuclei. It requires a calculation of the mean diameter of nuclei 
from each follicle type, which are then incorporated into the calculation along with 
the thickness of the section, to estimate the total number of cells. The Abercrombie 
equation is outlined below:  
 
Average number of nuclear points per section = A  x 
 
A: crude count of the number of nuclei counted in section 
M: thickness of section 
L: Average length of nuclei 
 
The mean diameter of nuclei (L) for each of the follicle types was measured, with a 
minimum of ten examples for each follicle stage used to obtain the mean. This 
number was then used to calculate the value within the brackets above, where the 
thickness of the section (M) was 5 μm. The results are outlined in Table 1. This was 
then multiplied with the crude count of nuclei in the section and with the selected ' 
number of sections that were used for counting to calculate the end approximate 


















2.4.1 Dewaxing and rehydration 
Slides were dewaxed in xylene (2x5 minutes) followed by rehydration through a 
series of decreasing ethanol concentrations (100% 2x5 minutes, followed by 95%, 
90% and 70% for 5 minutes each) before rinsing in ddH2O for 5 minutes.  
 
2.4.2. Antigen retrieval 
Slides were placed in a plastic slide holder filled with citrate buffer (0.01M) and 
covered with cling film. They were microwaved for 4x5 minutes, and the slide holder 
was topped up with 50 ml of buffer in between to ensure that the slides were well 
covered.  The antigen of interest becomes masked by the extensive cross-linking of 
proteins during tissue fixation and processing, but antigen retrieval uses heat to un-
fold the proteins within the tissue, exposing the epitope and therefore permitting 
successful binding of the antibody to the antigen. The slides were then left to stand in 
the citrate buffer for a minimum of 20 minutes, until cooled.  
 
2.4.3 Blocking 
In order to prevent any non-specific antibody binding and background staining, 
endogenous peroxidases in the tissue were blocked with 3% H2O2 in Methanol for 30 
minutes. The slides were then washed in PBS/0.1% Triton X (Sigma, TT9284) for 5 
minutes, twice and placed in a wet chamber: a shallow, plastic box with wet tissue 









L + M 
Table 2.1.Correction 
factor. The obtained 
values for each follicle 
type, calculated from 
the thickness of section 
(M) and average length 




paper in the bottom to prevent dehydration. The area around the tissue was dried and 
a PAPpen was used to draw around the tissue sections. To further reduce any non-
specific reactions, slides were then blocked with a solution of 20% Normal Goat 
Serum supplemented with 5%BSA and PBS (NGS/BSA/PBS solution: 2ml Serum, 
0.5g BSA, 8ml 1xPBS) and left in the wet chamber for one hour at room 
temperature. 
 
2.4.4 Primary antibody 
The primary antibody was diluted in the NGS/BSA/PBS solution (sections 2.4.3 & 
2.4.4). The blocking solution was tipped off the slides, 100 μl of the primary 
antibody solution was then applied to each slide and they were left in the wet 
chamber overnight at 4˚C. 
 
2.4.5 Secondary antibody 
Primary antibody solution was tipped off the slides and they were washed in dH2O 
for 5 minutes, followed by two more 5 minutes washes in PBS/0.1% Triton X. The 
secondary antibody (biotin conjugated) was diluted in the NGS/BSA/PBS solution 
(Section 2.4.5) and was applied at 100 μl per slide and left for one hour at room 
temperature in the wet chamber.  
 
2.4.6 Antigen detection 
Serum was tipped off the slides and they were washed in dH2O for 5 minutes, 
followed by two more 5 minutes washes in PBS/0.1% Triton X. The secondary 
antibody was detected with the help of the Vectastain ABC Elite kit (Vector 
laboratories, PK6100). The avidin-biotin complex (ABC) kit utilises the high affinity 
of avidin for biotin. The biotinylated secondary antibody binds to the primary 
antibody, which in turn is bound to the protein of interest. The biotin-binding sites 
bind to the biotinylated secondary antibody, resulting in more enzyme being attached 
to the target than if only using an enzyme-conjugated secondary or primary antibody. 
Two drops of solution A and two drops of solution B from the ABC kit were placed 
into 5ml of PBS and left for 30 minutes before use. Around 4 drops of the ABC 
solution were applied to each slide and left for 30 minutes in the dark at room 
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temperature. The slides were then washed in PBS/0.1% Triton X for 5 minutes, 
twice. 
 
The ABC complex was visualised with the help of 3,3'- diaminobenzidine (DAB) 
(Vector Laboratories, SK4100), which is the substrate for the peroxidase enzyme, 
resulting in dark brown staining. From the DAB kit, one drop of buffer, two drops of 
DAB and 1 drop of hydrogen peroxide (added immediately before use) were added 
to 2.5 ml of water to make up the DAB. The solution was wrapped in foil and added 
to the slides. The slides were left for about 1 minute, or until brown staining became 
visible under the microscope. To stop the reaction, the slides were washed in ddH2O. 
They were then washed several more times in ddH2O before being placed in 
haematoxylin for 30 seconds to counter-stain the nuclei. The slides were then 
rehydrated up through a series of ethanol solutions (70%, 90%, 95%, 100%x2, 
around 30 seconds in each), placed in mounting xylene for 5 minutes and 
coverslipped using DPX mountant. Once dry, the sections were visualised as 












The effect of AZTC on the pre-natal rodent 












Humans are exposed to thousands of man-made chemicals throughout their lifespan 
(Sharpe and Irvine, 2004, Propper, 2005, Woodruff and Walker, 2008, Rahman et al., 
2009). Pharmaceutical and chemical companies continually produce novel 
compounds in the form of new drugs or environmental chemicals, which can in some 
cases interfere with the endocrine and/or reproductive systems (Rahman et al., 2009). 
Therefore rigorous reproductive toxicity testing of such pharmaceuticals has been set 
in place within the pharmaceutical industry.  
 
 
The thousands of new compounds produced by the pharmaceutical industries require 
extensive testing for pharmacological activity and toxicological effects. Potential 
toxic effects are assessed throughout the developmental process of a compound 
where histopathological assessments of ovaries is conducted prior to reproductive 
toxicity testing in the repeat toxicity studies (Fig. 3.1) In the pharmaceutical industry, 
currently, in vivo reproductive toxicology tests are carried out relatively late in the 
drug development process, during the phase II clinical trials and development phase 
of a drug. Reproductive toxicity must cover both fertility and pre-natal 
developmental effects. Furthermore, analysis into effects on sexual behaviour, 
oestrous cycling, spermatogenesis, fertilization and implantation must be taken into 


























Figure 3.1. Different phases of pharmaceutical drug development (USA) (adapted from 
Cortvrindt and Smitz, 2002). Safety testing is a continuous process that starts during the 
pre-clinical phase and ends with post-marketing surveillance. Reproductive toxicity tests are 
carried out during the clinical test phase.  
 
3.1.1 Regulatory toxicity testing of pharmaceuticals 
Most regulatory testing requirements within the pharmaceutical industry are 
controlled by the EMA (European Medical Agency), FDA (USA) and PMDA 
(Pharmaceuticals and Medical Devices Agency, Japan). The guidelines are laid out in 
the core tripartite harmonised guideline issued by the International Conference on 
Harmonised tripartite guideline for the detection of toxicity to reproduction for 
medicinal products and toxicity to male fertility:ICH S5 (R2) 1993 which provides 
guidance on tests for reproductive toxicity (ICH, 1993) (2000 addendum).  In 
addition, a second ICH M3 (R2) guideline for the non-clinical safety studies for the 





The ICH (R2) guideline contains a description of the testing concept and 
recommendations, especially those addressing pre-mating treatment duration and 
suggested observations to assess for reproductive toxicity (ICH, 1993) (2000 
addendum). The ICH guidelines define the periods of treatment to be used in animals 
to assess for reproductive risk: fertility, implantation through organogenesis to 
closure of the hard palate and the pre and post-natal period through to the end of 
lactation. This allows identification of specific toxicity at key stages of the 
reproductive cycle.  
 
3.1.2 Regulatory toxicity testing of agrochemicals 
Agrochemicals, such as crop protecting agents, wood preservatives and veterinary 
disinfectants can result in potential health risks for anyone exposed to such 
chemicals. The preclinical designs to assess effects of potential toxicants on the pre-
natal ovary however, differ somewhat between pharmaceutical compounds (see 
previous section) and agrochemicals. While pharmaceutical companies analyse 
effects on long-term outcome, such as pregnancy after exposure in utero, 
agrochemical testing also includes a more detailed qualitative and quantitative 
histological assessment of the primordial follicle pool following pre-natal exposure. 
This involves dosing female rats 2 weeks prior to ovulation, to examine immediate 
effects on ovulation and fertilisation. Although the fundamental study designs for 
agrochemicals and pharmaceuticals are fairly similar, studies still have to use 
different approaches, partly due to the fact that therapeutic levels of pharmaceutical 
exposure is well studied, with controlled therapeutic exposure, whereas 
environmental agrochemical exposure is more difficult to predict, given that we do 
not know their levels in the environment or the likely duration of their exposure. 
Furthermore, the type of reproductive toxicology studies used in academic research 
also differ considerably from regulatory research, with academic testing usually 
focusing more on mechanistic studies, whereas regulatory research tends to 
concentrate on assessing potential risk using qualitative morphological examination 





3.1.3 DNA gyrase inhibitors for antibiotic development 
In recent years, inhibitors of Type II topoisomerases such as DNA gyrases and 
topoisomerase IV have become widely used as targets by the pharmaceutical industry 
in the development of novel antibiotics (Alt et al., 2011). Since topoisomerases are 
essential for cell function (Section 1.4) they have become particularly attractive 
targets in the development of novel antibiotics, as bacterial topoisomerases can be 
inhibited and bacterial function repressed. This is particularly important in the fact of 
today's ever-increasing threat of bacterial antibiotic resistance, in particular 
pathogenic bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) 
(Tse-Dinh, 2007, Oblak et al., 2007, Srommenger et al., 2014). 
 
Preliminary investigation into the expression pattern of Topo IIα in the developing 
rat ovary demonstrated that its expression was confined to the germ cells in the pre-
natal ovary, but became localised to the surrounding granulosa and stromal cells a 
few days after birth, around the same time as follicles began to form (personal 
communication, Dr. N Powles-Glover, AstraZeneca).  
 
3.1.3.1 AZTC 
Various novel antibiotics have been under pharmaceutical development at 
AstraZeneca. These antibiotics include bacterial DNA gyrase (Topo II) inhibitors, 
many of which have known homologues in mammalian cells. Some Topo II 
inhibitors affect spermatogenesis in a manner that indicates an effect on meiosis 
(Kallio and Lähdetie, 1997, Russell et al., 1998, Russell et al., 2000). The work 
presented here outlines the in vivo effects of a Topo II inhibitor: AZTC (Section 
1.4.2.1). This compound was selected due to preliminary in vivo toxicity studies 
demonstrating testicular effects.  
 
The in vivo AZTC study was planned by AstraZeneca independently of this PhD 
studentship, with the initial in vivo studies carried out shortly after the start of my 
PhD (Fig. 3.2). AZTC was selected as a potentially good compound to use to 
compare in vitro studies with the in vivo ones that had already been carried out at 
AstraZeneca. I therefore obtained and analysed ovaries from PND5, PND15 and 
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adult (13+ week) females exposed to AZTC in utero, using material that was 













Figure. 3.2. A timeline of the in vivo AZTC study from the start (Sept 2010) to completion (Aug 2014) of the PhD. The initial safety study of 
AZTC was carried out in 2011, where female rats were dosed with AZTC and ovaries from PND5 and PND15 and adult F1 females were collected. 
The first visit to AZ was carried out during this time. The second AZ visit was in 2012 when ovaries from PND 5 and PND15 F1 females were cut, 





The aim of this work was to analyse the size and health of the ovarian follicle pool in 
female rats that had been exposed to AZTC in utero. This was done to investigate 
how AZTC might affect the developing ovaries, since exposure occurred during the 
time period covering PGC proliferation, germ cell nest breakdown and meiosis. 
 
3.3 Methods 
3.3.1 Study design 
All the in vivo work described here was carried out by AstraZeneca staff on site, 
prior to and during my first visit to AstraZeneca. The studies were designed by Dr. N 
Powles-Glover and Dr. Jane Stewart. The oestrous cycles of female Han Wistar rats 
were monitored for 14 consecutive days, prior to mating with proven males. They 
were paired 1:1 with unrelated males of the same strain. Day 0 post-coitum was 
selected when the first evidence of mating was observed, identified by a vaginal plug 
in situ or by the presence of sperm in a vaginal smear. This was also the first day of 
dosing for females. The males were only used for mating and were not dosed.  
 
Females were dosed either with the vehicle control or one of two selected 
concentrations of compound from Day 0 post-coitum until parturition, therefore 
covering the period from implantation, embryonic and fetal development, up-to 
parturition. The high dose had previously reported effects on spermatogenesis in 
male rats (personal communication, Dr. N Powles-Glover, AstraZeneca). The lower 
dose was selected to evaluate a dose response. The test formulation was made up in 
vehicle (consisting of water containing 0.5% w/v hydroxypropyl methylcellulose and 
0.1% w/v polysorbate 80). The dose volume was 10 ml/kg and individual dose 
volumes were based on recorded body weight of each animal. Females were dosed 
once every morning, by oral administration (gavage) (Appendix B, pg. 260).  
 
All females were dosed from the day of mating until parturition and were allowed to 
litter. Females received either the control vehicle, low dose or high dose. F1 female 
pups were collected on days 5 PP (only control and high dose) and 15 PP (control, 
low and high dose). The gonads were dissected from the body and mounted 
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individually in 3% agarose gels and immersed in fixative (10% buffered formalin). 
The remainder of the F1 generation were weaned and allowed to mature. Oestrus 
cycle monitoring was carried out on the females from the F1 generation from day 64 
post-partum. A proportion of the control F1 males were retained until sexually 
mature, and were subsequently mated with treated F1 females. The remaining 
sexually mature F1 males were euthanised. Finally, ovaries from 13+ week old un-
mated F1 females were also collected and fixed as above (control, low and high 
doses). Ovaries were processed and embedded in wax by AstraZeneca staff as 
outlined in Section 2.2.  
 
3.3.2 Histological assessment 
Following the in vivo study outlined above which was conducted by AstraZeneca 
staff, I carried out the histological analysis of the PND 5, 15 and 13+ ovaries. 
Ovaries to be analysed were sectioned at 5 µm and H&E stained (Sections 2.2.3-
2.2.4). Ovaries from PND 5, 15 and 13+ week old females were examined, with 
every 6th section from PND 5 ovaries, every 20th section from PND 15 ovaries and 
every 50th section from 13+ week old F1 females. Follicle numbers, distribution and 
health was analysed in PND 5 and 15 ovaries. The 13+ week ovaries were analysed 
only to ascertain primordial follicle numbers and health. Due to effects observed 
primarily in primordial follicles in PND 15 ovaries it was considered not possible to 
successfully analyse other follicle types at this age. Due to the large volume of the 
ovary and the numerous CL, counting other follicle types would have been difficult 























Figure 3.3. Study design for pre-natal in vivo exposure of AZTC. Pregnant females were dosed by oral administration with vehicle 
control, or compound at either a low or high concentration, once daily until parturition. Ovaries from F1 females were collected at PND 5, 




Table 3.1. Study design outlining pup numbers from which ovaries were collected, cut 
and analysed, relative to mothers and dosage groups. Only one ovary was collected for 
histological analysis from each pup. At PND 5, a total of 5 pups were collected from 3 
different mothers treated with control vehicle and 5 pups were collected from 2 mothers that 
had received treatment. At PND 15, 6 pups were collected from 4 different control mothers, 5 
pups were collected from 2 mothers that had received the low dose, and 5 pups were 
collected from only one mother that had received the high dose of AZTC. 
 
 Treatment Mother # Pup # 
PND 5 
Control 22 4 
23 1, 3 
28 2, 3 
High dose 45 2, 3, 5 
48  1, 2 
PND 15 
Control 1 1 
2 2, 4 
5 3, 4 
6 1 
Low dose 8 1, 2 
9 1, 2, 3 
High dose 14 1 
16 2, 3 
17 2, 3, 4, 5, 6 
13+ weeks 
Control  343, 344, 347, 349 
Low dose  366, 371, 375 
High dose  89, 90, 91, 92 
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3.3.3 Statistical analysis 
Graphpad Prism was used for all statistical analysis of follicle number and 
distribution between control and treated ovaries. For all studies involving more than 
one dose group, data normality was assessed using Kolmogorov Smirnoff tests. 
Where data was not normally distributed, the Kruskal-Wallis non-parametric test was 
used to analyse the data. This was followed by a Dunns post-hoc test if the Kruskal-
Wallis test showed a significant difference. Where the data was normally distributed, 
a one-way ANOVA was used to determine if there were any significant differences 
between treated and untreated ovaries. This was followed by the Bonferroni post-hoc 
test if the ANOVA showed a significant difference. Since the PND 5 study only had 
two treatment groups, a two-tailed unpaired t-test was carried out on the data 
obtained from follicle counts on PND 5 ovaries.  
 
3.4 Results 
3.4.1 PND 5 ovary analysis 
Ovaries from PND5 females exposed to vehicle control or the high dose of AZTC in 
utero were collected and every 20th section was analysed for follicle numbers, 
distribution and health (Sections 2.2.3, 2.2.4 and 2.3). Unfortunately, the majority of 
the ovary sections had histological problems whereby many of the ovaries (both 
control and treated) had poor follicle morphology and appeared striated. It was 
therefore difficult to assess health properly in these sections, as it was not possible to 
be certain whether some follicles were unhealthy or whether they had an abnormal 
appearance due to poor histology (Fig. 3.4).  
 
No effect of AZTC was observed on follicle numbers (Fig. 3.5i), distribution (Fig. 
3.5ii) or health (Fig 3.6i,ii) in ovaries from exposed females compared with in vivo 
(n=5 for both groups). Despite the poor histology, though, there did appear to be a 
slight, non-significant decrease in the number of unhealthy follicles in treated PND5 



















Figure 3.4. Representative photomicrographs of PND5 ovaries from control (A) and 
treated (B) females, where poor histological morphology made follicle 




















































































Figure 3.5. Total number (i) & distribution (ii) of follicles in PND5 ovaries following 
exposure to AZTC in utero. No effect on follicle numbers was observed in AZTC exposed 
PND 5 ovaries when compared with control ovaries (p=0.8271) (i). Similarly, no effect was 
observed on follicle distribution within exposed ovaries (p=0.9735) (ii). Bars denote mean + 





































































Figure 3.6. Distribution of unhealthy follicles within ovaries of AZTC treated PND5 
females. AZTC exposure had no significant effect on the number of unhealthy follicles within 
PND 5 ovaries, when compared with control ovaries (p=0.205) (i). Similarly, no significant 
difference was observed in follicle distributions between control and treated ovaries although 
there appeared to be a slight non-significant decrease in the number of unhealthy primordial 
(p=0.232) and transitional follicles (p=0.206) in exposed ovaries (ii). Bars denote mean + 

















































3.4.2 PND15 ovary analysis 
Ovaries from PND15 females exposed to low or high dose of AZTC in utero were 
collected and every 40th section was analysed. Follicles were counted, and follicle 
distribution and health was analysed (n=5 for all groups).  
 
There were pups born to two high dose mothers (#14 & 16, see Appendix B) that 
appeared to have severely affected ovaries (Fig. 3.7). However, due to uncertainty 
over their exact provenance, they were excluded from the study. I was restricted to 
the use of ovarian tissue provided by AstraZeneca, and as a result, only the ovaries 
from female pups born to the high dose mother #17 could be analysed for the high 
dose group. 
 
Pre-natal exposure of females to the high dose of AZTC resulted in a significant 
increase in the number of follicles per ovary when compared with low-dose ovaries 
and controls (Fig. 3.8). When the follicles were classified into their follicle types it 
became clear that rise in follicle number was due to an increased number of 
primordial follicles in pup ovaries in the high-dose group (Fig 3.9i). A significant 
increase in the number of unhealthy follicles in ovaries of females exposed to the 
high dose of AZTC was also observed (Fig. 3.10i). A dose-dependent non-significant 
trend was also observed with increasing number of healthy follicles within exposed 
ovaries with increasing AZTC concentration (Fig. 3.10ii). When the unhealthy 
follicles were classified into their follicle types a dose dependent increase in 
unhealthy primordial and transitional follicles was observed, reaching significance at 
the high dose when compared with controls and low-dose ovaries (Fig. 3.11i). A 
similar trend was observed when the percentage of unhealthy primordial follicles was 


















Fig 3.7. Representative photomicrographs of ovaries from females pups born to 
mothers 14 and 16. Ovary sections from PND 15 females born to females 14 (a), 16 (b) and 
17 (c). Ovaries from females born to females 14 and 16  lacked follicles and were therefore 

























































Figure 3.8. Mean follicle numbers in PND 15 ovaries from treated and control females. 
A significant increase in follicle numbers was observed in ovaries exposed to the high dose 
of AZTC when compared with control and low dose ovaries (p=0.0002). Bars denote mean + 
sem; n=6 for controls and n=5 for both treatment groups. Means with different letters are 
















































































Figure 3.9. Comparison of follicle distribution between control and treatment PND 15 
ovaries, presented as total numbers (i) and percentages of total follicles (ii). There was 
a significant increase in the number of primordial follicles in ovaries of females exposed to 
the high dose of AZTC (p=0.016) (i). There was no significant effect on the number of other 
follicle types in the exposed ovaries. No significant difference was observed in percentages 
of follicle types across treatment groups (ii). Bars denote mean + sem; n=6 for controls and 
n=5 for both treatment groups. Follicle types: PMF: primordial, TRNS: secondary, PRIM: 
Primary, SEC: secondary, PreA: Pre-Antral, EarlyA: Early-Antral, LateA: Late-Antral. Means 






































































































































































Figure 3.10. Total number of unhealthy (i) and healthy (ii) follicles within ovaries of 
PND15 females. Ovaries exposed to the high dose of AZTC had significantly more 
unhealthy follicles than did low dose and control ovaries (p=0.038) (i). A non-significant dose 
dependent trend was also observed, with a slight increase in the number of total healthy 
follicles observed with increasing AZTC dose (p=0.091) (ii). Bars denote mean + sem; n=5 
for  all groups. Means with different letters are significantly different (p<0.05).  
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Figure 3.11. Comparison of the distribution of unhealthy follicles between control and 
treatment PND 15 ovaries, presented as total numbers (i) and percentages of total 
follicles (ii). Ovaries exposed to the high dose of AZTC had a significantly higher number of 
unhealthy primordial (p=0.032) and transitional (p=0.0078) follicles than did control and low 
dose ovaries. No significant differences were observed in the percentages of unhealthy 
follicles across treatment groups. Bars denote mean + sem; n=6 for controls and n=5 for 
both treatment groups. Follicle types: PMF: primordial, TRNS: secondary, PRIM: Primary, 
SEC: secondary, PreA/EarlyA/LateA: Pre-, Early- and Late Antral. Means with different 












3.4.3 Primordial follicle numbers in AZTC exposed 13+ week old ovaries 
To investigate if the observed increase in total follicle numbers and unhealthy 
follicles in AZTC-exposed PND15 ovaries was still observed when the females 
reached adulthood, ovaries from 13+ week old females that had also been exposed in 
utero were analysed histologically for primordial follicle numbers and health. Every 
50th section was H&E stained and PMFs within these sections were counted and 
classified according to health. In this case, only PMFs were analysed, with all other 
follicle types excluded from the analysis. No significant effects of AZTC were 




























































Figure 3.12. Total number of PMFs in ovaries 13+ week old females exposed to AZTC 
in utero. No significant difference was observed between PMF numbers in control, low- or 






































































































Figure 3.13. Percentage of healthy (i) and unhealthy (ii) PMFs in ovaries 13+ week old 
females exposed to AZTC in utero. No difference in percentage of healthy or unhealthy 
(p=0.293) PMFs was observed between treatment groups. Bars denote mean + sem; n=4 for 






In this study, female rats were mated and exposed to AZTC daily from the day of 
conception until parturition. Ovaries from F1 female pups that had been exposed to 
AZTC in utero were collected at varying time points: PND 5, PND 15 and 13+ 
weeks pp. 
 
3.5.1 Effect of pre-natal in vivo AZTC exposure on ovarian follicles  
Histological analysis of the ovaries revealed that no effect of AZTC exposure was 
observed within ovaries at PND 5. By PND 15 however, ovaries exposed to the high 
dose of AZTC had increased follicle numbers when compared with low dose and 
control ovaries. When the follicles were classified into their follicle types it became 
clear that the rise in follicle number was due to an increased number of primordial 
follicles in ovaries of the high-dose group. This was a surprising result as inhibition 
of mammalian Topo II, if it is indeed occurring here, would be expected to inhibit 
proliferation of cells within the ovary, resulting in a reduction of follicle number, 
rather than an increase. The lack of any effect of AZTC within the 13+ week old 
ovaries suggests that either the effect of AZTC on PMF numbers did not persist and 
was corrected in later life, or that the effect might  have been there, but too small to 
identify. On the other hand, the possibility of the PND15 finding being due to a litter 
effect must also be considered, since all the female PND 15 pups in the high dose 
group came from the same female. This was clearly far from ideal, where a minimum 
of 3-4 females should be used to avoid the possibility of a potential litter effect. 
  
In the PND 5 ovaries, follicle health was difficult to analyse robustly due to poor 
histological preparation of the tissue. None-the-less, there was no evidence of PND 5 
ovaries being affected by AZTC exposure. Exposed ovaries did, in fact, appear 
slightly healthier than controls, but this was not significant. When the health of the 
PND 15 ovaries was analysed however, there was a significant increase in unhealthy 
follicles, in particular primordial and transitional follicles, within the ovaries exposed 
to the high dose of AZTC. It was noted that although a large proportion of the 
'surplus' follicles were unhealthy, there was also a slight but non-significant increase 
in the number of healthy follicles. The unhealthy follicles would have presumably 
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gone on to become atretic and die, possibly explaining the absence of an effect of 
treatment on follicle numbers  in the adult ovaries collected at 13+ weeks. The PND 
15 effect on ovary health could, however, also be a litter effect.  
 
Germ cell nest breakdown, which occurs during pre-natal ovary development, is 
usually accompanied by a large wave of oocyte atresia. It is possible that AZTC 
interfered with germ cell nest breakdown and resulted in the higher number of 
surviving oocytes observed here. Previous studies investigating the effects of 
compounds interfering with germ cell nest breakdown have frequently reported the 
presence of binuclear oocytes or MOFs within treated ovaries, which are therefore 
considered an expected result of disruption to germ cell nest breakdown (Kim et al., 
2009), although no such binuclear oocytes or MOFs were observed here. This 
suggests that AZTC might not have been interfering in germ cell nest breakdown, or 
if it was, might have been doing so by an alternate pathway. A more likely possibility 
is that AZTC inhibited apoptosis and resulted in more surviving oocytes forming 
follicles. Germ cell death during nest breakdown has been suggested to be a 'quality 
control' mechanism, where abnormal or lower quality germ cells are discarded. It is 
therefore possible that if some germ cells 'escaped' the wave of apoptosis due to the 
presence of AZTC, they ended up forming follicles of lesser quality, thereby 
becoming unhealthy.  
 
A possible explanation for the lack of observed effects of AZTC at PND 5 is that 
they might not have been apparent yet at this point. If AZTC did have an effect on 
germ cell development, it may not have become apparent until a week or two after 
birth. The PND 5 ovaries might also not have been counted as effectively as the PND 
15 ovaries, as many were striated and difficult to analyse. It is possible that the effect 
observed at PND 15 may have corrected itself by adulthood, with the unhealthy 
follicles becoming atretic and dying, consequently reducing the number of follicles 
in the ovary to a similar number to that observed in the control ovaries by adulthood. 
As outlined above, however, it should be borne in mind that all high dose female 
offspring come from the one mother. Given that, the effect of AZTC here could, 




Immunohistochemical analysis of ovary health would have been ideal within these 
ovaries to identify apoptotic cells within exposed ovary, as well as to further support 
the results obtained by histological examination. Immunohistochemical staining for 
Cleaved-Caspase 3 was attempted (Cell Signalling, 9661) but this proved 
unsuccessful with no staining showing up in the tissue, possibly due to the poor 
morphology, over-staining or due to the antibody. This was not taken further due to 
the worries that the tissue was simply not high enough quality for 
immunohistochemistry.  
 
AstraZeneca had also collected ovaries from earlier time-points, during embryonic 
development and at birth. Time allowing, it would have been interesting to 
investigate the observed effect on follicle numbers using immunohistochemistry for a 
germ cell marker such as VASA, Gdf9, Zp3 and Figla, or Figla, (Hu et al., 2012) on 
embryonic ovaries to examine germ cell numbers within the embryonic ovaries 
during AZTC exposure, prior to follicle formation. 
 
Finally, it would have been ideal to investigate the observed effects in the PND 15 
study further by repeating the study with more litters being born to different exposed 
mothers. Unfortunately, this was not possible. 
 
3.5.2 Mechanisms of action of AZTC 
AZTC inhibits bacterial topoisomerase, which is believed to have mammalian 
homologues. Topoisomerases serve various functions in mammalian cells, being 
involved in both mitotic and meiotic divisions. As outlined above (Section 3.5.1), it 
is possible that AZTC was likely to inhibit mammalian topoisomerase, and therefore 
the expected outcome had been a reduction in oocyte numbers due to a potential 
effect on PGC proliferation or meiosis. No direct effect on somatic cells was 
expected as the exposure window in this study coincided with the period when Topo 
II is expressed in germ cells only. It was believed that if Topo II was inhibited within 
the ovarian germ cells, mitotic divisions were likely to become altered during PGC 
proliferation and fewer of the germ cells invading the ovaries during embryonic 
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development would be capable of dividing and increase germ cell number in the 
ovaries. Surprisingly, the opposite effect was observed here, with AZTC instead 
resulting in an increase in primordial follicle numbers. It is therefore possible that 
AZTC might not be inhibiting Topo II in mammalian cells, but is instead having a 
secondary or off-target effect resulting in the observed increase in primordial follicle 
numbers, although this would require further investigation. 
 
Unfortunately, the effects of AZTC on meiosis in vivo could not be determined. 
From histological analysis, the large majority of oocytes appeared to be in dictyate, 
but in order to fully investigate if AZTC was affecting meiosis in the pre-natal ovary, 
other tests would need to be carried out. Chromosome spreads on oocytes following 
pre-natal in vivo exposure, where the synaptonemal complex and pairing of the 
homologus chromosomes is visualised would be an interesting study to carry out. 
Other methods that could have potentially been carried out also involve 
immunhistochemistry to visualise meiotic markers such as Sycp3, Stra8 (Hu et al., 
2012) or diplotene markers Msy2 (Gu et al., 1998), PAR6 (Wen et al., 2009) or 
TRP63 (Suh et al., 2006, Myers et al., 2014).  
 
3.6 Conclusions 
An increase in follicle numbers and unhealthy follicles was observed within ovaries 
of 15 day old females exposed pre-natally to the high dose of AZTC in vivo. This 
was not consistent with effects observed in exposed ovaries when collected at earlier 
(PND5) or later (13+ weeks) time points. It is possible that the effect is solely due to 
a litter-effect in the one mother that gave rise to all female whose ovaries were 
examined at PND15. The results observed were also inconsistent with the expected 
effects of Topo II inhibition, indicating that AZTC might be having a secondary or 














The development of an embryonic mouse 







The pre-natal period of mammalian ovary development is a sensitive, yet crucial one, 
as it is during embryonic development that primordial germ cells migrate to the 
developing ovary, undergo a phase of rapid cell proliferation, enter prophase I of 
meiosis up-to dictyate, followed by a breakdown of germ cell nests and in some 
species, primordial follicle formation. The size of the primordial follicle pool in the 
newborn ovary determines, in part, the female's reproductive lifespan (Schindler et 
al., 2010). Follicle development is dependent on the establishment of an appropriate 
communication pathway between the oocyte and the surrounding granulosa cells 
through gap junctions, tranzonal projections, as well as via paracrine and endocrine 
signals (Sections 1.1.1.4 & 1.1.2.2). Despite this, relatively little is known about the 
factors and mechanisms that regulate early germ cell development, the establishment 
of the primordial follicle pool and the initiation of follicle growth.  
 
Various culture techniques have been developed to investigate early gonadal 
development in mouse (Adams and McLaren, 2002, Zhang et al., 2012, Buehr et al., 
1993), hamster (Yu and Roy, 1999) and in the human (Brieno-Enriquez et al., 2010, 
Childs et al., 2010, Angenard et al., 2011a, Farhi et al., 2011, Hartshorne et al., 
1999). Ovary culture can be a useful tool to investigate not only the factors and 
processes of early ovary development, but also the effects of potential reproductive 
toxicants on the ovary. However, to the best of my knowledge, the large majority of 
reproductive toxicity studies that have been carried out in vitro have examined 
effects on the post-natal ovary. This is possibly due to the fact that post-natal ovary 
and pre-antral follicle culture systems are more widely used and are fairly robust, but 
it also highlights the lack of an adequate embryonic ovary culture system for use in 
reproductive toxicology. 
 
Within the pharmaceutical industry, the majority of pre-clinical reproductive toxicity 
studies carried out to investigate the effects of pharmaceutical compounds on the pre-
natal ovary consist of assessing fetuses exposed to a compound in utero. Although 
this detects any immediate drastic reproductive effects associated with dysgenesis of 
the reproductive system, such as underdeveloped or dysfunctional ovaries and/or 
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reproductive tract, it does not pick up on subtle effects that the compound may have 
on the size of primordial follicle pool. Any compound that reduces the size of the 
primordial follicle pool could potentially shorten the reproductive life-span of the 
female. However, this would not be detected until much later, after the majority of 
time-points usually examined within the pharmaceutical industry. Since a woman's 
reproductive life-span is considerably longer than that of a rodent, it is crucial that a 
compound which can result in a premature exhaustion of the primordial follicle pool 
is discovered, as this could result in premature ovarian insufficiency (POI), defined 
by amenorrhea before the age of 40 (De Vos et al., 2010). The ability to demonstrate 
an effect of a compound on the pre-natal ovary, and compare these with effects to the 
neonatal or adult ovary, is therefore of novel and general interest to the reproductive 
toxicology community.  
 
4.1.1. Current available embryonic ovary culture systems 
The majority of available culture systems involve the post-natal ovary and germ cells 
that have already entered meiotic arrest. The fetal stage of reproductive development 
is a crucial and sensitive period, as it includes the migration of germline stem cells, 
and their proliferation, as well as entry into the first meiotic division. Pre-meiotic 
germ cells, not enclosed in follicles, may well be directly responsive to chemicals, 
making fetal development a particularly vulnerable period (Anderson et al., 2014). A 
culture system whereby embryonic mouse ovaries, containing oogonia undergoing 
the first meiotic division, can be cultured intact would have the potential to provide 
an important contribution to the field of reproductive biology and toxicology, 
particularly as aneuploidy predominantly occurs during the first meiotic division of 
oocytes (Eichenlaub-Ritter, 1996, Eichenlaub-Ritter, 1998, Plachot, 2001).  
 
As outlined previously (Section 1.3.1), any factors affecting embryonic ovary 
development can be examined in vitro using an embryonic organ culture. This allows 
for the examination of the mechanisms underlying prophase I of meiosis up-to 
dictyate, germ cell nest breakdown, and follicle formation. In the mouse, the gonadal 
ridge can first be identified in E10.5 mouse embryos as a narrow strip of tissue on the 
urogenital ridges. From around E12.5 onwards, gonads can be sexed simply by 
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inspection, but if collected prior to this stage the embryo tissue must be collected and 
sexed by PCR. Various different embryonic culture systems have been set up over 
the past two decades with the aim of investigating the mechanisms of early ovary 
development. McLaren and Buehr (1990) developed one of the earliest embryonic 
ovary culture techniques, using intact organ culture system or ovary fragments from 
E10.5-12.5 gonadal ridges (McLaren and Buehr, 1990). Histological analysis 
demonstrated the appearance of some growing oocytes, classified as dictyate by the 
authors on the basis of histological examination. However the authors state that 
follicles did form but photomicrographs provided shown in the paper do not show 
this. Furthermore, the ovarian capsule was not well maintained, with germ cells 
protruding into the surrounding medium.  This technique was then modified and used 
to examine the mesonephric contribution to testis development (Buehr et al., 1993), 
to examine the regression of the Mullerian duct (Donahoe et al., 1977), and again to 
investigate the mechanisms of sex determination in the indifferent gonad (Adams and 
McLaren, 2002). Dong et al. (2009) used a similar system and cultured ovaries from 
E12.5 which differentiated into germinal vesicle-stage oocytes, although they were 
unable to complete meiosis I (Dong et al., 2009).  
 
There has been relatively little success in culturing pre-meiotic ovaries through both 
meiotic divisions to produce mature oocytes, other than through the use of invasive 
techniques such as nuclear transfer (Obata et al., 2002). There is, however, one 
recent study which has shown that pre-meiotic germ cells from mice can be cultured 
right through to the metaphase MII stage, undergo fertilisation and form 2-cell 
embryos. This was achieved by firstly culturing pieces of E12.5 mouse ovaries for 28 
days in Activin-A supplemented medium, followed by isolation of oocytes within the 
tissue explants which were co-cultured with preantral granulosa cell monolayers for a 
further 6-7 days, and finally a maturation assay for 16-18h at the end of culture 
(Zhang et al., 2012).  
 
Establishing a culture system whereby mouse ovaries can be cultured from a pre-
meiotic stage to a mature, fertilizable oocyte and yield live pups, has proved 
challenging. A few studies have been somewhat successful, although the majority 
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involved either transplantation of the cultured ovary to the renal capsule of mice 
(Shen et al., 2006, Motohashi et al., 2009) or required a nuclear transfer into 
enucleated, fully grown oocytes from adult mice (Obata et al., 2002). 
 
4.1.2. Embryonic ovary culture in reproductive toxicology 
Out of the already relatively small number of embryonic and fetal ovary cultures that 
have been established, very few of these have been used to investigate potential 
reproductive toxicants on the developing ovary. The ones that have been carried out 
examined the effects of pre-natal mouse ovary exposure to 7,12-
Dimethylbenz(a)anthracene (DMBA), a polycyclic aromatic hydrocarbon (PAH) 
found in cigarette smoke (Matikainen et al., 2002) and Bisphenol A (BPA) (Brieno-
Enriquez et al., 2012), uranium (Angenard et al., 2011b), or human fetal ovary 
exposure to tamoxifen (Yu et al., 2014). In contrast, there are a vast number of 
studies that have investigated potential reproductive toxicants on the post-natal ovary 
in vitro, looking at effects of compounds such as cyclophosphamide, doxorubicin 
(DXR), BPA and Diethylstylbestrol (DES) (Iguchi et al., 1990, Xu et al., 2002, 
Devine et al., 2004, Miller et al., 2005, Desmeules and Devine, 2006, Myllymaki et 
al., 2005, Chen et al., 2007, Craig et al., 2010, Soleimani et al., 2011). It is therefore 
clear that post-natal ovary and follicle cultures have already made a useful and 
powerful contribution to the field of reproductive toxicology testing. However, the 
pre-natal phase of development includes the period of meiotic entry and early 
prophase I, which is a particularly vulnerable time in oocyte development. This has 
been repeatedly demonstrated during spermatogenesis in males, where different 
reproductive toxicants often result in chromosomal aberrations during prophase I of 
meiosis (Kuriyama et al., 2005, Marchetti et al., 2006, Geoffroy-Siraudin et al., 2010, 
Geoffroy-Siraudin et al., 2012, Liu et al., 2013). Furthermore, in females, the period 
of germ cell nest breakdown and formation of the primordial follicle pool is 
vulnerable to perturbations, which could have dire consequences for future fertility. 
It is therefore surprising that more efforts have not already been made to develop 
embryonic ovary culture systems to be used as an efficient and quick way to screen 
potential reproductive toxicants on the developing ovary. The lack of alternative test 
systems to supplement in vivo studies has frequently been commented on (Davila et 
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al., 1998, Jackson, 1998, Cortvrindt and Smitz, 2002). This has led to an increased 
demand for an adequate in vitro pre-natal ovary culture model that could be used to 
gain insight into the mechanisms of chemical exposure and to pinpoint potentially 
hazardous products on reproductive function, in a highly controlled manner. 
 
4.1.3 The role of the synaptonemal complex in prophase I of meiosis. 
As outlined in Section 1.1.1.2., meiosis is the specialised cell division that reduces 
the chromosome content of cells, to generate a haploid gamete containing one copy 
of each chromosome. Prophase I of meiosis, up to the point at which the oocytes 
arrest at dictyate, occurs during mammalian embryonic development. Homologous 
chromosomes start to pair up during the leptotene stage of prophase I, by finding 
their homologues and aligning their axes. The chromosomes require a proteinaceous 
structure, the synaptonemal complex (SC), in order to synapse. The SC becomes 
incorporated between the homologous chromosomes between leptotene and 
zygotene, and brings their axes together (Zickler, 2006). The SC is composed of 
three elements, the axial (SYCP2 and SYCP3), transversal (SYCP1) and central 
elements (SYCE1, SYCE2 and TEX12) (Fig. 4.1) (Baillet and Mandon-Pepin, 2012). 
Recombinase proteins DMC1 and RAD51 interact with the axial elements and assist 
in the recognition between the homologous chromosomes, facilitating their synapsis 
(Tarsounas et al., 1999). The SC forms by incorporating the transverse element into 
the SC as it forms a connection between the axial elements, thereby 'zipping' up the 
homologous chromosomes (Ollinger et al., 2010). By pachytene, the SC is fully 
formed along the chromosomes, resulting in full synapsis. The SC then begins to 
break down, and the germ cells arrest at the diplotene stage of prophase I. 
 
SC assembly is commonly used to investigate chromosome behaviour and monitor 
the progression of prophase I in early oocytes. In the mouse embryo, SYCP3 
expression is absent at E12.5, but appears in over 80% of female germ cells by 
E13.5. Mouse germ cells are therefore in pre-meiotic stage at E12.5 and enter 















Figure 4.1. Graphic representation of SC formation and breakdown during prophase I of meiosis. The SC is composed of three elements, the 
axial, transversal and central elements. The axial element consists of SYCP2 and SYCP3 proteins, the transverse one consists of SYCP1 protein, 



















4.1.4. Role of mesonephros in early ovary development 
The indifferent mouse gonad develops along the inner surface of a rudimentary 
nephric organ, the mesonephros, during early embryonic development. In the male, 
the mesonephros eventually develops into the testicular efferent ducts whereas in the 
female embryo, it undergoes complete atrophy and regresses. During embryonic 
development, as the gonads differentiate into testes in males, the mesonephric duct 
becomes the Wolffian duct. The Wolffian duct contributes to the rete testes in the 
male, as well as the rete ovarii in the female. It has been suggested that cells from the 
mesonephros migrate to the gonad and contribute to the somatic environment during 
gonadal differentiation (Upadhyay et al., 1979, Wartenberg, 1981, Upadhyay et al., 
1981). During testes development, interstitial cells derived from the mesonephros 
have been shown to be crucial for normal testis cord differentiation (Buehr et al., 
1993). In the female, the mesonephros has also been suggested to be the source of 
somatic cells that invade the ovary and contribute to the ovarian interstitial and pre-
granulosa cell populations, until the mesonephros eventually becomes invaded by a 
septum of connective tissue, separating it from the ovary (Upadhyay et al., 1979).  
Furthermore, the mesonephros has been shown to play a role in meiotic initiation of 
the mouse ovary by producing RA, a meiosis-inducing factor which diffuses to the 
ovary and induces the germ cells to enter meiosis (Bowles and Koopman, 2007b) 
(Section 1.1.1.2). 
 
4.1.5 Growth factors involved in early ovary development 
During embryonic development, the gonadal ridges release various soluble growth 
factors that influence PGC proliferation and survival (Godin et al., 1990). Leukemia 
inhibitory factor (LIF) and SCF (also known as KL) are commonly used factors in 
tissue culture media and stem cell media.  LIF is a glycoprotein used primarily in 
stem cell cultures to suppress spontaneous differentiation of the cells, thereby 
maintaining stem cells in a long-term pluripotent state. It does, however, also have 
anti-apoptotic effects on PGCs in ovary culture (Pesce et al., 1993). SCF, amongst 
other factors, is implicated during embryonic development in promoting PGC 
survival and proliferation, as well as PGC migration toward the developing ovary (de 
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Felici, 2000). Furthermore, it promotes the initiation of primordial follicle growth 
(Durlinger et al., 2002) and plays a crucial role in primordial germ cell survival. 
 
4.2 Aims 
The aim of this work was to bridge, adapt and improve existing culture methods to 
generate a culture system that would span meiotic entry to meiotic arrest, germ cell 
nest break-down, follicle formation and initiation of follicle growth.  
 
4.3 Materials and Methods 
4.3.1 Method development of the embryonic mouse ovary culture 
The initial culture was learned and adapted from a culture technique previously 
established by Dr. Ian Adams & Dr. Anne McLaren (Adams and McLaren, 2002). 
This culture system had been used to examine sex determination of the bipotential 




CD-1 mouse breeding harems were set up in a cage (2 females with each proven 
male) and maintained on a 12:12h light/dark cycle. Females were checked the 
following morning from the presence of a copulation plug, which was designated as 
0.5 dpc. E12.5 or E13.5 mice were obtained from pregnant CD-1 females and ovaries 
dissected as described below (Section 4.3.5). 
 
4.3.3 Preparation of culture plate and agar block 
2% agar (Sigma, A1296) was prepared in 1xPBS in a duran bottle and autoclaved 
before use. In a laminar flow hood the agar was poured into 10 cm petri dishes and 
allowed to set in the flow hood. Once set, the moulded agar was cut into equal 1cm x 
1cm square blocks using a sterilised razor blade. The remaining agar was discarded. 






4.3.4 Preparation of the rich PGC medium (Rich medium) 
The medium used was Dulbecco’s Minimal Essential Medium (DMEM) (Life 
technologies, 41965039), supplemented with 10% Fetal Calf Serum (Thermo Fisher, 
SV30143/SV3060), 1% 200 mM L-glutamine (Invitrogen, 25030024), 0.2% 50 mM 
β-mercaptoethanol (Life technologies, 31350), 1% sodium pyruvate (Sigma, S8636), 
1% 100 x penicillin/streptomycin (Invitrogen, 15140-122) and 1% of amphotericin B 
(Sigma, A9528) diluted to a stock solution of 2.5 mg/ml into DMSO (Sigma, 
D2650). This medium will from this point onwards be referred to as the rich 
medium. The medium was aliquotted into a 33mm petri dish containing an agar cube 
(See Section 4.3.3), ensuring the agar cube was well covered by medium, and was 
first left to incubate in the culture dish for 30 minutes at 37°C, allowing the medium 
to penetrate the block fully. The medium was then removed, replaced with fresh 
medium and left to equilibrate for another 30 minutes before ovaries were placed on 
the block. 
 
4.3.5 Isolation of ovaries from mouse embryos 
Pregnant females were collected and culled by cervical dislocation. The uterus was 
removed from the mother and placed in a petri dish containing 1xPBS at 4°C. An 
incision was made along the uterus to release the embryos, which were then 
dissected out of their gestational sacs and decapitated. Embryos were placed in a new 
petri dish containing fresh 1xPBS at 4°C and kept on ice. The remainder of the 
dissection was carried out under a microscope at 20-30x magnification. Since the 
stage of gestation was critical, embryos were staged by examining the shape of the 
hind limb bud (Fig. 4.2). A small ventral incision was made in the embryo, and the 
lungs, heart, bowel and liver were removed out of the peritoneal cavity. This left 
clearly visible the mesonephros (Mullerian and Wollfian ducts) and the attached 
genital ridges. At this embryonic stage, it is possible to distinguish the females from 
the males by visual examination, as the testis can be identified by a characteristic 
circuitous capsular vessel that will become the testicular artery, and by its transverse 
sex cords that will become the seminiferous tubules. The ovary on the other hand, is 
longer and thinner and lacks any of the vessels or cords visible in the male gonad. 
Female gonads, including the mesonephros, were dissected from each side and 
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placed in a fresh dish of 1xPBS. Unless stated otherwise, the mesonephros was 
removed using sterilised syringe needles. The ovaries were picked up using a 200 µl 
pipette and placed in the culture medium to be rinsed, ensuring that minimal PBS 
was transferred along with the ovary. The ovary was then placed on top of the agar 
block and the level of media was adjusted so that the media was at the same level as 
the top of the agar block. Too much media caused the ovary to float off the block, 
whereas too little resulted in the ovary drying out. Therefore the ovary needed to be 
cultured at the ideal level of media to ensure optimal media/air interface. All 










4.3.6. Method development 
In order to improve and optimise the basic culture system described above, various 
different refinements were tried in order to support the germ cells in the embryonic 
ovaries from a pre-meiotic stage up to follicle formation and initiation of follicle 
growth. The different steps taken to optimise the culture system are outlined below.  
 
4.3.6.1. Starting material for culture 
Initial experiments included ovaries from both E12.5 and E13.5 mouse embryos, to 
determine the optimal starting point for the embryonic ovary culture. E12.5 ovaries 
were cultured for 6 or 12 days and E13.5 ovaries for 5, 6 or 11 days. It was 










      Figure 4.2. Limb bud stages used to measure gestational age of mouse      
     embryos.  
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time of birth in vivo, or around E18.5-E19.5. The longer 11-12 day cultures were also 
carried out, in order to investigate if the culture system would support follicle 
growth. 200 µl of fresh media was added to the culture every other day, and the 
media was completely replaced with fresh media after 6 days of culture. Embryos 
younger than E12.5 were not used since the gonads cannot be sexed by visual 
examination alone at this point. On the other hand, E14.5 and older embryos were 
not selected due to meiotic entry of oocytes at E13.5, since the culture starting point 
should, ideally, begin prior to meiotic entry of oogonia.  
 
4.3.6.2. Hanging droplet and membrane culture 
A hanging droplet culture was also attempted alongside the initial agar cultures, to 
investigate if the hanging droplet culture might show signs of being a more 
promising technique to culture embryonic gonads in small volumes. To set up a 
hanging droplet culture, a 96 well plate was used and 25 µl of rich medium (Section 
4.3.4) was added to the lid above one of the wells. Dissected E12.5 ovaries were 
washed in 1xPBS and transferred into the droplets of media using sterilised 
dissection forceps to minimise transfer of PBS into the droplet. ddH2O was added to 
any wells that did not contain an ovary, to avoid the droplets drying out. The lid was 
then carefully rotated and placed on top of the culture plate so that the ovaries and 
droplets hung from the lid above the culture well. E12.5 ovaries were also cultured 
for 6 days on a floating membrane in a 24 well plate containing 1 ml of rich medium, 
with half the medium replaced every other day.  
 
4.3.6.3. Bridging of embryonic ovary culture & neonatal ovary culture 
The embryonic gonad culture medium contains various growth factors that are 
essential for early oogonial development, but not required for later follicle growth. In 
order to test whether this rich medium was detrimental to later stages, a new system 
was tried, bridging the embryonic ovary culture with the neonatal culture system that 
was already established in the Spears lab, and using two different media (Sections 
2.1.2 & 4.3.4). E13.5 ovaries were initially cultured for 6 days in the rich embryonic 
gonadal culture medium, and were then transported using a 200 µl pipette onto a 
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membrane in a well containing the simple (neonatal) culture medium for a further 6 
days. 
 
In a later experiment, ovaries were kept on the agar block for the full 12 days but the 
rich medium was replaced with the simple medium at earlier time-points, as it was 
hypothesised that 6 days of exposure to the rich culture medium was potentially still 
too long, hindering associations between the oocyte and granulosa cells and 
inhibiting appropriate follicle formation and/or follicle growth. The methodology 
steps are outlined in Figure 4.3.  
 
4.3.6.4. Importance of β-mercaptoethanol for embryonic ovary health in vitro 
β-mercaptoethanol is a widely used reducing agent in cell culture medium as it 
prevents the levels of oxygen radicals from rising to a toxic level. In order to 
establish whether β-mercaptoethanol was required for the early stages of embryonic 
ovary culture, 12 day cultures were set up as described above, with and without 






















Figure 4.3. Bridging and developing the embryonic ovary culture system.  Diagram 
outlining the different approaches taken to optimising the embryonic ovary culture system, 
using E12.5 and/or E13.5 ovaries. These include the hanging droplet culture (a), 6 day 
membrane culture with PGC media (b), 6 day agar culture with PGC media, with or without 
βmercaptoethanol (c), 12 day culture with PGC media (d), 12 day culture where ovaries are 
transferred from PGC medium over to the P0 membrane culture system after 6 days in 
culture (e) and a 12 day culture system where ovaries are left on the agar for the whole 12 






Rich medium Simple medium















 Days in culture: 0                       6                                  12 
Ovary stage:    E13.5                                'P0'                                       'P4' 
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4.3.6.5. Inclusion of mesonephros during culture 
The mesonephros was originally dissected away from the embryonic ovary, as it 
regresses naturally around E16.5 in vivo (Upadhyay et al., 1979). However, due to its 
role in providing somatic cells to the developing ovary, later cultures were also set up 
where the mesonephros was not removed from the ovary prior to culture. The ovaries 
were cultured as outlined previously (Section 4.3.3-4.3.5) for 12 days on a 2% agar 
block where the rich medium was replaced by the simple medium at day 3 of culture. 
Cultured ovaries with the mesonephros removed and P4 un-cultured ovaries were 
used as controls.   
 
4.3.6.6. Inclusion of serum second-half of culture period 
Absence of serum from the culture medium of small pre-antral follicles has 
previously been reported to increase follicular apoptosis (Murray et al., 2001). 
Furthermore, unpublished observations from the Spears laboratory involving co-
cultures between neonatal mouse ovaries and individual pre-antral follicles, 
(requiring 5% mouse serum in the culture medium) resulted in what appeared to be a 
slight increase in the number of in secondary follicles within the cultured neonatal 
ovaries (unpublished observation, Lisa Campbell, Federica Lopez & Norah Spears). 
Serum was therefore considered as a potentially good way to improve the culture 
system. Given that, the effect of adding serum to the culture medium was 
investigated to see if it could produce healthier primary follicles and potentially 
result in secondary follicle formation. E13.5 mouse ovaries were cultured for 3 days 
in the rich medium, 3 days in the simple medium, and finally a further 6 days in 
simple medium supplemented with 5% mouse serum (cultured on an agar block for 
the whole 12 days of culture).  
 
4.3.6.7. LIF and SCF 
SCF is frequently included in ovary culture due to its role in follicle initiation and 
maintenance of primordial follicle health (Farini et al., 2007). LIF is another 
commonly used factor in stem cell media for maintaining cells in a pluripotent state 
but is also an important factor for primordial germ cell survival and proliferation 
(Pesce et al., 1993). However, due to the inclusion of FBS in the medium which 
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already contains a variety of growth factors, these factors were not added to the 
embryonic ovary culture at this stage. 
 
4.3.6.8. In vivo tissue collected for controls. 
Ovaries from embryonic mice at E17.5, E18.5 and pups at P0 and P4 were collected 
to be examined alongside the cultured ovaries for an in vivo comparison in order to 
give a rough idea of the developmental stage of cultured ovaries.  
 
4.3.6.9 Histology 
Ovaries were fixed, processed, sectioned and H&E stained as outlined previously 
(See Section 2.2). Ovary and follicle morphology and health was then analysed 
histologically (See Section 2.3). 
 
4.3.7 Histological analysis and follicle counts of E13.5 cultured ovaries (+/- 
mesonephros) compared with P4 in vivo ovaries  
E13.5 ovaries were cultured with and without the mesonephros on an agar block for 
12 days (3 days complex medium, 9 days simple medium). In vivo ovaries from P4 
pups were collected for controls. Ovaries were fixed in formalin, washed in 70% 
ethanol, embedded in agar, processed, embedded, cut and H&E stained as described 
in Section 2.2. Every 6
th
 section from each ovary was photographed at x20 
magnification. Follicles were counted blind and categorised as outlined in section 
2.3.  
 
4.3.8 Ability of cultured germ cells to progress through prophase I of meiosis.  
Oocyte spreads were carried out on cultured E13.5 ovaries in order to investigate 
whether the germ cells within these cultured ovaries were capable of progressing 
through prophase I up-to the pachytene stage of meiosis I.  
 
4.3.8.1. Sucrose solution 
8.56g of sucrose were added to 50 ml of dH2O. It was then aliquoted and frozen at -





4.3.8.2. Hypotonic Extraction Buffer  
The hypotonic extraction buffer was made by adding 3 ml 1 mM Tris, 10 ml 500 mM 
sucrose, 1 ml 0.5M EDTA and 0.5g sodium citrate to 100 ml dH2O. The pH was then 
adjusted to 8.2, 10 ml aliquots were made and stored at -20˚C until use. Immediately 
before use, 5 µl 1M DDT and 50 µl PMSF were added to the 10 ml aliquot.  
 
4.3.8.3. Paraformaldehyde fixative 
A stock of 10% PFA was made by dissolving it in dH2O with a couple of drops of 
5M NaOH at 60˚C in a water bath. 1.5 ml 10 % Triton-X (Sigma, TT9284) was 
added for every 100 ml of PFA fix and pH was set to 9.2 using drops of 10mM Boric 
Acid.  
 
4.3.8.4. Oocyte spread procedure 
E13.5 ovaries were collected and cultured for 6 days on an agar block as outlined 
previously (Sections 4.3.3-4.3.5). Meanwhile, glass slides were boiled and left 
soaking in 1% PFA in a coplin jar before use. Following culture, ovaries were moved 
to M2 medium (Sigma, M7167) at 4˚C and kept on ice for up-to 30 minutes, while 
being transported. They were washed in 1xPBS at 4˚C and transferred into a 
hypotonic extraction buffer for 15-30 minutes. 10 µl of the 500 mM sucrose solution 
was placed on a glass slide along with one ovary from the PBS wash, and the ovary 
was pierced with a needle for approximately 5 minutes. Around 10 µl of this solution 
(now also containing a suspension of cells from the ovary) was picked up and 
dropped in the top corner of a slide that had been removed from the fixative, with its 
edges having been wiped with a tissue. The drop was then 'zig-zagged' down the 
fixative-coated slide so that the suspended cells spread out over the slide. The slide 
was placed in a humid chamber with hot tap water and left over-night at room 
temperature. The next morning, the lid on the humid chamber was opened and slides 
allowed to air dry for 1-2 hours. Once dry, slides were placed into a coplin jar 
containing 1XPBS at 4 ˚C for immunostaining.  
 
4.3.8.5. Sycp1 and Sycp3 immunostaining 
A blocking solution was made by adding 100 µl of 1.5%BSA (0.15g BSA in 10 ml 
1xPBS), 10 µl 10% Tween and 50 µl goat serum into 840 µl 1xPBS. Slides were 
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washed in 1xPBS for 5 minutes and placed in a humid chamber. 50 µl of the block 
was added to each slide, a plastic cover-slip was placed on top and left for 1 hour at 
room temperature. The plastic cover-slip was then removed, the block was drained 
off and the primary antibodies were diluted in the block. The primary antibodies used 
were Sycp1 (ab15090-100, Abcam) and Sycp3 (sc-74569, Santa Cruz), both diluted 
1:200 in the blocking solution. 50 µl per slide of the primary antibodies were added 
to the slide, a new plastic cover-slip was placed on top and the slides were incubated 
in the humid chamber for a further 2 hours at room temperature. Following 
incubation, the slides were washed 3x5 minutes in 1xPBS.  The secondary 
antibodies, Anti-Rabbit Fluor 488 (A-11008, Invitrogen) and Anti-Mouse Alexa 
Fluor 594 (A-11005, Invitrogen) as well as DAPI were all diluted in block (1:500), 
adding a cover-slip and incubated in the dark at room temperature for 1 hour. Slides 
were washed for 3x5 minutes in PBS before 2 drops of PD mountant was added and 
left at room temperature for 10-30 minutes, before Vectashield soft-mount was 
added. A glass cover was carefully placed on top and once dry, the slides were then 
sealed with nail varnish and stored at 4˚C until visualised. 
 
4.3.8.6. Visualision of immunofluorescence.  
The immunofluorescence was visualised with an imaging system comprising of a 
Hamamatsu Orca AG CCD camera (Hamamatsu Photonics (UK) Ltd), Zeiss 
Axioplan II fluorescence microscope with Plan-Neofluor or Plan apochromat 
objectives, a lumen 200W metal halide light source (Prior Scientific Instruments, 
Cambridge, UK) and Chroma #89014ET single excitation and emission filters or 
Chroma #89000ET single excitation and emission filters (Chroma Technology Corp., 
Rockingham, VT). A piezoelectrically driven objective mount (PIFOC model P-721, 
Physik Instrumente GmbH & Co, Karlsruhe) was used to control the movement in 
the z dimension. Volocity (Perkinelmer Inc, Waltham, MA) was used to perform 
hardware control as well as to capturing and analyse images. The images were 
deconvolved using a calculated PSF (point spread function) with the constrained 
iterative algorithm of Volocity (Perkinelmer Inc, Waltham, MA) and a single 2D 






Figure 4.4. Representative nuclei for each stage of early 
prophase. At leptotene, chromosomes condense and very little 
synapsis is observed By zygotene, synapsis begins to be visible 
although it is incomplete. At pachytene, full synapsis between 
homologous chromosomes occurs.   
4.3.8.7. Analysis of pachytene nuclei frequency 
Slides were carefully scanned and any nuclei in leptotene, zygotene or pachytene 
were imaged. Nuclei in any of these three stages of prophase will appear differently 
to other non-meiotic cells (or cells in pachytene) since the immunofluorescence 
detects the SC, which is not present during mitosis and has partly broken down by 
the diplotene stage. The nuclei were then analysed and categorised according to their 












4.3.9 Biotin tracer study 
In order to visualise and analyse follicle architecture and basement membrane 
formation in the cultured embryonic ovaries, permeability of the ovaries was 
assessed by using a biotin tracer study. This study was adapted and modified from 
previous studies that had aimed to examine the integrity of the blood-testis barrier 
and the presence of functional TJs in the ovary, in which the authors had injected 
and/or cultured gonads with a biotin tracer (Mora et al., 2012, Elkin et al., 2010).  
 
4.3.9.1 Ovary culture with biotin tracer 
E13.5 and P0 ovaries were collected and cultured for 12 and 6 days respectively (for 
embryonic ovary culture, see Sections 4.3.3-4.3.5, for P0 ovary culture, see Section 
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2.1.) EZ-Link-Sulfo-NHS-LC-Biotin (Thermo Scientific, 21335) was diluted in 
1xPBS (containing 1mM CaCl2) at a concentration of 5 mg/ml. 500 µl of the 
biotin/PBS solution was added to 2 wells in a 24 well culture plate, a membrane 
placed on top and the PBS allowed to warm to 37˚C in an incubator before the 
ovaries were added (Section 2.1). At the end of the culture period, ovaries were 
transferred from the culture to the well containing the Biotin/PBS solution and 
placed back in the incubator for 30 minutes, to allow the biotin to perfuse. The 
ovaries were then moved off the membrane and placed in the well to allow them to 
be fully immersed in the solution for a further 5 minutes. The same 30 minute 
Biotin/PBS culture was carried out for ovaries from P4 pups, as a positive control.  
 
4.3.9.2. Histology 
The ovaries (cultured and P4 in vivo ovaries) were fixed in 4% buffered formalin for 
24 hours, followed by a wash in 70% ethanol. They were then processed, embedded 
and sectioned as outlined in section 2.2.  
  
4.3.9.3. Immunofluorescence  
Fluorescence was used for the detection of biotin. Slides were dewaxed and 
rehydrated (See Section 2.4.1) followed by a one hour incubation with a 
NGS/BSA/PBS blocking solution as outlined in section 2.4.3. The primary antibody 
incubation step was omitted since the biotin was already within the ovaries following 
culture. To detect the biotin, slides were incubated at RT for 1 hour in the dark, with 
a solution containing Streptavidin 488 fluorescent antibody (Alexafluor, Invitrogen, 
UK #S11223). Streptavidin has a very high binding affinity for biotin. The 
Streptavidin antibody was diluted at 1:200 following the same steps as outlined in 
section 2.4.6. Slides were then washed in ddH2O and PBS + Triton X (while kept in 
the dark) followed by a 20 minute incubation with DAPI counterstain (Invitrogen, 
D3571), diluted 1:10000 in ddH2O. The slides were then mounted with Vectashield 
(Vector, H-1400) and a glass cover carefully placed on top. Once dry, the slides were 
sealed with nail varnish and stored at 4˚C until visualisation. Slides were later 





4.3.10 Antibody detection of laminin-α1 
Immunohistochemistry was carried out to for Laminin, the major component of the 
basal lamina, on 13.5 ovaries that had been cultured for 12 days (Sections 4.3.3-
4.3.5), cultured P0 ovaries (Section 2.1) and uncultured ovaries from P4 pups, to 
investigate whether the cultured ovaries support the appropriate establishment and 
localisation of the basal lamina. Laminin was detected in the ovary using DAB as an 
amplified step. Firstly, slides were blocked and the primary antibody (Laminin: 
Abcam, ab11575) was diluted 1:300 in the blocking solution, before being applied to 
the slides. The slides were incubated overnight at 4 ºC in a humidified chamber. 
Slides were washed and incubated for 1 hour with the secondary antibody solution, 
diluted 1:200 (goat anti-rabbit biotinylated antibody, Dako). Slides were then washed 
and incubated for 30 minutes with the ABC kit (Vectastain, PK6100) before being 
washed and incubated with DAB (Vektor, SK4100) until brown staining appeared 
(Section 2.4.6). Slides were then counter-stained, cover-slipped and imaged (Section 
2.4.6). 
 
4.3.11 Statistical analysis 
Graphpad Prism was used for all statistical analysis of follicle number and 
distribution between cultured ovaries and in vivo ovaries. Data normality was 
assessed using Kolmogorov Smirnoff tests. Where data was not normally distributed, 
the Kruskal-Wallis non-parametric test was used to analyse the data. This was 
followed by a Dunns post-hoc test if the Kruskal-Wallis test showed significant 
difference. Where the data was normally distributed, a one-way ANOVA was used to 
determine if there were any significant differences between cultured ovaries and P4 







4.4.1. Method development 
4.4.1.1. Starting material for culture  
Ovaries from E12.5 and E13.5 mouse embryos were dissected and used as starting 
material. These stages were selected due to the entry of oogonia into meiosis around 
E13.5. Ovaries were initially cultured for 5-6 days on 2% agar in the rich medium 
(Sections 4.3.3-4.3.5). Ovary sections were H&E stained and analysed. An E17.5 
ovary was also dissected, fixed, processed, sectioned and stained in the same manner, 
to be compared with the cultured ovaries.  
 
E13.5 ovaries that had been cultured for 6 days contained larger cells with oocyte-
like appearance and with nuclei that appeared to be in the dictyate (Fig. 4.5c). These 
cells looked morphologically very similar to those observed in the E17.5 ovary, 
although much fewer of these germ cells were observed in the cultured ovary 
(Fig.4.5d). E12.5 ovaries cultured for 6 days, and E13.5 ovaries cultured for 5 days 
showed no signs of any larger oocyte-like cells, with the germ cells appearing to still 
be in the zygotene/pachytene stage of meiosis (Fig. 4.5a and 4.5b). E13.5 ovaries 
were therefore chosen as a starting point for future cultures. This also allowed the 
mesonephros to be dissected away with more ease than was the case with the E12.5 
embryo, with a lower chance of tearing the ovary during mesonephros removal.  
 
Early method development steps also involved attempts to culture E12.5 ovaries in a 
hanging-droplet culture or on a floating membrane in a 24 well plate containing the 
rich medium for 6 days (Fig. 4.6). Neither the hanging droplet culture nor the 
membrane culture resulted in oocyte-like cells forming, unlike those observed in 












Figure 4.5. Histological analysis of embryonic ovaries cultured for 5-6 days. E12.5 
ovaries were cultured for 6 days (a), E13.5 ovaries were cultured for 5 & 6 days (b, c).  E17.5 
in vivo ovary was used as a control (d). Oocyte-like cells with nuclei that appeared to be in 
the diplotene stage of meiosis were observed in E13.5 ovaries that had been cultured for 6 
days in the embryonic ovary culture system (c). These oocytes had many similar 





Figure 4.6. Representative 
photomicrographs of E12.5 
ovaries cultured in an agar 
droplet and on a membrane. 
E12.5 ovaries were cultured for 
6 days in a hanging droplet 
culture (a) or on a membrane 
floating on PGC media (b). 
Although the ovaries cultured 
on a membrane appeared 
healthier than the ones in the 
hanging droplet culture, neither 




4.4.1.2. Bridging embryonic and P0 ovary cultures 
Following on from the shorter 5-6 day cultures, E13.5 (Fig. 4.7a) and E12.5 (Fig. 
4.7b) ovaries were then cultured for 12 days on 2% agar blocks in petri dishes 
containing the rich medium, and examined histologically. Histological analysis of the 
ovarian structures that developed within these ovaries demonstrated that, although 
they were smaller, they resembled in vivo ovaries in terms of general morphology 
(Fig. 4.7). Following the 12 day culture, ovaries contained both small non-growing 
oocytes within primordial follicles as well as growing oocytes, but the majority of 
oocytes did not appear healthy, particularly in the E12.5 cultures (Fig. 4.7a-b). 
Several germ cell nests and bi-nuclear oocytes were observed in cultured E12.5 
ovaries (see asterisk in Fig.4.7b). Many oocytes contained large vacuoles, with the 
nucleus becoming displaced to one side of oocyte. Furthermore, granulosa cells did 
not appear to form any visible associations with the oocytes, where they failed to 
form the appropriate coronal arrangement around the oocytes. This was further 
characterised by a lack of basement membrane formation around the follicles.  
 
Neonatal mouse ovaries cultured in the presence of the simple medium are capable of 
forming healthy follicles which can initiate growth. In order to test the hypothesis 
that the various growth factors present in the richer medium were disruptive to 
follicle formation and growth, it was therefore attempted to bridge the embryonic 
ovary culture and the P0 culture system (Section 2.1.2). It was hypothesised that this 
would improve oocyte health and follicle formation. E13.5 ovaries were initially 
cultured for 6 days on an agar block with the rich medium, followed by a transfer to 
the neonatal ovary culture system, where they were cultured for a further 6 days on a 
membrane floating on the simple medium (Section 2.1.2). Although this culture 
system showed fairly large improvements in oocyte health, several atretic follicles 
were still observed in these ovaries (Fig 4.7c, white arrow). Furthermore, there were 
large areas of unevenly distributed and unhealthy stroma (See Figure 4.7b, circle) 
and the ovarian capsule was not well maintained, with the ovary edges appearing 
frayed and containing necrotic cells (See Figure 4.7c, black arrow). This, as well as 
the fact that the ovaries spread out into a thin layer on top of the membrane, suggests 
that the ovaries were unable to maintain their structural integrity on a tough surface, 
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such as the membranes, and perhaps required the more permissive and gentle support 
of the agar. Therefore, another culture was attempted where E13.5 ovaries were kept 
on the agar block for the whole 12 days of culture, where the rich medium was 
replaced with the simple medium after 6 days of culture, roughly around the point of 
which follicles would begin to form. At the end of culture, these ovaries appeared 
considerably healthier than the ones that had been cultured on membranes for the 
latter half of the culture duration (Fig. 4.7d). The oocytes and stroma appeared 
healthier, with the ovary capsule also remaining intact. However, the follicles still 
lacked the appropriate BM formation, and germ cell nests were also observed (Fig. 
4.7d, circle and insert). 
 
To investigate if the embryonic ovary might benefit from an even earlier removal of 
the rich medium containing growth factors, the rich medium was replaced with the 
simple medium at a series of earlier time-points. E13.5 ovaries were cultured as 
outlined before, for 12 days, but the rich medium was replaced with the simple 
medium at different stages of culture, on days 3, 4, 5 and 6 (Fig. 4.8). When the 
media was replaced at the later stages (days 4, 5 and 6), the basement membranes did 
not appear to establish appropriately (Fig. 4.8a-c). However, when the media was 
replaced on day 3 of culture, the BM within the ovaries became clearly visible and 
the granulosa cells exhibited a more physiological association with the oocytes, 
















Figure 4.7. Photomicrographs of embryonic ovaries cultured for 11-12 days outlining different methodologies. E13.5 (a) and E12.5 ovaries 
(b) cultured for 12 days on agar with rich media, producing largely unhealthy oocytes (b, insert) and some MOFs (b, insert: asterisk). E13.5 ovaries 
cultured for 6 days with rich media on an agar block & transferred onto a membrane with simple media another 6 days (c). These ovaries looked 
better, but still contained many unhealthy oocytes (c, white arrow), areas of necrosis (c, circle) and with badly maintained ovarian capsule (c, black 
arrow). E13.5 ovaries kept on agar for the duration of the culture, with culture medium changed to simple medium on day 6 of culture produced the 
healthiest looking oocytes, although granulosa cell layers and basal lamina formation still failed to establish appropriately & germ cell nests appeared 

















Figure 4.8. Photomicrographs of cultured ovaries changed over to P0 media at 
different time-points. E13.5 ovaries were cultured for 12 days with the rich medium initially, 
which was then replaced with the simple medium on different stages of culture: at day 6 (a), 
day 5 (b), day 4 (c) and day 3 (d). When the rich medium was replaced by the simple 
medium at day 3, basement membranes appeared better established than if replaced at later 
stages of development (d, black arrows). 
 
4.4.1.3 Importance of β-mercaptoethanol for the embryonic ovary health 
β-mercaptoethanol is a commonly used reducing agent in cell culture as its ability to 
scavenge hydroxyl radicals prevents the build-up of toxic levels of oxygen radicals. 
In order to investigate its importance in the embryonic ovary culture, E13.5 ovaries 
were cultured for 6 days with and without β-mercaptoethanol. Ovaries cultured 
without β-mercaptoethanol had fewer germ cells at the oocyte stage when compared 
with those cultured with β-mercaptoethanol (See Figure 4.12). As a result, β-





























Figure 4.9. Photomicrographs of representative E13.5 ovaries cultured with (a) and 
without (b) β-mercaptoethanol, and a histogram outlining the number of oocyte-like 
cells counted in ovaries cultured with or without β-mercaptoethanol (c). At the end of 
the 6 day culture, ovaries that had been cultured with β-mercaptoethanol appeared to have 
relatively more larger oocyte-like cells (ai and aii: black arrows) than did ovaries cultured 
without it (bi: black arrows). Some of the ovaries deprived of β-mercaptoethanol in culture 
were found to be completely void of such cells (bii). When quantified, ovaries cultured 
without β-mercaptoethanol were found to have an average of 12.5 oocyte-like cells, 
compared with 91.5 when β-mercaptoethanol was kept in the medium. Bar denotes ±SEM. 





























 serum in last half of culture
4.4.1.4 Effect of mouse serum during second half of the culture period 
E13.5 mouse ovaries were cultured for 12 days as previously described (Sections 
4.3-4.5) on 2% agar for 3 days in rich medium and 9 days in simple medium (n:3). 





 day of culture). No differences were observed between ovaries when examined 










Figure 4.10. Photomicrographs of cultured E13.5 ovaries with or without mouse serum 
during second half of culture. E13.5 ovaries were cultured for 12 days (3 day PGC media, 
9 day P0 media) either with no mouse serum (a) or with mouse serum during the latter 6 
days of culture (b). No obvious differences were observed histologically between the ovaries.  
 
 
4.4.1.5 Histological analysis of E13.5 cultured ovaries compared with P4  ovaries. 
E13.5 ovaries that had been cultured for 12 days on agar (3 days rich medium, 9 days 
simple medium), with (n=5) and without (n=3) the mesonephros, as well as ovaries 
from P4 mouse pups, (n=3) were fixed, processed and cut (Section 2.2). Every 6th 
ovary section was H&E stained and counted (Section 2.3).  
 
E13.5 ovaries, cultured for 12 days either with or without the mesonephros, 
demonstrated a typical follicular distribution pattern throughout the ovary with non-
growing primordial follicles surrounding the periphery of the ovary, and growing 
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transitional and primary oocytes in the inner part of the cortex and medulla (Fig. 
4.11). However, follicle numbers were significantly reduced however at the end of 
the 12 day culture when compared with the P4 ovary. The average number of 
follicles in the P4 ovaries was 1563±138, compared with 672±109 follicles in ovaries 
cultured with the mesonephros, and 536±304 in ovaries cultured without the 
mesonephros (Fig. 4.12a). Despite this reduction in follicle pool, there were still 
large numbers of follicles left in the cultured ovaries and the follicles appeared 
morphologically normal and healthy with only a slight, non-significant increase in 
unhealthy follicles in the cultured ovaries compared with P4 ovaries (3% increase 
without and 3.6% increase with mesonephros, p=0.38) (Figure 4.12b).  
 
There was a significant reduction in the number of primordial and secondary follicles 
in cultured ovaries compared with in vivo (primordial follicle numbers: 535±114 (in 
vitro +meso), 359±290 (in vitro –meso) vs. 1389±120 in vivo. Secondary follicle 
numbers: 1.2±0.9 (in vitro +meso) and 2.1±5.1 (in vitro –meso) vs. 13±1 in vivo). 
Transitional and primary follicle numbers remained unaffected (Fig 4.13). However, 
when the follicle ratios were examined, by calculating the percentages of each 
follicle type present in each ovary, the cultured ovaries contained follicles at stages 
in comparable ratios to those in P4 in vivo ovaries (77.1% primordial, 17.0% 
transitional and 5.6% primary in cultured ovaries with mesonephros, 65% primordial, 
25% transitional and 9% primary in cultured ovaries without the mesonphros vs. 
88%, 7.8% and 2.8% respectively, in vivo) (Fig 4.14). Although there was no 
significant difference between ovaries cultured with and without the mesonephros, 
ovaries consistently showed trends towards the in vivo method when the 
mesonephros was left attached. Given that, ovaries cultured with the mesonephros 


















Figure 4.11. Follicular organisation in 
cultured ovaries. Low power 
photomicrographs of embryonic ovaries 
cultured with (a) and without (b) the 
mesonephros, compared with a P4 in vivo 
ovary (c). Cultured ovaries, both with and 
without the mesonephros, demonstrate a 
normal distribution pattern of follicles 
throughout the ovaries, with non-growing 
follicles surrounding the periphery of the ovary 
and growing oocytes in the inner part of the 
cortex and medulla. 
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Figure 4.12. Total follicle numbers (i) and percentage of unhealthy follicles (ii) within 
cultured E13.5 ovaries, with and without mesonephros, compared with P4 un-cultured 
ovaries. E13.5 ovaries had significantly lower follicle numbers at the end of cultured than P4 
ovaries (p<0.05) (i), but follicle health within these ovaries was not significantly affected (ii). 
Bars denote mean + sem; n=5 for +meso, n=3 for P4 and - meso. Means with different 



































































































Figure 4.13. Distribution of follicle types in embryonic ovaries cultured with or without 
the mesonephros. Cultured E13.5 ovaries had significantly lower primordial (p<0.05) follicle 
numbers at the end of culture compared with P4 ovaries. Transitional, primary and 
secondary follicle numbers were not affected by the culture system (i). Cultured E13.5 
ovaries had significantly lower percentage of primordial and secondary follicle at the end of 
cultured compared with P4 ovaries (p<0.05). The proportion of transitional and secondary 
follicles was not affected by the culture system (ii). Bars denote mean + sem; n=5 for +meso, 




























4.4.2 Ability of cultured germ cells to progress to the pachytene stage of prophase 
I.  
Meiotic spreads were carried out on E13.5 ovaries that had been cultured for 6 days 
on an agar block. In vivo E18.5 ovaries were used as controls. Nuclei were counted 
and categorised into their respective stages of prophase I: leptotene, zygotene or 
pachytene. Homologous chromosomes in the oocyte nuclei from cultured ovaries 
were capable of progressing through leptotene and zygotene, to fully synapse at the 
pachytene stage of meiosis in an identical manner to E18.5 in vivo oocyte nuclei 
(Fig. 4.15). However, proportionally, fewer nuclei reached pachytene in vitro 
compared with in vivo; 23% in vitro compared with 50% in vivo (Fig. 4.16). The 
embryonic ovary culture system is therefore capable of supporting early meiosis of 
oocytes until the pachytene stage, although there was a slight delay when compared 























Figure 4.15. Distribution of cultured nuclei in prophase I of meiosis compared with in 
vivo. Nuclei from E13.5 cultured ovaries were capable of reaching the pachytene stage of 
meiosis, with 23% of nuclei reaching pachytene by 6th day of culture. However, this number 
was about half that observed in vivo, where 50% of nuclei had reached pachytene at E18.5. 
Roughly equal numbers of nuclei were observed in zygotene between in vivo and in vitro. 
Three times as many of the cultured nuclei were still in leptotene when compared with in vivo 
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Figure 4.14. Nuclei from cultured 
and in vivo ovaries at pachytene. 
Chromosomes in oocyte nuclei 
from cultured E13.5 ovaries were 
capable of reaching full synapsis at 
pachytene (a,b). In vivo E18.5 
pachytene nuclei were used as 




4.4.3 Laminin-α1 protein expression in the cultured ovary 
Laminin-α1 was selected as it is located within the basement membrane of follicles 
of all stages of development. Antibody detection proved problematic as intense 
staining was located in the BM of follicle, in the ECM of the stroma and the 




















4.4.4. Use of a biotin tracer to examine follicular architecture 
Due to the problematic antbibody detection of laminin in cultured ovaries, a biotin 
tracer study was therefore tried to investigate follicular architecture and the 
establishment of basal lamina in cultured ovaries. Cultured E13.5 and P0 ovaries, as 
well as in vivo P4 ovaries, were incubated with a biotin tracer which was later 
visualised using a fluorescent antibody detection system. The biotin permeated freely 
into ovarian follicles at all stages, and was observed in stromal ECM, BM, as well as 
between GCs and in the ZP. While the follicles within the P4 uncultured ovaries 
showed clear structural organisation and basal membrane formation (Fig. 17a), 
cultured ovaries (P0 and E13.5) showed less follicular organisation, and fewer 
follicles appeared to have established a BM. Nevertheless, a large number of follicles 
within the cultured ovaries demonstrated appropriate formation of BM (Fig.4.17b,c). 
The stain intensity in the ZP of cultured oocytes appeared much greater than in that 
of in vivo ovaries. Furthermore, the ZP stain was much greater than that of the BM in 















Figure 4.17. Biotin tracer study. Sections from a P4 in vivo ovary (a), cultured P0 (c) and 
E13.5 ovaries (b,d). Follicular organisation was less structured in cultured ovaries. Although 
the BM was a lot less defined in most E13.5 follicles, it was still visible in certain follicles 
ranging from the primordial to primary stage (see arrows). Follicles in P0 ovaries showed 






A culture technique was established here whereby embryonic ovaries were 
successfully cultured from a pre-meiotic stage of ovary development, through 
prophase I of meiosis up-to dictyate, followed by a phase of follicle formation and 
growth. Various methodologies were attempted in order to optimise and bridge an 
existing embryonic ovary culture system with an existing neonatal ovary culture 
system. These included modifications to the culture medium (±βmercaptoethanol, 
inclusion of serum in the latter half of culture, varying the time-points for changing 
over to the simple medium), culture techniques (hanging droplet, membrane, agar) 
and inclusion or exclusion of the mesonephros prior to culture. Ovary health and 
morphology were examined histologically, chromosome spreads were carried out to 
investigate the progression of oocytes through meiosis, and biotin tracer studies were 
carried out to examine follicle architecture. 
 
4.5.1. Optimisation of the early embryonic culture system 
As the first germ cells in the mouse ovary enter meiosis around E13.5 (Peters, 1969, 
Peters, 1970), this was considered a suitable starting point for a culture system 
designed to encompass from meiotic entry of germ cells, through to meiotic arrest. 
Furthermore, these ovaries appeared to develop better in culture and produced 
healthier looking oocytes than ovaries from younger embryos (E12.5).  Therefore, 
E13.5 ovaries were selected as a starting point. For the initial shorter cultures, several 
methods of culture techniques were attempted, including a hanging droplet, floating 
membrane and agar block culture; ovaries cultured on the agar block were able to 
better maintain their structural integrity and consistently appeared healthier than 
those cultured using the other methods.  
 
Cultured ovaries are usually slightly developmentally delayed when compared with 
the in vivo ovary (Wang et al., 2013). Here, during the initial shorter culture (6 days), 
embryonic ovaries had developed from a pre-meiotic stage, to the rough equivalent 
stage of around E17.5-E18.5 in vivo. The oocytes within these cultured ovaries had 
become larger and contained nuclei that appeared to be in the dictyate stage of 
meiosis, looking morphologically very similar to in vivo germ cells.  
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4.5.2 Bridging the embryonic and neonatal culture systems 
In an attempt to bridge the embryonic ovary culture with the neonatal ovary culture, 
and in order to allow ovaries to establish primordial and perhaps growing follicles, a 
longer embryonic ovary culture was carried out (12 days). As above, several 
different methodologies were attempted. Ovary health was found to be best when 
they were left on the agar throughout the culture period, with rich medium replaced 
by a simple medium on day 3 of culture. When the medium was changed at later 
time-points, granulosa-oocyte associations would not fully establish, and the BM 
would not form, although growing oocytes were observed. This suggests that optimal 
granulosa cell association might not be required for initial growth of oocytes.  
 
It was speculated that the rich medium might potentially contain too many factors 
and hormones interfering with oocyte growth and follicle formation in later stages of 
culture, perhaps being required only for early meiosis and oocyte development. The 
rich medium was therefore changed over to the simple medium at a series of earlier 
time-points to investigate if follicle morphology would improve. The best method 
turned out to be when ovaries were kept in the rich medium for the shortest time 
period (3 days). The granulosa cell layers established better and a BM became visible 
around an increasing number of follicles.  
 
4.5.3 Serum does not affect follicle growth in later stages of embryonic culture 
Further attempts at improving the methodology of the culture system were carried 
out where serum was added back into culture medium for the final 3 days of culture, 
in an effort to 'push' some follicles beyond the primary follicles stage, although this 
proved unsuccessful. This was not surprising as in vitro conditions are associated 
with a delay in the primary to secondary follicle transition within cultured ovaries 
(Wang et al., 2013). However, considering that the ovaries still appear very healthy 
at the end of culture, it would be interesting to carry out longer cultures, to examine 







4.5.4 The presence of germ cell nests within cultured embryonic ovaries 
Germ cell nests were observed fairly frequently in ovaries at the end of culture, 
where around 2-6 germ cells remained associated in small clusters, with few if any 
associated flattened granulosa cells. Germ cell nest breakdown usually occurs around 
the time of birth in the mouse. Germ cell nests are believed to be maintained during 
fetal development due to the high levels of maternal E2 which inhibits germ cell nest 
breakdown and protects oocytes from programmed cell death (Tingen et al., 2009). 
As the pups are born, the radical drop in the level of circulating E2 has therefore 
been suggested to lead to germ cell nest breakdown within the neonatal ovaries 
(Chen et al., 2007). One possibility is that the Phenol Red within the DMEM and α-
MEM in the culture medium was having a weak estrogenic effect on the ovaries, as 
Phenol Red has been shown to bind to the estrogen receptor and elicit weak 
estrogenic effects in cultured tissues (Berthois et al., 1986). Therefore, for future 
experiments it might be possible to use phenol red-free DMEM and α-MEM, to 
investigate if this helps reduce the occurrence of germ cell nests at the end of culture. 
 
4.5.5 The effect of culturing embryonic ovaries with or without the mesonephros.  
Initially, the aim was to culture the ovaries without the mesonephros. This was 
carried out on the principle that the in vitro ovary was more likely to benefit from the 
absence of the mesonephros in the long term, given that it degenerates around E16.5 
in the mouse in vivo. The mesonephros grows particularly well in culture, so it was 
also thought that it might spread out, overpower and interfere with ovary 
development, thereby hindering the ovary’s ability to grow in vitro. It was then later 
speculated that the dissection process, whereby the mesonephros was removed, could 
potentially result in subtle damage to the ovary. This led to culturing embryonic 
ovaries with the mesonephros attached. These ovaries ended up appearing 
morphologically very healthy and with better established BM around the follicles. 
Suprisingly, the mesonephros did not take over or fuse with the ovary. It remained 
attached to one side of the ovary and appeared to be more beneficial to ovary 
development than had been expected, with follicle numbers and ratios slightly closer 
to those observed in the in vivo ovaries, than if the mesonephros was removed prior 
to culture. It is possible that this difference was due to the subtle damage that the 
114 
 
ovary sustained whilst dissecting away the mesonephros using insulin needles, 
resulting in a small loss of follicles. On the other hand, considering the evidence for a 
mesonephric contribution of stromal cells to the ovary during embryonic 
development (Upadhyay et al., 1979), it is possible that if the mesonephros is 
dissected away too early, fewer cells end up invading the ovaries resulting in fewer 
somatic cells to form associations with oocytes. Finally, it is also possible that the 
mesonephros supplies the ovary with factors, such as RA, that contribute to meiotic 
entry (although the effect of RA has been debated; Section 1.1.1.2), and therefore if 
removed early, it could disrupt meiotic entry. A study has previously been carried out 
where the mesonephros was dissected from the ovary after a few days in culture 
(Obata et al., 2002). This was also attempted, but was near impossible to do without 
damaging the ovary. 
 
4.5.6 The effect of embryonic ovary culture on follicle numbers 
Follicles in ovaries cultured on agar were counted and categorised according to 
follicle health and stage. The significant drop in follicle numbers in cultured ovaries 
compared with in vivo ovaries has been repeatedly reported in cultures of fetal 
ovaries (Tavendale et al., 1992, McLaren and Buehr, 1990). A likely possibility is 
that the culture system is not yet optimised enough to allow the majority of germ 
cells to survive meiosis and germ cell nest breakdown to form follicles, or that it 
results in a larger wave of apoptosis during germ cell nest breakdown than normal. 
Oxidative stress and free radical damage are potential triggers for cell atresia in the 
developing ovary (Tilly and Tilly, 1995), as local tissue damage during ovary 
dissection or the culture environment might increase oxidative stress. However, the 
inclusion of β-mercaptoethanol, a free radical scavenger, in the culture medium 
should limit this. This was somewhat supported by the lack of visible oocytes when 
ovaries were cultured without β-mercaptoethanol. It is, also possible that the culture 
system could be interfering with the end stage of germ cell proliferation, prior to 
meiotic entry, resulting in fewer oogonia entering meiosis in the first place. This is 
unlikely however, since germ cell proliferation ceases before meiotic entry (Peters 
and Crone, 1967, Okhubo et al., 1996). Nevertheless, it is possible that the beginning 
of culture might overlap with the tail-end of germ cell proliferation, as not all germ 
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cells enter meiosis synchronously. Another possibility is that the stromal 
environment in culture is less healthy or contains fewer stromal or pre-granulosa 
cells than in vivo. This could result in the ovary being less able to support oocyte 
growth and follicle formation, with potentially fewer pre-granulosa cells making 
associations with oocytes. Inappropriate granulosa-oocyte cell associations appears 
to be a recurring issue observed in cultured embryonic ovaries both in the cultures 
described here and in a previous experiment examining cultured embryonic ovaries 
(McLaren and Buehr, 1990). It would, therefore, be interesting to investigate the 
presence of proliferating germ cells in ovaries at the start of the culture, for example 
by examining the expression of Ki67 (proliferation marker) and VASA (germ cell 
marker) at E13.5 or by adding BrdU during the first day of culture. Furthermore, it 
might be possible to study the number of apoptotic germ cells during germ cell nest 
breakdown in cultured ovaries, which could be compared to the number of germ cells 
lost during germ cell nest breakdown in in vivo ovaries, to determine if it is during 
this stage that oocytes are lost during culture.  
 
There is increasing evidence to suggest that PGCs require the presence of certain 
specific growth factors to avoid undergoing apoptosis. PGCs and early oocytes, are 
therefore, most likely dependent on growth-factors for survival. These include for 
example SCF/KL, bFGF and LIF, as well as insulin growth factor-I (IGF-I) and 
neurotropin 4/5 (Tilly, 2001, Morita et al., 1999, Lobascio et al., 2007). It would be 
interesting to investigate if the presence of these factors, in particular LIF and/or 
SCF, which promote primordial germ cell survival and proliferation in vitro, might 
reduce the number of germ cell lost during the culture period. 
 
The observed reduction in the number of secondary follicles observed in the ovary 
was an expected result, as outlined above, neonatal mouse ovary cultures have been 
shown to delay the primary-to-secondary follicle transition (Wang et al., 2013).  
 
4.5.7. Cultured ovaries had a normal geographical organisation of follicles  
Histological examination showed that the geographical pattern of follicles within the 
cultured embryonic ovaries appeared normal, corresponding closely to the 
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organisation of follicles within the in vivo P4 mouse ovary. Non-growing primordial 
follicles were arranged around the outside of the ovary, with larger growing follicles 
located more centrally and by the medulla. This has been investigated previously 
where it was suggested that the growth pattern of follicles is established before birth, 
around E13.5, possibly related to the timing of meiotic entry (Byskov et al., 1997). A 
prior study using ovaries from before this time-point (E13.5) failed to develop a 
normal pattern of follicular organisation (Byskov et al., 1997). This further supported 
the argument for selecting E13.5 ovaries over E12.5 ones as starting material for this 
embryonic ovary culture system. 
 
4.5.8 Progression of cultured oocytes through prophase I of meiosis 
In order to investigate if homologous chromosomes within the cultured oocytes were 
capable of fully synapsing, meiotic chromosome spreads and SC visualisation were 
carried out on cultured oocytes at the time-point by which the majority of oocytes 
were expected to have progressed to the pachytene stage of prophase I. Many 
pachytene nuclei were observed from cultured oocytes, demonstrating that the 
culture system supports oocyte development to the pachytene stage of meiosis. 
Although similar number of oocytes had reached zygotene in both cultured and in 
vivo ovaries, fewer cultured oocytes had reached pachytene and a greater number 
were still at leptotene. It is therefore likely that the cultured oocytes were slightly 
delayed in comparison to the in vivo ovary. This result was not surprising given that 
a delay in ovary development is frequently observed in vitro, with follicle formation 
and growth often observed slightly later in cultured ovaries than at the equivalent age 
in vivo (Wang et al., 2013). The cultured ovaries in this study had been left in culture 
a day longer than their equivalent day in vivo, and were therefore expected to be 
roughly at the same meiotic stage as the in vivo ovary. This suggests that the meiotic 
delay is slightly greater than previously expected. It would be interesting to 
investigate if the culture system supports oocyte meiosis to dictyate, by examining 
whether the chromosomes are all paired using a chromosome spread technique 
(Henderson and Edwards, 1968), or by examining the expression of diplotene 
markers such as Msy2 (Gu et al., 1998), PAR6 (Wen et al., 2009) or TRP63 (Suh et 
al., 2006, Myers et al., 2014). 
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4.5.9. Investigation of the follicular architecture and basement membrane 
formation 
P4 ovaries cultured briefly with a biotin tracer showed clear follicular organisation 
and BM formation in follicles of all stages. Cultured ovaries appeared less organised, 
and although the BM was visible for many follicles, it was less apparent than in vivo. 
This was partly due to the fact that the ZP in cultured oocytes stained more intensely 
than in vivo ovaries. The bright staining of ZP relative to the BM in cultured ovaries 
therefore made it more difficult to visualise the BM. It is possible that the in vivo 
ovaries had lower ZP stain because they were larger in volume than embryonic 
ovaries, meaning that the biotin tracer took longer to diffuse through the ovaries, 
resulting in less stain. It is also plausible that the ZP had hardened in culture. The ZP 
hardens naturally following fertilization in order to serve as a sperm barrier to avoid 
polyspermic fertilization, but prolonged exposure of oocytes to artificial culture 
conditions has been reported to induce zona hardening (De Vos and Van 
Steirteghem, 2000). If this occurred during the embryonic ovary culture, it might be a 
reason for the more concentrated ZP stain in cultured oocytes. Finally, it is also 
possible that the BM is less established in cultured ovaries, allowing more biotin to 
diffuse through the membrane and into the follicle resulting in a more intense ZP 








This chapter details the development of a novel culture system that supports the 
growth and development embryonic mouse ovaries from a pre-meiotic stage, up-to a 
post-natal stage of follicle growth. It supports the development of germ cells through 
prophase I of meiosis to pachytene, albeit with a slight delay compared with in vivo, 
followed by the formation of primordial follicles and initiation of follicle growth. 
Although fewer follicles remain at the end of the 12 day culture period compared 
with the in vivo P4 ovary, the follicles are morphologically normal and healthy, and 
exist in comparable ratios to those in vivo. 
 
4.7. Future directions 
The next priority would be to investigate if the primordial follicles could progress to 
the secondary follicle stage during culture, by leaving the ovaries in the simple 
culture medium for longer periods. If successful, the ovaries could then potentially 
be disaggregated to carry out individual oocyte-cumulus cell complex cultures and 
extend the culture system further into antral follicle growth. Ideally, the individual 
cumulus-oocyte complexes could then be matured to a pre-ovulatory stage and 
'ovulated' to complete meiosis I in vitro. It would also be important to carry out 
analysis into whether the oocytes are appropriately established in dictyate by 
carrying out chromosome spreads or immunohistochemistry. Although histological 
analysis of the chromosomes can give a good idea of the meiotic stage of a germ cell 












Use of the embryonic ovary culture system for 















The testing of female reproductive toxicology is complex, where effects on both the 
pre- and post-natal ovary must be carefully considered. Although the majority of 
reproductive toxicology tests are currently performed in vivo (Sections 1.2 and 4.1), 
various ovary cultures have been established that have also been used in reproductive 
toxicity studies. These in vitro studies have been primarily carried out through 
academic research, consistently demonstrating the value of in vitro culture as 
potential preliminary investigations or secondary screening for potential reproductive 
toxicants (Iguchi et al., 1990, Chen et al., 2007, Devine et al., 2002a, Devine et al., 
2004, Miller et al., 2005, Gupta et al., 2006, Wan et al., 2010, Inada et al., 2012, 
Zhou et al., 2008, Xu et al., 2002, Desmeules and Devine, 2006, Soleimani et al., 
2011). The large majority of these in vitro studies have, however, only been 
conducted on the post-natal ovary. Very few pre-natal ovary cultures have been tried, 
with an even smaller proportion of these having been used to examine the effects of 
potential toxicants on the developing ovary. To date, no adequate in vitro model has 
been validated for use within the pharmaceutical industry or environmental 




Etoposide (VP-16) is a chemotherapeutic agent used in the treatment of lung cancer, 
germ cell cancers, leukemia, neuroblastomas, Kaposi's sarcoma, and lymphomas 
(Hande, 1998, Gupta et al., 1987). The effective therapeutic dose of etoposide in 
adults ranges between 100-230 mg/m
2
, which results in a plasma concentration of 
between 5-60 μg/ml (Hande et al., 1984).  
 
5.1.1.1. Mechanisms of action 
Etoposide is an alkylating agent that has been suggested to interfere with the ability 
of Topo II to re-ligate the nick in the DNA strand, resulting in increasing DNA 
fragmentation and consequent cell death (Chen et al., 1984, Ross et al., 1984, Gupta 
et al., 1987, Fortune and Osheroff, 2000) Another mechanism of action for etoposide 
has also been suggested, where it is thought to poison Topo II by increasing the 
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steady-state concentration of covalent DNA cleavage complexes within the Topo II 
enzyme, which turns Topo II into a physiological toxin that introduces high levels of 
single and double strand breaks (DSBs) into the DNA. The increasing amount of 
DSBs rises triggers a series of events, eventually resulting in apoptotic cell death 
(Hande, 1998).  
 
5.1.1.2 Reproductive toxicity of etoposide 
Around 1.5 million people were diagnosed with cancer in the year 2010. From this 
group, around 10% were younger than 45 and 1% younger than 20 (Jensen et al., 
2011). Due to modern cancer therapy treatments, the overall 5-year survival rate has 
improved to nearly 80% for patients under 50 (Jensen et al., 2011). The side-effects 
of chemotherapy treatment, however, frequently involve premature ovarian 
insufficiency (POI) and loss of fertility (Fisher et al., 1979, Meirow et al., 1999, 
Wallace et al., 1989, Tauchmanova et al., 2002, Mackie et al., 1996, Familiari et al., 
1993). When the increasing survival rate of cancer survivors is joined with the 
potential reproductive effects of chemotherapy treatments, this has resulted in cancer 
patients' rising concerns for future fertility. Fertility preservation has become an 
emerging field, but fertility preservation treatments are not always possible, or 
successful (Sonmezer and Oktay, 2004).  
 
Etoposide treatment has been shown to induce ovarian effects in mice and hamsters, 
where the frequency of aneuploid oocytes and chromosome aberrations were 
increased following exposure (Mailhes and Marchetti, 1994, Tateno and Kamiguchi, 
2001b). The evidence for the reproductive toxicity of etoposide in the human ovary 
has, however, been somewhat conflicting. A study investigating the fertility of 
women following etoposide exposure, demonstrated ovarian effects such as 
amenorrhea, anovulatory cycles or hypomenorrhea observed in a number of the 
female patients. Over half of these patients however, maintained normal ovulatory 
cycles, with a few successful pregnancies reported in several of the women who had 
previously been amenorrheic (Choo et al., 1985). Furthermore, a study investigating 
the fertility of an 18 year old woman who previously received a chemotherapeutic 
treatment that included etoposide, reported no effects on primordial follicle density 
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when compared with age-matched controls who had not received chemotherapy 
(Oktem and Oktay, 2007).   
 
Etoposide has been prescribed to pregnant women where an aggressive malignancy 
posed a severe threat to the mother's life, such as lung cancer (Han et al., 2005, 
Kluetz and Edelman, 2008, Siepermann et al., 2012). The treatment was considered 
relatively safe for the fetus during the second and third trimesters and healthy babies 
were born following in utero etoposide treatment. Their development has been 
normal during the 6 years that the follow-up study has been carried out but no data 
has been reported on possible effects of etoposide on the reproductive system in 
these children, since none have reached puberty. As a result it is not known whether 
etoposide exposure resulted in adverse effects on their fertility, which may not 
become known until their adulthood. Furthermore, drugs targeting topoisomerases 
can increase genetic instability and therefore induce mutations within the developing 
germ cells. This could be transmitted to future generations but would not become 
apparent until the F2 generation (Baguley and Ferguson, 1998). It is therefore of high 
importance to investigate the potential effects of chemotherapeutic agents, such as 
etoposide, on the ovary, in particular the pre-natal ovary. An improved understanding 
of the mechanisms of mutagenesis is important not only to improve cancer therapy 
but also to fully understand the actions of topoisomerase targeted drugs, including 
etoposide (Baguley and Ferguson, 1998). 
 
5.2 Aims 
The primary aim of this work was to validate the novel mouse embryonic ovary 
culture by comparing the results following culture of embryonic ovaries with AZTC, 
with those from the in vivo study, where AZTC exposure had also occurred during 
embryonic development. Etoposide was selected as a relevant second study 
compound as it is also a Topo II inhibitor and has previously been prescribed to 






5.3 Materials and Methods 
5.3.1 Isolation of embryonic ovaries 
CD-1 mouse breeding harems were set up as outlined in Section 4.3.2. Mouse 
embryos at E13.5 were collected, ovaries dissected and placed in 1xPBS (Section 
4.3.5).  
 
5.3.2 Preparation of culture plates and medium 
2% agar was prepared and cut into 1cm
2
 blocks using a sterilized blade (Section 
4.3.3). The preparation of the rich PGC medium and the simple P0 medium was 
carried out as previously described (Rich medium: Section 4.3.4 and simple medium: 
Section 2.1.2). The agar block was placed in a 33mm petri dish, covered with the rich 
medium and placed in the incubator for 30 minutes to allow the PBS to diffuse out of 
the agar block (Section 4.3.4). The medium was then replaced with fresh rich 
medium, which was again allowed to incubate for 30 minutes to allow the media to 
equilibrate, prior to culture. 
 
5.3.3 Assessment of Topo IIα expression in the in vivo and in vitro mouse ovary.  
The expression of Topo IIα within the in vivo rat ovary was found to change from 
within the germ cells pre-natally, to the surrounding somatic and granulosa cells a 
few days after birth, as follicles began to form (Section 3.1.3).  Therefore, to 
investigate if Topo IIα followed the same expression within the cultured ovaries, 
immunohistochemistry to detect Topo IIα was carried out on cultured embryonic 
ovaries. Embryonic ovaries (E13.5) were cultured for 12 days on agar as outlined 
above (5.3.2). Ovaries were collected at each day of culture, from day 1-12. Ovaries 
were washed in 1xPBS for 5 minutes, fixed in 70% buffered formalin and processed 
(Section 2.2). In vivo mouse ovaries were also collected from E13.5-PND6, so that 
the expression pattern of Topo IIα in culture could be compared with the in vivo 
ovary at the equivalent stages.  
 
5.3.3.1 Immunohistochemistry for Topo IIα 
Topo IIα was detected in the ovary using DAB as previously described (Section 2.4). 
The primary antibody used was a rabbit polyclonal anti-Topoisomerase IIα (Abcam, 
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ab52934) at a 1:200 dilution. The secondary antibody used was biotinylated goat 
anti-rabbit (Dako) antibody at a 1:200 dilution. Antibodies were diluted in a solution 
of non-immunised goat serum (Section 2.4.3). Topo IIα was detected with DAB 
(Section 2.4.6). Immunohistochemistry for Topo IIα in the in vivo mouse ovaries was 
carried during my second visit to AstraZeneca (Fig. 3.2.), where a pressure cooker 
was used for antigen retrieval and an automatic stainer was used for immunostaining. 
Immunohistochemistry for the cultured embryonic ovaries was carried out in 
Edinburgh following the same protocol as outlined previously (Section 2.4).  
 
5.3.4 Embryonic ovary cultures with AZTC 
The studies outlined in this chapter were carried out prior to the experiments where 
the ovary was found to consistently culture slightly better with the mesonephros 
(Sections 4.3.6.5 & 4.4.1.5). As a result, all cultures described here were carried out 
without the mesonephros. Due to time-constraints these cultures were not repeated 
with the mesonephros attached. E13.5 ovaries were cultured for 3 days with the rich 
medium and 9 days with the simple medium. AZTC was dissolved in dimethyl 
sulfoxide (DMSO). An initial dose response study was carried out where the medium 
was supplemented with AZTC at final concentrations of 1, 10, 100, 200 and 500 μM. 
Due to the very poor follicle morphology of ovaries cultured with 200 and 500 μM 
AZTC, the final concentrations of 1, 10 and 100 μM were chosen for the study. The 
medium was supplemented with either DMSO or AZTC for the first 6 days of culture 
and ovaries were moved to control culture on day 6 of culture (Fig. 5.1). A total 8 
ovaries were counted for the control and 10 μM group, and 7 ovaries for the 1 and 








Figure 5.1. Outline of the methodology used for AZTC exposure in the embryonic 
ovary culture. Embryonic ovaries cultured 12 days on agar, in rich medium for 3 days and 
simple medium for 9 days. AZTC was added to the culture medium during the first 6 days of 
culture and replaced with control medium during the latter 6 days of culture.   
 
 
5.3.4.1 Meiotic chromosome spreads on AZTC treated ovaries. 
In order to assess the ability of cultured oocytes to progress through meiosis in the 
presence of AZTC, oocyte spreads were carried out on E13.5 ovaries that were 
cultured for 6 days with DMSO or 100 μM AZTC as previously described (Section 
4.3.8). By the 6th day in culture the majority of oocytes were expected to be at 
pachytene if they developed as with in vivo control oocytes. Ovaries were first placed 
in a hypotonic extraction buffer for 15-30 minutes, followed by a sucrose solution 
where the ovaries were pierced with a needle to release the cells from the ovary. 10 
μl of this cell suspension was picked up, placed on a pre-fixed slide and zig-zagged 
down the slide to spread out the cell suspension. The slides were placed in a humid 
chamber overnight and left air dry for 1-2 hours the following morning (Section 
4.3.8). The slides were immunostained for Sycp1 and Sycp3 antibodies as outlined 
previously (Section 4.3.8.5) and visualised.  
 
5.3.5 Embryonic ovary cultures with Etoposide 
The ovarian effects of another Topo II inhibitor, etoposide, were investigated. This 
was carried out in order to investigate if the effects observed following etoposide 





Initially, a dose-response study was carried out on cultured neonatal (P0) CD1 mouse 
ovaries. The neonatal (P0) ovary culture was set up outlined previously (Section 2.1). 
Etoposide was dissolved in DMSO and the culture medium was supplemented with 
etoposide at the final concentrations of 25 ng, 250 μg or 25mg/ml for the whole 
duration of culture. This range of doses was selected to cover the plasma 
concentrations (5-60 μg/ml) reached in patients following etoposide treatment.  
 
The embryonic ovary culture outlined above (Section 5.3.2) was repeated with 
etoposide at final concentrations of 50, 100 and 150 ng/ml (Sigma, E1383) during the 
inital 6 days of culture (Fig. 5.2). Ovaries were cultured for 12 days, for 3 days in 
rich medium followed by 9 days in simple medium (Section 4.3.6). A total of 6 
ovaries were assessed for each treatment group from 2 independent cultures. 
 
Similarly to above, these experiments were carried out prior to the methodology 
experiments where the ovary was found to consistently culture slightly better with 
the  mesonephros (Sections 4.3.6.5 & 4.4.1.5), and therefore all cultures described 







Figure 5.2. Outline of the methodology used for Etoposide exposure in the embryonic 
ovary culture. Embryonic ovaries cultured 12 days on agar, in rich medium for 3 days and 
simple medium for 9 days. Etoposide was added to the culture medium during the first 6 






5.3.6. Histological examination of cultured ovaries 
E13.5 ovaries were cultured on an agar block for 12 days (3 days rich medium, 9 
days simple medium, with AZTC or etoposide added during the first 6 days of 
culture). Ovaries were fixed in formalin, washed in 70% ethanol, embedded in agar, 
processed, embedded, cut and H&E stained as described in Section 2.2. Every 6
th
 
section from each ovary was photographed at x20 magnification. Follicles were 
counted blind as treatment and categorised as outlined previously (Section 2.3). 
 
5.3.7. Detection of double-strand DNA breaks by γH2AX immunofluorescence in 
ovaries exposed to etoposide. 
The expression of γH2AX was detected within etoposide treated ovaries collected 
from the initial neonatal dose-response culture as well as following the embryonic 
ovary culture. (Note: the immunofluorescent staining protocol on the neonatal 
etoposide-treated ovaries was carried out by Stephanie Morgan). Fluorescence was 
used to detect γH2AX using the Vector Mouse On Mouse kit (Vector, BMK-2202). 
This kit was selected to reduce the amount of background staining previously 
observed when conventional immunofluorescent staining was carried out. Slides 
were dewaxed and re-hydrated as described previously (Section 2.4.1), followed by a 
30 minute incubation in 3% H2O2/90% methanol. Slides were washed in buffer and 
incubated for 30 minutes in a blocking solution (Vector labs, M.O.M. blocking 
solution), followed by a wash and a further 5 minute incubation in MO.M. diluent 
solution. The solution was tipped off and the slides were incubated with the primary 
antibody γH2AX (Abcam, 22551) diluted at 1:200 for 30 minutes at room 
temperature. Slides were washed and incubated with the biotinylated secondary 
antibody solution (M.O.M. kit) for 10 minutes. Slides were then washed and a 
solution containing streptavidin 488 fluorescent antibody (Alexafluor, Invitrogen 
UK, S11223) was applied at 1:200 dilution for 5 minutes, while the slides were kept 
in the dark. Finally, the slides were incubated for 20 minutes in a solution of DAPI 
counterstain (Invitrogen, D3571) diluted at 1:10000 in H2O. Slides were washed and 
mounted using Vectashield (Vector, H-1400), coverslipped and photographed using a 





5.3.8 Statistical Analysis 
Graphpad Prism was used for all statistical analyses of follicle number and 
distribution between DMSO control ovaries and ovaries exposed to AZTC or 






5.4.1 Expression pattern of Topo IIα in the mouse ovary in vitro & in vivo 
Topo IIα expression was observed within the germ cells during pre-natal ovary 
development, but changed to the surrounding granulosa and somatic cells at birth 
(Fig. 5.3). A similar expression pattern was observed in the cultured ovaries, where 
during the first 6 days of culture, Topo IIα was expressed within the germ cells. 
Around day 6-7 of culture, as follicles began to form, Topo IIα expression became 
localised to the surrounding granulosa and stromal cells (Fig. 5.4). Cultured ovaries 
had more non-specific background staining than did in vivo ovaries. Fewer granulosa 
and stromal cells appeared to stain positive within the cultured ovaries than in the in 
vivo ones, but the expression pattern was, nonetheless, consistent between in vitro 















Figure 5.3. Expression of Topo IIα in the in vivo mouse ovary throughout pre- and post-natal development.  Topo IIα was expressed 
within the germ cells pre-natally, but shortly after birth, as follicles began to form, its expression became localised to the surrounding granulosa 

















Figure 5.4. Expression of Topo IIα in the cultured embryonic mouse ovary throughout the 12 days of culture.  Similarly to in vivo, Topo 
IIα was detected within the germ cells during the first 6 days of culture, prior to follicle formation. Around day 7 of culture, as follicles began to 





















Figure 5.5. Comparison of the expression pattern of Topo IIα in the in vivo mouse ovary vs. the cultured embryonic mouse ovary.  The 
same expression pattern is observed in the embryonic cultured ovary as is seen in the in vivo ovary. Topo IIα is expressed within the germ cells 
during the equivalent phase as ‘pre-natal’ ovary development, for the first 5-6 days of culture, until follicle formation. Once follicles begin to 







5.4.2 Effect of AZTC on the pre-natal ovary 
E13.5 ovaries were cultured for six days initially with either DMSO or AZTC, followed 
by a further 6 days in control medium. A dose response study was carried out, where 
media contained final concentrations of AZTC at 1, 10, 100, 200 and 500 μM (Fig. 5.6). 
Ovaries cultured with 1, 10 and 100 μM concentrations of AZTC contained follicles 
ranging from primordial to primary stages, although by 100 μM the ovaries and follicles 
looked considerably less healthy. At the higher AZTC concentrations of 200 and 500 
μM no follicles were observed and the ovaries appeared shrunken and atretic. The two 
top doses were therefore excluded from future studies.  
 
E13.5 ovaries were cultured in the presence of DMSO or AZTC during the equivalent 
of the pre-natal phase development (n=8 for control and medium dose, n=7 for low and 
high doses). Ovaries exposed to the highest AZTC dose (100 μM) had significantly 
reduced follicle numbers (p=0.0309) whereas at the lower doses a slight, non-significant 
increase in follicle number was observed (Fig. 5.7). When follicles were distributed into 
the different follicle types a similar pattern was observed, with a slight non-significant 
increase in PMF numbers in low and medium doses, and with PMF numbers 
significantly dropping at the high dose (p<0.001) (Fig. 5.8i). AZTC had no significant 
effect on the number of TRNs, PRIM or SEC follicles. When the distribution of the 
percentage of follicles was examined, again a similar trend was observed for PMFs with 
increasing percentage of PMFs at the low and medium dose, with the percentage of 
PMFs significantly reduced at the high dose (p<0.001) (Fig. 5.8ii). Here, however, a 
significant increase in TRNS and PRIM percentages was also observed, with 
proportionally more TRNS and PRIM follicles remaining in high dose ovaries when 
compared with control ovaries.  
 
When follicle health was examined, a slight dose-dependent increase in the number of 
unhealthy follicles was observed at the low and medium doses, but this was not 
significant. At the high dose, the number of unhealthy follicles was significantly 
reduced when compared with the medium dose (p=0.0034) (Fig. 5.9i). The percentage 
of unhealthy follicles within exposed ovaries compared with controls was not 
significantly affected (p=0.767) (Fig.5.9ii). When examining the distribution of 
unhealthy follicles, a significant increase in the number of unhealthy PMFs was 
observed at the low (p<0.05) and medium (p<0.001) doses, followed by a significant 
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reduction in the number of unhealthy PMFs at the highest dose when compared with 
low and medium doses. Other follicle types appeared un-affected by AZTC treatment 
(Fig. 5.10i). The percentage of unhealthy follicles within exposed ovaries were not 
significantly different to controls (p=0.835) (Fig. 5.10ii).  
 
In order to determine the cell type responsible for the follicles being classified as 
unhealthy, and to determine which cell type was being targeted by AZTC, follicles were 
further classified into unhealthy due to the oocyte only, granulosa cells only, or both 
due to an unhealthy oocyte and granulosa cells. Nearly all the follicles within the AZTC 
















Figure 5.6. Dose response study with AZTC. Photomicrographs of ovary sections that had 
been treated with DMSO or with AZTC at final concentrations of 1, 10, 100, 200 or 500 μM. 
Ovaries treated with 200 and 500 μM AZTC appeared very atretic and shrunken with no 
remaining follicles. Ovaries at lower concentrations contained mostly healthy and some 
























































Figure 5.7. Total number of follicles within cultured ovaries. No effect of AZTC was 
observed on the follicle number within ovaries at the low and medium doses, although there 
appeared to be a slight non-significant increase in follicle numbers up-to the medium dose. A 
significant reduction in follicles had occurred within ovaries exposed to the high dose of AZTC 
after 12 days of culture (p=0.0309). Bars denote mean + sem; n=8 for control and 10 μM, n=7 






































































Figure 5.8. Distribution of follicle numbers (i) and percentages (ii) within embryonic 
ovaries cultured with AZTC. A slight non-significant increase in the number of primordial 
follicles was observed in the low and medium dose ovaries, although this number significantly 
dropped at the high dose (p<0.001) (i). A similar effect is observed when the percentages of 
primordial follicles were examined, with a significant increase in the percentages of transitional 
follicles (low vs. high dose: p<0.05; medium vs high dose: p<0.01) and PRIM follicles (p<0.05) 
was also observed at the high dose ((ii). Bars denote mean + sem; n=8 for control and 10 μM, 
n=7 for 1 and 100 μM. Follicle types: PMF: primordial, TRNS: secondary, PRIM: Primary, SEC: 





















































































































Figure 5.9. Follicle health within AZTC exposed ovaries. A slight non-significant, yet dose 
dependent increase was observed in the number of unhealthy follicles at the low and medium 
doses of AZTC, with a significant drop in the number of unhealthy follicles at the high dose 
when compared with the medium dose (p=0.0034) (i). No effect was observed on the 
percentage of unhealthy follicles between treated and control ovaries (p=0.767) (ii). Bars denote 
mean + sem; n=8 for control and 10 μM, n=7 for 1 and 100 μM. Means with different letters are 






















































































































































Figure 5.10. Distribution of unhealthy follicles within AZTC-treated ovaries. A significant 
dose-dependent increase in the number of unhealthy PMFs was observed up-to the medium 
dose, after which the number dropped to below that of control ovaries. No effect of AZTC was 
observed on other follicles types (i). When the percentages of unhealthy follicle types was 
examined, no significant differences were observed between control and treated ovaries 
(p=0.835) (ii). Bars denote mean + sem; n=8 for control and 10 μM, n=7 for 1 and 100 μM. 
Follicle types: PMF: primordial, TRNS: secondary, PRIM: Primary, SEC: secondary. . Means 



















































Follicles classified as unhealthy




































































Figure 5.11. Distribution of follicles classified as unhealthy due to an unhealthy oocyte, 
granulosa cells or both. Unhealthy follicles were further classified into  damaged cell types, 
with the vast majority of follicles being classified as morphologically unhealthy due to an 
unhealthy oocyte (i). No follicles were classified as being unhealthy due to both unhealthy 
oocytes and granulosa cells, and less than 0.1% of follicles were classified as unhealthy due to 
unhealthy granulosa cells at the medium dose of AZTC  (ii). Bars denote mean + sem; n=8 for 





5.4.3 Meiotic chromosome spreads on AZTC treated ovaries.  
In order to investigate if AZTC interfered with the ability of oocytes to progress through 
meiosis to the pachytene stage, meiotic chromosome spreads were carried out and the 
SC was visualised by immunofluorescence. Oocyte nuclei were obtained from 
embryonic ovaries that had been cultured for 6 days in the presence of 100 μM AZTC. 
Unfortunately, a low yield of oocytes made it difficult to carry out any further analysis 
into the proportion of meiotic stages within the treated ovaries (leptotene, zygotene or 
pachytene). Despite this, several pachytene nuclei were observed within the treated 
ovaries, appearing morphologically very similar to those observed in control ovaries 
















Figure 5.12. Meiotic chromosome spreads on control (A, B) and AZTC treated (C,D) 
ovaries. The chromosomes were capable of fully synapsing in the presence of AZTC (C,D) in a 





5.4.4 Effect of Etoposide on the pre-natal ovary 
5.4.4.1. Dose response study 
An initial dose-response study was carried out on cultured neonatal ovaries (CD1) to 
assess the appropriate doses of etoposide to be used, with final concentrations of 
etoposide in culture of 25, 250 ng/ml and 25 μg/ml. Ovaries treated with the lowest dose 
(25 ng/ml) appeared fairly healthy with varying stages of follicles and the occasional 
unhealthy granulosa cell (Fig. 5.13a, black arrows). Ovaries treated with the medium 
dose (250 ng/ml) appeared very unhealthy, with atretic oocytes and striated stroma, 
whereas ovaries receiving the highest dose (25 μg/ml) contained severely unhealthy 
stroma with no remaining follicles (Fig. 5.13d). Etoposide concentrations of 50, 100 and 
150 ng/ml were therefore chosen for future experiments (n=9 for DMSO control, n=6 
for 50 ng/ml, n=5 for 100 ng/ml and n=8 for 150 ng/ml). These doses were selected as 
they are lower than the doses that resulted in a complete destruction of oocytes but are 
also far lower the range of serum concentration measured following etoposide treatment 
(5-60 μg/ml). 
 
Pre-natal in vitro exposure to etoposide resulted in a significant decrease in follicle 
numbers when compared with DMSO control (p<0.01) ovaries (Fig. 5.14). When the 
follicles were classified into their follicle types it became clear that the reduction in 
follicle numbers was due to a dose-dependent decrease in the number of primordial 
(p=0.0085) and transitional (p=0.0041) follicles with increasing dose of etoposide. No 
effect was observed on primary or secondary follicle numbers (Fig. 5.15i). When the 
percentages of each follicle type was examined, while no significant effect was 
observed on the proportion of primordial follicles within exposed ovaries, a significant 
reduction was observed in the proportion of transitional follicles at the highest dose 
when compared with control (p<0.01), low (p<0.05) and medium (p<0.05) dose ovaries 
(Fig. 5.15ii). A non-significant trend was also observed where the proportion of primary 
follicles increased slightly with increasing etoposide dose (Fig. 5.15ii). When analysing 
follicle health within etoposide exposed ovaries, it became evident that the number of 
unhealthy follicles within treated ovaries did not follow a normal dose-response curve. 
A slight non-significant increase in unhealthy follicle number was observed in low dose 
ovaries, with no effect observed at the middle dose. A significant reduction in unhealthy 
follicle numbers was observed however when compared with low-dose ovaries and 
DMSO controls (p=0.005, Fig. 5.16i). When the unhealthy follicles were classified into 
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their follicle types, a similar effect was seen as in Fig. 5.16i, where a non-significant 
increase was observed in the number of unhealthy PMFs in low dose ovaries, after 
which the number dropped back to the equivalent to that of control ovaries. A 
significant increase was observed in unhealthy PMF numbers from low to high dose 
ovaries (p<0.01). The number of TRNs follicles was also significantly reduced at the 
top dose when compared with controls (p<0.01 and middle (p<0.01) dose ovaries (Fig. 
5.17i). A significant increase in the percentage of unhealthy follicles within ovaries 
exposed to the top dose when compared with controls (p<0.05) (Fig. 5.16ii). When the 
percentage of unhealthy follicle types was examined however, no significant differences 
were observed between control and treated ovaries (Fig. 17ii). 
 
In order to determine the cell type responsible for the follicles being classified as 
unhealthy, and to determine which cell type was being targeted by etoposide, follicles 
were further classified into unhealthy due to the oocyte only, granulosa cells only, or 
both due to an unhealthy oocyte and granulosa cells. Nearly all the follicles within the 
etoposide treated embryonic ovaries were classified as unhealthy due to an unhealthy 























Figure 5.13. Dose response study for etoposide. Neonatal ovaries cultured either with 
DMSO (a) or etoposide at concentrations of 25 (b), 250 ng/ml (c) or 25 µg/ml (d). At the lowest 
dose, follicles remained fairly healthy with some unhealthy granulosa cells visible (b, black 
arrows), whereas middle dose ovaries appeared very unhealthy with all the oocytes appearing 
















A: DMSO B: 25ng/ml



















Figure 5.14. Follicle numbers within etoposide treated ovaries. Ovaries exposed to the high 
dose of etoposide had significantly reduced follicle numbers when compared with control 
(p<0.01) ovaries. Bars denote mean + sem; n=9 for DMSO control, n=6 for 50 ng/ml, n=5 for 




























































































































Figure 5.15. Distribution of follicles within ovaries exposed to etoposide. There was a 
significant dose-dependent reduction in the number of primordial (p=0.0085) and transitional 
(p=0.0012) follicles with increasing dose of etoposide. No effect was observed on primary or 
secondary follicle numbers (i). When the percentages of each follicle type was examined, no 
significant effect was observed on the proportion of primordial follicles within exposed ovaries, 
but a significant reduction was observed in the proportion of transitional follicles at the highest 
dose when compared with control (p<0.01), low (p<0.05) and medium (p<0.05) dose ovaries (ii). 
Bars denote mean + sem; n=9 for DMSO control, n=6 for 50 ng/ml, n=5 for 100 ng/ml and n=8 
for 150 ng/ml. PMF: primordial, TRNs: transitional, PRIM: primary, SEC; secondary. Means with 


























































































































Figure 5.16. Follicle health within ovaries exposed to etoposide. A slight non-significant 
increase in unhealthy follicle number was observed in low dose ovaries, with a significant 
reduction at the high dose (i) (p=0.005). A significant reduction in unhealthy follicle numbers 
was obeserved when compared with low-dose ovaries (p<0.01) but not DMSO controls (i). 
There was also a significant increase in the percentage of unhealthy follicles within ovaries 
exposed to the 100 ng/ml dose when compared with controls (p=0.0449) (ii). Bars denote mean 
+ sem; n=9 for DMSO control, n=6 for 50 ng/ml, n=5 for 100 ng/ml and n=8 for 150 ng/ml. 

















































































































































































Figure 5.17. Distribution of unhealthy follicles within etoposide treated ovaries. A non-
significant increase was observed in the number of unhealthy PMFs at the low dose, after which 
the number dropped back to the equivalent to that of control ovaries. A significant difference 
was observed in unhealthy primordial follicle numbers between low and high dose ovaries 
(p<0.01). The number of transitional follicles was also significantly reduced when compared with 
controls (p<0.01), and middle (p<0.01) dose ovaries (i). When the percentage of unhealthy 
follicle types was examined, no significant differences were observed between control and 
treated ovaries (ii). Bars denote mean + sem; n=8 for control and 10 μM, n=7 for 1 and 100 μM. 
Follicle types: PMF: primordial, TRNS: secondary, PRIM: Primary, SEC: secondary. Means with 















Follicles classified as unhealthy




























































































Follicles classified as unhealthy






























































































Figure 5.18. Distribution of follicles classified as unhealthy due to an unhealthy oocyte, 
granulosa cells or both. Unhealthy follicles were further classified into  damaged cell types, 
with the vast majority of follicles being classified as morphologically unhealthy due to an 
unhealthy oocyte (i). Below 2% of follicles at the low dose were classified as unhealthy due to 
unhealthy granulosa cells (ii) and below 1% of follicles were classified as unhealthy due to both 
unhealthy oocytes and granulosa cells at the low and medium dose (iii). Bars denote mean + 








5.4.5. Expression of γH2AX, a marker for double strand DNA breaks in etoposide 
treated ovaries  
Sections from cultured neonatal ovaries treated with 250 ng/ml etoposide and cultured 
embryonic ovaries that had been treated with 50, 100 or 150 ng/ml etoposide were 
stained for γH2AX (Figs. 5.19-20). There appeared to be an increase in cells from both 
the post-natal and pre-natal exposure groups expressing γH2AX. Following post-natal 
etoposide exposure, the expression was observed in both oocytes and a few somatic 
cells (Fig. 5.19), whereas within the embryonic ovaries that received the pre-natal 
































Figure 5.19. γH2AX expression in the cultured neonatal ovary following post-natal 
etoposide exposure. Neonatal ovaries cultured with DMSO or with 250 ng/ml etoposide for 6 

































































5.20. γH2AX expression in the cultured embryonic ovary following pre-natal etoposide 
exposure (i) and a histogram representing the number of yH2AX positive cells in DMSO 
vs. high dose ovaries (ii). E13.5 ovaries cultured for 6 days in the presence of DMSO or 
etoposide (50, 100 or 150 ng/ml), followed by another 6 days in culture media. Insert shows 
negative control. Yellow arrows depict examples of oocytes expressing γH2AX (i). There is a 
slight increase in the number of yH2AX expressing cells in etoposide treated ovaries, although 
this did not reach significance (ii) (n=3, p=0.136). 



















5.5.1 The expression pattern of Topo IIα within the in vivo & in vitro mouse ovary.  
Immunohistochemical detection of Topo IIα was carried out on cultured embryonic 
ovaries and in vivo ovaries. Ovaries were collected at a series of time-points from E13.5 
through to end of culture (12 days), or up-to PND6 in vivo. In the pre-natal in vivo 
ovary, prior to follicle formation, Topo IIα was detected specifically within the germ 
cells. Around birth, when follicles began to form and flattened pre-granulosa became 
visible around the germ cells, the expression became localised to the surrounding 
granulosa cells and stromal cells. As follicles began to grow into transitional and 
primary follicles, expression became increasingly visible within the surrounding 
granulosa cells while still being expressed in the stroma. The same expression pattern 
was observed within the cultured oocytes, where the change in expression was observed 
between days 6 and 7 of culture, at the same time as follicles began to form within the 
culture system. This result is consistent with a previous observation in the in vivo rat 
ovary, where the expression of Topo IIα was observed within the germ cells during pre-
natal ovary development,  whereas it became localised to the surrounding somatic cells 
as follicles began to form a few days after birth (personal communication, Dr. N 
Powles-Glover, AstraZeneca) (Section 3.1.3). The change in localisation did occur a 
few days earlier in the mouse ovary, but this was expected as the rat ovary is slightly 
delayed when compared with the mouse ovary. Follicles form at birth in the mouse 
ovary, whereas they do not appear until a few days after birth in the neonatal rat ovary 
(Rajah et al., 1992, Sarraj and Drummond, 2012).  
 
As far as I am aware, no prior studies had been carried out investigating expression 
pattern of Topo IIα within the rodent ovary. The expression pattern of Topo IIβ 
however had been previously described in the rodent ovary, where it was localised to 
the oocytes at all developmental stages. Topo IIβ was also weakly expressed in the 
granulosa cells of primordial follicles, becoming more pronounced in the granulosa 
cells of larger growing follicles (Zhang et al., 2013) (Section 1.4).  
 
5.5.2. The effect of pre-natal AZTC exposure on ovarian follicles. 
Ovaries exposed to the highest dose of AZTC (100 µM) had significantly fewer follicles 
remaining at the end of the culture when compared with control, low- and medium dose 
ovaries. When the follicles were classified into their follicle types, the number of 
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primordial follicles firstly appeared to increase slightly in a dose-dependent manner at 
the low (1 µM) and medium (10 µM) doses, although this was not statistically 
significant. At the highest dose however, the number of primordial follicles dropped 
significantly. There also appeared to be slightly fewer transitional follicles in the high 
dose ovaries although again, this was not statistically significant. AZTC therefore 
resulted in what appeared to be a slight rise in follicle numbers at the lower doses, but a 
near complete obliteration of follicles at the highest dose, with very few follicles 
remaining at the end of the culture period. When the percentage of follicle distribution 
was analysed, a similar effect was observed for the percentages of primordial follicles, 
with a slight increase at low and medium doses, but a significant drop at the highest 
dose. The percentage of transitional and primary follicles did however increase; the 
opposite effect to what was observed when total numbers were considered. This is 
probably better interpreted as result of the substantial loss of primordial follicles, 
leaving behind proportionally more transitional and primary follicles, rather than an 
induction in follicle growth by AZTC. 
 
AZTC had an effect on follicle health within the cultured ovaries, where a slight 
increase in the number of unhealthy follicles was observed at the low dose, nearly 
doubling at medium doses, although this was not significant. At the highest dose 
however, this number dropped to below that of the control ovaries, being significantly 
lower than that of the medium dose ovaries. This result is most likely due to the large 
amount of follicles lost in the high dose ovaries, where the wave of apoptosis has 
already passed, with the few remaining follicles being healthy. This effect was further 
confirmed when the unhealthy follicles were classified into their follicle types and a 
dose-dependent significant increase in unhealthy follicles was observed at the low and 
medium doses, and again a significant drop in the number of unhealthy follicles at the 
highest dose when compared with the low and medium doses. The percentage of 
unhealthy follicle types showed no significant difference however, demonstrating that 
proportionally, there was no difference between the percentage of unhealthy follicles of 
treated and control follicles. It is difficult to draw conclusions from this result 
considering the extensive loss of follicles within the high dose ovaries. This was most 
likely due to a large increase in atretic follicles at an earlier time-point during the 
culture, which would have gone on to die. As a consequence, follicle numbers within 




5.5.3. Comparison of in vivo and in vitro AZTC studies  
Many of the results observed here were consistent with the results from the in vivo study 
where female rats were dosed pre-natally and ovaries collected at PND15 (Chapter 3). 
Despite the obvious difference in species between the two studies (rat vs. mouse), the 
exposure windows were similar, in that exposure occurred during meiotic entry, germ 
cell nest formation and nest breakdown, meiotic arrest and potentially the earliest stages 
of follicle formation (in vitro), but not during the main bulk of follicle formation and 
initiation of growth. The exposure window in vivo does, however, start earlier than 
could be accomplished in vitro, or from the time of conception. This means that 
exposure in vivo also occurred during the time of germ cell migration and proliferation. 
Despite these differences in study design, the majority of the results between in vitro 
and in vivo did appear to complement each other, but only in regards to the low and 
medium doses of the in vitro study. Follicle numbers within exposed ovaries appeared 
to increase slightly at the low and medium dose in vitro, where follicle numbers were 
also significantly increased in the in vivo AZTC exposed PND15 rat ovaries. When the 
number of primordial follicles were examined within these ovaries, it became clear that 
the observed rise in total follicle numbers was due to an increase in primordial follicles, 
this effect reached significance in vivo but the same trend was also observed in vitro. 
Furthermore, the number of unhealthy primordial follicles significantly increased 
consistently both in vivo and in vitro at the low and medium doses. However, in 
cultured ovaries exposed to the high dose of AZTC, a large significant drop in the total 
number and primordial follicle numbers was observed, as well as a drop in the number 
of unhealthy follicles. This difference between in vivo and the high dose in vitro ovaries 
could be due to various reasons, making it difficult to effectively compare the two 
studies. Firstly it is not known how the in vitro doses compare with how much is 
reaching the ovaries in vivo. AZTC has to pass through the placenta before reaching the 
ovaries in vivo. This means that a lower concentration of AZTC might be reaching the 
in vivo ovaries as it might not pass as easily through the placenta, resulting in less 
exposure to the embryo. It is therefore possible that the doses reached in vivo are only 
equivalent to the low and medium doses in vitro. On the other hand, another possibility 
is that AZTC could accumulate in the placenta and in the embryo, with the embryo 
having a higher metabolic rate than the mother, this could, in fact, result in increased 
AZTC exposure of the embryo. Secondly, the cultured embryonic ovaries might be 
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more vulnerable and sensitive to the drug than those exposed in vivo and therefore a 
lower concentration in vitro could do more damage than the equivalent exposure in vivo. 
The cultured ovaries have been removed from their surrounding ovarian bursa and 
normal blood supply, meaning that AZTC might have more of a direct access to the 
follicles as the medium diffuses through the ovary, as opposed to being delivered 
through the blood supply in vivo. The culture environment will also most likely not 
provide the same support as the real life situation, meaning the ovarian cells might be 
more susceptible to damage or struggle to repair themselves. It is nevertheless possible 
that if the in vivo study had been carried at a higher dose then the same results might 
have been observed as in the in vitro study, where the primordial follicle numbers 
drastically dropped at the highest dose. Considering the effect of culturing the ovaries 
with 200 and 500 µM AZTC, where no follicles remain at the end of culture, it is highly 
likely that this would be the case. Unfortunately this could not be tested (Section 3.3.1). 
With regards as to whether the results observed following the in vivo PND 15 study 
(Section 3.4.2) were due to an observed litter-effect from only being able to use a litter 
born the one mother, or if it was a true finding, the findings presented here suggest that 
the previous in vivo results were a result of AZTC exposure to the pre-natal ovary due to 
the fairly close correlation between in vivo and in vitro studies. These results are 
encouraging as despite the difficulty in predicting the similarities between dosages, the 
results reflect each other closely when comparing the low and medium AZTC dosed in 
vitro ovaries to the in vivo exposed ones, suggesting that the embryonic ovary culture 
could potentially be a useful tool in future reprotoxicity studies as an investigatory tool 
for ovarian toxicants. 
 
5.5.4 Effect of AZTC on meiosis  
Embryonic ovaries that had been cultured in the presence of DMSO or the top dose of 
AZTC (100 µM) for 6 days were collected and meiotic spreads were carried out with 
immunofluorescent staining for Scp3 and Scp1. Unfortunately, due to the lower yield of 
oocytes from the AZTC treated ovaries, not enough nuclei were visible to carry out full 
analysis of the proportion of nuclei in leptotene, zygotene or pachytene. However, 
several nuclei were observed in which the homologous chromosomes appeared to have 
fully synapsed. Although it is possible that AZTC was interfering with meiosis, 
resulting in this reduced number of follicles surviving, some oocytes were able to 
progress to pachytene in the presence of AZTC. However, the loss of oocytes following 
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the high dose of AZTC could also be due to a different effect, such as on apoptosis for 
example, which might be un-related to meiosis. This study would therefore have to 
repeated to elucidate this further, with ovaries exposed to varying doses of AZTC. A 
higher yield of oocytes could then be quantified appropriately to determine if AZTC is, 
in fact, affecting meiosis.  
 
5.5.5 Mechanism of action of AZTC 
Since AZTC was added to the media only during the first 6 days of culture, exposure 
was limited to the time period that Topo IIα and Topo IIβ were expressed within the 
germ cells. Ovaries were placed in fresh control media at the 6th day of culture, and 
therefore the end of the exposure window coincided with the change in Topo IIα 
expression from germ cells to the surrounding somatic cells. The results described here 
coincided quite closely with the results outlined in Chapter 3 and therefore similar 
conclusions will be drawn about the effect of AZTC on the pre-natal ovary. AZTC was 
believed to potentially inhibit mammalian Topo II with the expected effect on 
proliferating cells and a reduction in oocyte number, although the start of the embryonic 
culture most likely does not overlap with the tail-end of proliferation, as it encompasses 
the beginning of meiosis. The role of Topo II in meiosis is still not fully understood, but 
the expression of both paralogues of Topo II was confined to the germ cells during this 
time. The slight dose-dependent increase in follicle numbers observed at the lower 
doses of AZTC was an un-expected result, yet consistent with previous observations in 
vivo (Section 3.4.2). A reduction in follicle number was observed during the embryonic 
ovary culture but only at the highest dose (100 µM). Hence, AZTC could potentially be 
inhibiting Topo II but could have an antagonistic effect at lower doses, only acting as a 
'classic' Topo II inhibitor at the higher doses where we observe the consequent loss of 
follicles. There was no obvious effect on stromal cells which would have also been 
expected to become atretic following AZTC exposure as they are rapidly diving, 
although by the end of culture (6 days after the AZTC has been removed) these might 
have already died. No effect on granulosa cell health was observed, although this was 
expected. This is because AZTC was removed prior to the time that Topo II (α and β) 
was expressed within the granulosa cells and the phase of granulosa cell proliferation. 
 
Topo II has previously been shown to be expressed in dividing cells during mitotic 
phases of the cell cycle although its presence within non-cycling cells is not clear (Heck 
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et al., 1988). Topo II has been localised at the bases of chromatin loops where it is 
closely associated with the stable maintenance of chromosomes (SMC) family of 
proteins and believed to regulate the topology of the loop. It was shown to have 
maximum condensation during mitosis and meiosis (Baguley and Ferguson, 1998). 
Here, the expression of Topo II was shown to be localised to germ cells during meiosis 
in the pre-natal ovary. Therefore, since AZTC exposure occurred during meiosis, at the 
point at which Topo II was expressed within the germ cells, a likely effect on meiosis 
was expected. Furthermore, the in vivo effect of AZTC on male rats elicited effects on 
spermatogenesis (Section 3.3.1). Unfortunately, the meiotic chromosome spreads did 
not yield enough nuclei to fully analyse meiotic stages effectively, although this was 
most likely due to the observed loss germ cells at this high dose. Despite this, several 
nuclei were observed where full synapsis had occurred. Furthermore, although fewer 
oocytes remained at the end of culture, the follicles that did survive were able to form 
follicles and from histological analysis the oocytes appeared to be at dictyate, (although 
a larger number of oocytes would have been required to investigate if there was a severe 
meiotic delay caused by AZTC). It is indeed possible that a few oocytes managed to 
develop to pachytene and that the majority were not able to enter leptotene, resulting in 
the severe lack of observed oocytes in prophase I, as the immunostaining only detects 
germ cells that have entered meiosis and are therefore at leptotene, zygotene or 
pachytene. This makes it difficult to comment on the effect of AZTC on meiosis at this 
point without further investigation. It is possible to speculate that AZTC was inhibiting 
Topo II, but perhaps Topo II is not crucial for prophase I of meiosis, or perhaps other 
enzymes might be present to compensate for the loss of Topo II activity. On the other 
hand, it is also possible that AZTC did not inhibit Topo II and was eliciting effects on 
the embryonic ovary through secondary or off-target effects. 
 
A possible secondary target for AZTC is through inhibition of other enzymes that bear 
similar morphology to Topo II such as the 90 kDa heat shock protein family (Hsp90). 
Hsp90 are molecular chaperones ubiquitely expressed in eukaryotic cells. They play a 
fundamental role in the folding and activation of proteins that are essential for cell cycle 
regulation, steroid hormone signalling and response to cellular stress (Wandinger et al., 
2008, Young et al., 2001). Hsp90 proteins are also key players in the maintenance of 
cellular homeostasis (Taipale et al., 2010). The structure of the N-domain of the Hsp90 
molecule has similar topology to the N-terminal ATP binding domain of the Topo II 
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molecule (Dunbrack et al., 1997, Prodromou et al., 1997). Since the exact mechanism of 
AZTC inhibition on Topo II is unknown, the possibility that AZTC might be inhibiting 
other proteins with similar topology to Topo II cannot be excluded. If AZTC also acts 
by inhibiting Hsp90, this might contribute to the observed results in the ovary following 
AZTC exposure.  
 
It must also be borne in mind that AZTC was developed as an antibacterial agent, but 
the rich ovary culture medium also contains another source of antibiotic in the medium, 
a  penicillin-streptomycin (pen-strep) solution (Section 4.3.4). Although the pen-strep 
solution is not supposed to affect the ovaries within the culture system, there is a slight 
possibility that the pen-strep and AZTC might have additive effects which would not 
occur if AZTC was present within the culture media alone. However, this culture 
system is vulnerable to infections and could therefore not be carried out without 
including pen-strep added to the culture medium. 
 
Differences have been shown between eukaryotic and prokaryotic Topo II (Gupta et al., 
1987). In prokaryotes, the Topo II molecule consists of two sub-units: DNA gyrase A 
protein (GyrA) and DNA gyrase B protein (GyrB), making the active form a A2B2 
heterodomier. In eukaryotes however, Topo II exists as a homodimer where the fused A 
and B sub-units are equivalent to the monomer (Kampranis et al., 1999). Consequently, 
certain Topo II targeted drugs have been reported to have different effects on 
prokaryotic vs. eukaryotic cells. Etoposide and Teniposide, for example, show high 
mutagenicity to mammalian cells at relatively low concentrations (50 ng/ml) but have 
very little effect on prokaryotic cells (Gupta et al., 1987). Since AZTC was being 
created as an antibacterial agent, targeting bacterial Topo II, it is therefore possible that 
AZTC might not elicit the same effects on Topo II in eukaryotic cells, despite homology 
between bacterial and mammalian Topo II.  
 
5.5.6. The effect of pre-natal etoposide exposure on ovarian follicles. 
Etoposide resulted in a dose dependent reduction on follicle numbers, reaching 
significance at the top dose of etoposide (150 ng/ml) when compared with controls and 
low dose ovaries. When follicles were distributed into their follicle types it became 
apparent that the reduction in follicle number was due to a reduction in primordial and 
transitional follicles, with a slight decrease in primary follicle numbers as well, although 
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this was not significant. The number of unhealthy follicles within etoposide treated 
ovaries showed a similar trend as those exposed to AZTC, with a slight, non-significant 
increase in the number of unhealthy follicles at the low dose, but dropping significantly 
at the high dose when compared with the low dose. This was observed for both for 
primordial and transitional follicles. When the proportion of unhealthy follicles was 
examined, there was a significant increase in the proportion of unhealthy follicles at the 
middle dose, but again, a drop in numbers at the highest dose. As already outlined 
above for AZTC, since the ovaries remain in culture for 6 days following the end of 
etoposide treatment, the most likely explanation for this is that the wave of apoptosis 
induced by the high dose of etoposide results at an earlier time-point in culture, causing 
the follicles to become atretic and die. As a consequence, fewer follicles remain at the 
end of culture, but the few remaining follicles are healthy. At lower doses, the follicles 
might not be as strongly affected, and follicles may therefore take longer to become 
atretic and die. 
 
5.5.7. Etoposide resulted in increased DSB formation within exposed ovaries 
Etoposide has been suggested to inhibit Topo II by interfering with the nick closure 
reaction, resulting in DNA fragmentation and increased DBSs within the DNA (Gupta 
et al., 1987). DSBs are highly deleterious lesions in genomic DNA that can be generated 
by Topo II poisons including etoposide. If DSBs are not efficiently repaired, 
chromosomal aberrations and apoptosis occurs. Here, immunofluorescent staining was 
carried out for the DSB marker, γH2AX, in neonatal ovaries cultured with etoposide 
and in embryonic ovaries that had been exposed to etoposide for the initial 6 days of 
culture, during meiosis, but had then been left in control medium for a further 6 days. 
DSBs play a crucial role in meiosis where they are used to mediate the immunoglobulin 
class-switch recombination event (Daboussi et al., 2002) and therefore γH2AX 
immunofluorescence staining could not be carried out on pre-natal ovaries, as DSBs 
normally occur during meiosis. A large increase in γH2AX staining became visible in 
ovaries exposed to etoposide both pre-natally (150 ng/ml) and post-natally (250 ng/ml), 
at doses that are considerably lower than the 5-60 μg/ml concentration measured in 
human plasma following treatment with etoposide (Hande et al., 1984). This was an 
expected result as etoposide has previously been shown to induce DSBs, suggesting that 
etoposide utilises the mechanism of DNA strand breaks to induce cell death (Smart, 
2008). γH2AX expression was primarily observed within the germ cells of pre-natally 
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exposed ovaries, whereas γH2AX expression was detected within the germ cells but 
also appeared to be expressed within the surrounding somatic cells in the post-natally 
exposed ovaries. This could potentially be due to etoposide exposure occurring during 
the phase of somatic cell proliferation in the post-natal ovary, affecting cell division, 
whereas in the pre-natal ovary culture, follicle formation occurs after etoposide has been 
removed from the culture medium and therefore granulosa cells were able to form and 
divide without any interference by etoposide. An interesting next step would be to 
confirm the observed differences in γH2AX expressions within germ and somatic cells 
between the pre- and post-natal exposure ovaries. This could be done by carrying out 
immunofluorescent staining for γH2AX in conjunction with cell specific markers for 
germ cells, such as vasa, MVH or GDF-9, for example. 
 
5.5.8 How might etoposide affect the unborn ovary?  
The results presented here show a concerning, dose-dependent effect of increased 
etoposide exposure that results in a reduction of the follicle pool and decreased follicle 
health, with a corresponding increase in DSBs. Although there are some differences 
between the mouse cultures described here and the real-life situation of in-utero human 
exposure, these results still indicate a cause for concern, in particular since etoposide 
has been prescribed to pregnant women. Although these women did give birth to 
healthy children, little can be done to investigate potential effects etoposide had on the 
developing ovary given the short follow-up time possible at present. The effects will not 
become apparent for another 6-30 years when the daughters born to these women begin 
their own menstrual cycles and/or try to conceive children of their own. 
 
Inter-species differences are the primary concern at hand here, where effects observed 
in the mouse ovary might not be reflected in what is observed in the human ovary. It is 
possible that the cultured embryonic ovary might be more delicate, resulting in an 
increased effected at lower doses than what would be observed in vivo. Cultured ovaries 
might also have a higher rate of cellular uptake of etoposide than what might occur in 
vivo. Furthermore, in-utero, some of the etoposide might be filtered through the 
placenta, although the majority of the current evidence points towards the ability of 
etoposide to cross the placenta and reach the developing fetus (Ostrea et al., 2004, 
Hengstler et al., 2002). Despite this, the exposed cultured ovaries demonstrate clear 
dose-dependent effects following etoposide exposure which should be carefully 
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considered, as it is likely that if etoposide targets the DNA within mouse germ cells in 
culture, that similar effects might be observed in the human fetus in vivo. Moreover, 
topoisomerase-targeted drugs can elicit genetic mutations which could be transmitted to 
future generations and therefore the effects of the pre-natal etoposide exposure would 
perhaps not become clear until after two generations. 
 
The exposure of cultured mouse ovaries to another chemotherapy drug, cisplatin, at the 
same concentrations as are measured in patient serum levels, has been shown to induce 
in ovary damage. Cisplatin is known to induce moderate damage to the patient’s 
fertility, demonstrating that the effects observed using mouse ovary culture techniques 
can correlate closely with the reproductive effects that occur following chemotherapy 
treatment in humans (Morgan et al., 2013). 
 
5.5.9 Comparing the effects of pre-natal AZTC and etoposide exposure  
As outlined above, both AZTC and etoposide resulted in an unusual dose-response 
curve in that a higher proportion of unhealthy follicles were observed at lower and 
medium doses than at the top doses. The results did not, however, complement each 
other with regards to follicle numbers within the ovaries. AZTC initially resulted in an 
increase in follicle numbers followed by a drop at the top dose, whereas follicle 
numbers reduced in a dose-dependent manner following etoposide exposure. It is worth 
noting that the observed increase in follicle numbers following AZTC exposure is a 
fairly unusual result from prior work in the Spears Laboratory with various reproductive 
toxicants and chemotherapy drugs (Personal Communication, Prof. N. Spears), as the 
more commonly observed effect of drug-induced ovary disruption, is a loss in follicle 
numbers. One potential explanation for this result is that AZTC is, in some way, 
affecting the wave of apoptosis associated with germ cell nest breakdown which is 
believed to remove any germ cells that are of a lesser quality (Pepling and Spradling, 
2001). AZTC might inhibit apoptosis, or it might disrupt the process of germ cell nest 
breakdown and result in more germ cells forming. Indeed, some multioocyte follicles 
have been observed, but this has also been observed in control ovaries and is therefore 
not necessarily an effect of AZTC. Whether AZTC inhibits mammalian Topo II in a 
manner similar to etoposide is difficult to comment on and would require further 
studies, as the results here do not correspond as closely as was expected. AZTC could 
still be inhibiting mammalian Topo II but potentially via an alternate pathway.  
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5.5.10. Could the embryonic ovary culture be a potential tool for use in future 
reproductive toxicity studies?  
The embryonic ovary culture used here to test the potential reproductive effects of two 
Topo II inhibitors: AZTC and etoposide. The in vitro effects of AZTC were compared 
with effects from the in vivo study where the window of exposure resembled that of the 
embryonic ovary culture. The results from the PND15 in vivo AZTC study and the 
embryonic ovary culture correlated quite closely, but only in regard to the low and 
medium dosed cultured ovaries. Despite this, it is a very encouraging result as it 
suggests that the culture system might be a good and potentially, a more sensitive tool 
for preliminary investigations into potential reproductive effects of novel 
pharmaceutical compounds. 
 
The second drug tested here, etoposide, showed surprising results, where at doses 
considerably lower than the serum level following etoposide treatment, major effects 
were observed on the follicle pool and ovary health. This is a worrying result as, if it 
translates to the human, it could suggest that girls born to mothers that have had to 
undergo chemotherapy might suffer from fertility problems later in life. These results do 
correlate with previous studies where ovarian effects of etoposide were observed in 
mice and hamsters, with increased frequency of aneuploid oocytes and chromosome 
aberrations (Mailhes and Marchetti, 1994, Tateno and Kamiguchi, 2001a). 
 
It should be borne in mind that chemotherapy treatment does not usually just involve 
one chemotherapy drug, which could further cause further complications when trying to 
elicit which drug has the reproductive effect, or whether a combination of drugs 
aggravates the reprotoxicity effects. Therefore, in vitro cultures where drugs can be used 
alone or in combination could be an important and effective tool in determining the 
mechanisms of action of drugs, and how effects may differ when used alone or in 






Embryonic ovaries cultured with the low and medium dose of AZTC demonstrated 
effects that were consistently similar to what was observed in the PND 15 in vivo ovary 
following AZTC exposure. Another Topo II inhibitor and potential ovarian toxicant was 
then used to test the efficiency of the embryonic ovary culture system. Etoposide 
elicited effects on the follicle pool and health, suggesting potential effects on fertility on 
girls born to mothers who have had to undergo etoposide treatment during pregnancy. 
These results suggest that the embryonic ovary culture could be used as a preliminary 
screening tool for novel or pre-existing pharmaceutical drugs or potential reproductive 
toxicants. Furthermore, these cultures could be used as a way to elucidate if 
chromosomal sensitivity of oocytes to certain compounds or drugs is dependent on 
meiotic stages.  
 
5.7 Future directions 
In the future, it would be interesting to carry out further embryonic ovary cultures using 
other suspected or known reproductive toxicants, or Topo II inhibitors. These could 
include drugs such as teniposide and doxorubicin (Hande, 1998), or chemicals found in 
cigarette smoke, such as DMBA or B[a]P, that have been shown to affect the pre-natal 
ovary in vivo (Borman et al., 2000, Igawa et al., 2009, Matikainen et al., 2002, Mattison 
and Thorgeirsson, 1979). Future work could also involve repeating the meiotic 
chromosome spreads on more AZTC-treated ovaries to obtain a larger number of 
oocytes so that the proportion of oocytes in the different stages of early prophase-I 
could be analysed effectively. It would also be interesting to carry out meiotic 
chromosome spreads on etoposide treated ovaries. The γH2AX immuno could also be 
carried out on AZTC treated ovaries, to investigate if AZTC elicits the same DSBs in 
culture as is observed following etoposide treatment. Finally, it would be interesting to 
investigate if a single high dose of AZTC or Etoposide elicited a different response than 
the continuous dose, as was carried out here, since cells can develop a resistance to 
drugs. A single high dose exposure might therefore produce a more devastating effect 




























Topoisomerases, AZTC and etoposide have already been described in detail in previous 
chapters (Sections 1.4 and 5.1.1, respectively) and will therefore not be outlined again 
here.  
 
6.1.1 The rodent neonatal ovary culture. 
In rodent ovaries, primordial follicle assembly occurs around the time of birth. The 
process of follicle formation and the subsequent initiation of follicle growth are two 
separate processes both covered by the culture of neonatal ovaries (Devine et al. 
2002b). The neonatal ovary culture involves culturing of a whole rodent ovary from 
after birth for up to 20 days (Eppig and O'Brien, 1996, Parrott and Skinner, 1999, 
O'Brien et al., 2003, Devine et al., 2002b). It is an appropriate culture system for 
studying the biology of primordial follicle assembly and the primordial-to-primary 
follicle transition, and is thus a valuable asset to toxicological research to identify 
potentially hazardous compounds that could interfere with these processes, or for 
scientists looking to investigate factors involved in early follicular growth. 
 
6.1.2. Strain differences in ovarian follicles in mice  
The mouse is a commonly used model in mammalian research studies, including studies 
in reproduction and reproductive toxicology. Since both women and mice share crucial 
reproductive aspects such as being born with a finite number of follicles, the mouse is a 
good model system for studying effects of potential ovotoxicants on the ovary and 
follicle pool.  
 
There are various mouse strains available to use in laboratory studies, including CD-1, 
C57BL/6J, C57BL/10, CBA, BALB/c, C3H, FVB, and SWR. These strains are widely 
used for transgenic and gene knockout technologies as well as in reproductive toxicity 
studies. Inter-strain differences have been reported in various strains of mice, including 
susceptibility to fibrosis, drug metabolism, sensitivity to hormones, testosterone levels, 
ovary function, ovotoxicity and follicle endowment (Mattison and Thorgeirsson, 1979, 
Canning et al., 2003, Thomas et al., 2010, Pepling et al., 2010, Brouillette et al., 2004, 
Walkin et al., 2013). Some of these differences can be explained through years of 
inbreeding, where some animals (such as CD-1 mice) were selected due to their larger 
litter sizes, which is a result of an increased ovulation rate. Over the years, this may 
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have altered the follicle population and ovarian responsiveness to gonadotropins, 
including a decrease in negative feedback on gonadotropins. As a result, CD-1 mice are 
more resistant to the effects of estrogen exposure, including the effects of certain 
estrogenic endocrine disruptors (Spearow et al., 1999). It is therefore important to be 
aware of inter-strain differences when it comes to investigating potential ovotoxicants, 
as choosing one strain over another may result in diverse outcomes, where CD-1 mice 
might not respond to a xenobiotic in the same manner as other mouse strains, resulting 
in a potential endocrine disruptor ‘slipping under the radar’. Despite this, relatively little 
research has gone into investigating the differences between different strains of mice, in 
particular regarding the reproductive axis. This emphasizes the need to identify and 
study genetic variation between mouse strains, to further understand their sensitivity to 
gonadotropins, differences in ovarian function, vulnerability to disease and metabolic 
rate, to name a few.  
 
6.2. Aims 
The aim of this work was to carry out neonatal ovary cultures to investigate the effects 
of AZTC on the post-natal ovary, to compare with the effects with those observed when 
AZTC exposure occurs pre-natally. Another Topo II inhibitor, etoposide was then 
selected as a second study compound to evaluate its effects on the post-natal ovary 
compared with the effects of AZTC. 
 
6.3 Materials and Methods 
6.3.1. Animals 
An initial experiment was set up where newborn (P0) female offspring from C57BL6 x 
CBA crosses (F1) were collected and ovaries were dissected for a 6 day culture. 
However, due to low litter numbers in the C57BL6/CBA mice this study was repeated 
with CD-1 mice, because the CD-1 pairs were having considerably larger and more 
frequent litters than the C57BL6/CBA pairs. Furthermore, CD-1 mice had already been 
used for the embryonic ovary cultures due to their large litter sizes (Chapters 4 and 5). 
CD-1 females were therefore selected for all subsequent newborn ovary cultures to 






6.3.2. Neonatal ovary culture 
Ovaries from P0 or P4 CD-1 or F1 female pups were dissected and placed in pre-
warmed L-15 medium as previously described (Section 2.1). Neonatal ovaries (P0 or 
P4) were cultured for 6 days on a floating membrane on simple medium in 24-well 
plates (Sections 2.1.2-2.1.3). The medium was placed in the incubator for 30 minutes to 
equilibrate before ovaries were placed on the membranes. 
 
6.3.3. Experiment 1: Assessment of Topo IIα expression in the cultured neonatal 
mouse ovary.  
Newborn (P0) ovaries (CD-1) were cultured for 6 days as outlined above, and were 
collected at each day of culture, on days 1-6. Ovaries were washed in 1xPBS for 5 
minutes and fixed in 70% buffered formalin and processed as outlined previously 
(Section 2.2). In vivo mouse ovaries had already been collected from P0-P6 (Section 
5.3.3). The expression pattern of Topo IIα in cultured neonatal ovaries was compared 
with ovaries at the equivalent stage in vivo. 
 
6.3.3.1 Immunohistochemistry for Topo IIα 
Topo IIα expression was detected in the ovary following the same protocol as outlined 
previously (Section 5.3.3.1). The primary antibody was a rabbit polyclonal anti-
Topoisomerase IIα (Abcam, ab52934) and the secondary antibody was a biotinylated 
goat-anti rabbit (Dako); both were diluted at a 1:200 dilution in NGS/BSA/PBS 
(Section 2.4). Slides were blocked in the NGS/BSA/PBS solution before applying the 
primary antibody. The primary antibody was left on the slides overnight at 4˚C (Section 
2.4.4). Slides were incubated with the secondary antibody for one hour at room 
temperature (Section 2.4.5). Topo IIα was detected with DAB (Section 2.4.6).  
 
6.3.4. Experiment 2: P0 and P4 ovary cultured with AZTC 
An initial dose-response study was carried where the medium was supplemented with 
AZTC at final concentrations of 1, 10, 100 and 500 µM AZTC in DMSO. The final 
concentrations of 1, 10 and 100 µM were selected for the study due to poor follicle 
morphology of ovaries cultured at higher doses. P0 (experiment 2a) or P4 (experiment 
2b) ovaries were cultured for 6 days with either DMSO, 1, 10 or 100 µM AZTC. For the 
P0 experiment, a total of 5 ovaries were assessed for each treatment group from 3 
independent cultures. For the P4 experiment, a total of 4 ovaries were assessed for each 
treatment group, from 2 independent cultures.  
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6.3.5. Experiment 3: PND 0 ovaries cultured with etoposide.  
The effect of another Topo II inhibitor, etoposide, was also investigated on the neonatal 
ovary, to investigate if the effects of AZTC exposure correlated with that of a known 
Topo II inhibitor. 
 
Initially, a dose response study was carried out on cultured P0 CD-1 mouse ovaries, 
where ovaries were cultured for 6 days with either DMSO, or etoposide at final 
concentrations of 25 ng, 250 µg or 25 mg/ml in DMSO throughout the culture period. 
This range of doses was selected to cover the plasma concentrations (5-60 μg/ml) 
reached in patients following etoposide treatment (Section 5.3.5). A total of 6 ovaries 
were assessed for each treatment group, from 4 independent cultures.  
 
Final etoposide concentrations of 50, 100 and 150 ng/ml were selected for experiments. 
Ovaries were cultured for 6 days as outlined previously (Section 2.1).  
 
6.3.6. Histological examination of cultured ovaries 
At the end of culture, ovaries were washed in 1xPBS and placed in either Bouins 
fixative for 1-2 hours or in 10% buffered formalin overnight (Section 2.2.1). Ovaries 
were washed in 70% alcohol and left for 2-24 hours in 70% ethanol with eosin. Ovaries 
were then placed in tissue processing cassettes and processed (Section 2.2.2) before 
being embedded in plastic moulds and filled with wax. 5 µm sections were cut and 
every 6th section was H&E stained (Section 2.2.4) and analysed for follicle numbers, 
types and health. Follicles were counted blind to treatment and categorised as outlined 
previously (Section 2.3).  
 
There were several ways in which the data could be analysed and presented, where 
either total follicle number (healthy, unhealthy, types, etc), or the percentage 
(proportion) of follicles were presented. While neither method is necessarily superior 
and examining both gives a better idea, or the 'bigger picture' of what is happening 
within the ovary, up-on reflection it was decided to present the data as percentages of 
total follicle numbers. This was the chosen method as I felt this demonstrated better the 
true distribution of follicles (healthy and unhealthy), especially in ovaries where total 
follicle numbers had decreased. The data was also analysed in terms of total numbers 
but these results were not included in this chapter to avoid complications when it came 
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to comparing all the different analyses (total numbers, percentage, follicle distributions, 
health, etc.) as well as comparing P0 vs P4 ovaries, AZTC and etoposide, and F1 vs 
CD-1. The excluded tables have therefore been placed in the Appendix instead (See 
Appendices C-F).  
  
6.3.7. Statistical Analysis 
Graphpad Prism was used for all statistical analyses of follicle number and distribution 
between DMSO control ovaries and ovaries exposed to AZTC or Etoposide as outlined 
previously (Section 3.3.3).  
 
6.4 Results 
6.4.1. Experiment 1: Expression pattern of Topo IIα in the cultured neonatal ovary 
After one day of culture, Topo IIα expression could still be observed within many germ 
cells, as well as some stromal cells. By the second day of culture, very few germ cells 
and stromal cells were expressing Topo IIα. Topo IIα became limited to granulosa cells 
around days 3-4 of culture, with germ cells no longer expressing Topo IIα. By the fifth 
and sixth day of culture, Topo IIα expression was confined to the granulosa cells of 
growing follicles, although not all granulosa cells were found to be expressing Topo IIα. 
Some expression was also observed in stromal cells at this point (Fig. 6.1). The 
expression pattern correlated fairly closely with the in vivo ovary (Fig. 5.3, repeated in 
















Figure 6.1. Expression pattern of Topo IIα in the cultured neonatal mouse ovary. Topo IIα 
was still detected within germ cells during the first two days of culture, but became localised to 
the surrounding granulosa cells and stromal cells around the third day of culture. By the end of 
culture, Topo IIα was expressed mainly in the granulosa cells of growing follicles and in some 


















Figure 6.2. Comparison of the expression pattern of Topo IIα in the in vivo mouse ovary vs. the cultured neonatal mouse ovary. The 
same expression pattern was observed in the neonatal cultured ovary as was previously seen in the in vivo ovary. The top line of images here 
is repeated from Fig. 5.3. Topo IIα expressed was still observed within some germ cells around and shortly after birth, and in the first two days 
of culture. Expression of Topo IIα was then found exclusively within the somatic cells, in the granulosa and stromal cells around day 2-3 in vivo 





6.4.2. Experiment 2: Effects of AZTC on the cultured newborn mouse ovary 
6.4.2.1. Dose response study 
Following the initial dose response study, no obvious histological effects were 
observed at the 1, 10 and 100 µM concentrations following a 6 day culture of 
newborn mouse ovaries (P0) with AZTC. At the 500 µM concentration however, the 
ovaries were shrunken and the ovarian stroma appeared to be very morphologically 














Figure 6.3. Dose response study with AZTC. Photomicrographs of ovary sections that had 
been treated with DMSO or AZTC at final concentrations of 1, 10, 100, or 500 μM. Ovaries 
exposed to 500 μM appeared very atretic with poor ovary morphology and no remaining 
follicles. Ovaries at lower concentrations contained healthy follicles at stages ranging from 





6.4.2.2. Experiment 2a: Newborn ovary cultures with AZTC (CD1) 
Newborn (P0) CD1 ovaries were cultured with DMSO or 1, 10 or 100 µM AZTC for 
6 days (n=6 for all treatment groups) as described previously (Section 2.1). At the 
end of the 6 day culture (n=5 for all groups), there was no significant effect on the 
total number of follicles within the ovaries. There appeared to be a slight, dose-
dependent reduction in follicle number with increasing AZTC dose, but this was not 
statistically significant (p=0.287) (Fig. 6.4i). AZTC had no significant effect on the 
percentage of primordial (p=0.424), transitional (p=0.474) or primary (p=0.213) 
follicles. There was, however, a significant decrease in the percentage of secondary 
follicles with increasing AZTC-dose (0.029) with the two-way ANOVA, but this was 
not supported by post-hoc tests (Fig. 6.4ii).  
 
AZTC did not have an effect on the percentage (p=0.098) of unhealthy follicles 
within AZTC-treated ovaries, where the trend observed did not follow a regular 
dose-response pattern (Fig. 6.5i). That is, a slight increase in the proportion of 
unhealthy follicles was observed up-to the middle dose, which dropped again at the 
top dose. When the distribution of unhealthy follicles was examined, a significant 
increase was observed in the percentage of unhealthy transitional follicles at the 
medium dose when compared with controls (p=0.033) (Fig. 6.5ii), with this number 
dropping again at the top dose. A similar trend was observed for the percentage of 
unhealthy primordial follicles as well, but this did not reach statistical significance 
(p=0.387) (Fig 6.5ii). 
 
In order to determine the cell type responsible for the follicles being classified as 
unhealthy, and to determine which cell type was being targeted by AZTC, follicles 
were further classified into unhealthy due to the oocyte only, granulosa cells only, or 
both due to an unhealthy oocyte and granulosa cells. Nearly all the unhealthy 
follicles within the AZTC treated CD-1 P0 ovaries were classified as such due to an 
unhealthy oocyte (Fig. 6.6). There was a slight increase in the proportion of follicles 
classified as unhealthy due to an unhealthy oocyte, up-to the medium dose, but this 
did not reach significance (p=0.089) (Fig 6.6i). A very small proportion (less than 
1%) of follicles had been classified as unhealthy due to unhealthy granulosa cells. 
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There appeared to be slightly more unhealthy follicles due to unhealthy granulosa 
cells in control ovaries when compared with treated ovaries but this was not 































































































Figure 6.4. Total number of follicles within CD-1 P0 cultured ovaries. AZTC had no 
significant effect on the total follicle number within exposed ovaries compared with controls 
(p=0.287). A non-significant, dose-dependent trend was however observed where exposed 
ovaries appeared to have slightly fewer follicles with increasing dose of AZTC (i). AZTC had 
no significant effect on the distribution of follicles within the neonatal ovary when the 
percentage of total follicles was examined (ii). Bars denote mean + sem; n=5 for all groups. 

































































































































Figure 6.5. Follicle health within CD-1 P0 AZTC exposed ovaries. A slight non-significant 
increase was observed in the percentage of unhealthy follicles at the low and medium doses 
of AZTC, but this number dropped at the high dose (p=0.240) (i). Upon analysing the 
distribution of unhealthy follicles, the same trends were observed for the percentage of 
unhealthy follicles, where, again, a slight non-significant increase of unhealthy primordial 
follicles at the low and medium doses but a drop at the highest dose (p=0.387). The 
percentage of transitional follicles did significantly increase at the medium dose (p=0.033) 
and dropping at the highest dose (ii). Bars denote mean + sem; n=5 for all groups PMF: 
primordial, TRNS: secondary, PRIM: Primary, SEC: secondary. Means with different letters 






















































































































Figure 6.6. Distribution of follicles classified as unhealthy due to an unhealthy oocyte, 
granulosa cells or both. Unhealthy follicles were further classified into damaged cell types, 
with the vast majority of follicles being classified as morphologically unhealthy due to an 
unhealthy oocyte (i). There were no significant effects on the percentage of unhealthy 
follicles due to unhealthy granulosa cells or due to both unhealthy oocytes and granulosa 





6.4.2.3. Experiment 2b: Neonatal (P4) ovary cultures with AZTC 
Neonatal (P4) CD-1 mouse ovaries were collected and cultured for 6 days with 
DMSO or with AZTC at final concentrations of 1, 10 or 100 µM, as outlined 
previously (Section 2.1). Since Topo IIα was still expressed within the germ cells up-
to 2 days after birth, this experiment was carried out to investigate whether a 
different effect might be observed if AZTC exposure occurred when Topo IIα was 
expressed within somatic cells of the ovary. 
 
AZTC resulted in a slight, but non-significant reduction in total follicle number in all 
ovaries exposed to AZTC (p=0.075) (Fig 6.7i). When the follicles were distributed 
into their respective types, however, there was a significant reduction in the 
proportion of primordial follicles, but only at the medium dose (p=0.028). There was 
also a significant increase in the proportion of transitional follicles in the medium 
dose ovaries compared with controls (p=0.031) (Fig. 6.7ii).  
 
When follicle health was examined, there was a significant increase in the proportion 
of unhealthy follicles at the medium dose (p=0.004) (Fig. 6.8i). The high dose 
ovaries did have a slightly higher proportion of unhealthy follicles when compared 
with controls, but this did not reach statistical significance (Fig. 6.8i). When 
examining the distribution of unhealthy follicles, a significant increase in the 
percentage of unhealthy primordial (p=0.010) and transitional (p=0.002) follicles 
was observed at the medium dose when compared with control and low dose ovaries 
(Fig. 6.8ii), followed by a reduction in percentage of unhealthy primordial follicles at 
the high dose, although the number was still relatively higher than controls, but not 
significantly so. 
 
In order to determine the cell type responsible for the follicles being classified as 
unhealthy, and to determine which cell type was being targeted by AZTC, follicles 
were further classified into unhealthy due to the oocyte only, granulosa cells only, or 
both. Nearly all the unhealthy follicles within the AZTC treated embryonic ovaries 
were classified as such due to an unhealthy oocyte. The proportion of follicles 
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classified as unhealthy due to an unhealthy oocyte significantly increased, similarly 
























































Figure 6.7. Total number (i) and distribution (ii) of follicles within CD-1 P4 ovaries 
cultured with AZTC. AZTC had no significant effect on follicle numbers within exposed 
ovaries (p=0.075), although all ovaries receiving AZTC treatment consistently contained 
slightly fewer follicles than controls (i). AZTC resulted in a significant reduction in the 
percentage of primordial follicles (p=0.028) in medium dose ovaries when compared with 
controls, and similarly, a significant increase in the percentage of transitional follicles was 
observed at the medium dose when compared with controls (p=0.031). No significant effect 
was found on the percentage of primordial or transitional follicles within low or high dose 
ovaries, or on other follicle types within treated ovaries (PRIM, p=0.644 . SEC, p=0.447) (ii). 
Bars denote mean + sem; n=4 for all groups. Follicle types: PMF: primordial, TRNS: 
secondary, PRIM: Primary, SEC: secondary. Means with different letters are significantly 

































































































































Figure 6.8. Follicle health within AZTC-exposed CD-1 P4 ovaries. There was a 
significant increase in the percentage (p=0.004) of unhealthy follicles at the medium dose 
when compared with control and low dose ovaries (i). There was a significant increase in the 
percentage (p=0.010) of unhealthy primordial follicles at the medium dose compared with 
control and low dose ovaries. There were also significantly more unhealthy transitional 
follicles at the medium dose when compared with all other treatments (p=0.0002). No effect 
was found on the percentage of unhealthy primary (p=0.355) or transitional (p=0.354) 
follicles (ii). Bars denote mean + sem; n=4 for all groups. Follicle types: PMF: primordial, 
TRNS: secondary, PRIM: Primary, SEC: secondary. Means with different letters are 
























































































































Figure 6.9. Distribution of follicles classified as unhealthy due to an unhealthy oocyte, 
granulosa cells or both. Unhealthy follicles were further classified into damaged cell types, 
with the vast majority of follicles being classified as morphologically unhealthy due to an 
unhealthy oocyte. Furthermore, there was a significant increase in the number of unhealthy 
follicles due to an unhealthy oocyte at the medium dose when compared with control and low 
dose ovaries (p=0.006) (i). AZTC had no significant effect on the proportion of follicles 
classified as unhealthy due to unhealthy granulosa cells or both (granulosa: p=0.338, both: 
p=0.680). (ii). Bars denote mean + sem; n=4 for all groups. Follicle types: PMF: primordial, 
TRNS: secondary, PRIM: Primary, SEC: secondary. Means with different letters are 









6.4.3. Experiment 3: Neonatal (P0, CD-1) cultures with etoposide 
Etoposide was selected as a secondary study compound due to its known Topo II-
inhibitory properties (Section 5.1.1). If similar effects were observed in ovary 
cultures with etoposide as were observed with AZTC, then this would suggest that 
AZTC also acts by inhibiting Topo II. However, if the results were different, it would 
either mean that AZTC does not interfere with Topo II directly, or that it does so by a 
different pathway than etoposide. 
 
An initial dose-response study had been previously carried out on cultured neonatal 
(P0) ovaries to assess the appropriate doses of etoposide to use in culture (Section 
5.3.5). Following the dose-response study, final concentrations of 50, 100 and 150 
ng/ml were selected for future experiments (n=5 for high dose ovaries, n=4 for all 
other treatment groups). These doses were selected as they were lower than the doses 
that resulted in complete follicle atresia but were also lower than the range of serum 
concentration measured in patients following etoposide treatment (5-60 μg/ml) 
(Section 5.1.1). 
 
Post-natal in vitro exposure to etoposide had no significant effect on follicle numbers 
within the ovaries, although a dose-dependent, but not-significant, reduction in 
follicle numbers was observed with increasing dose of etoposide (p=0.249) (Fig. 
6.10i). Etoposide had no significant effect on the proportion of primordial, 
transitional, primary or secondary follicle types (Fig. 6.10ii).  Upon analysing follicle 
health within the exposed ovaries, there was a slight, dose-dependent increase in the 
percentage of unhealthy follicles observed with increasing etoposide dose, although 
this did not reach statistical significance (p=0.216) (Fig. 6.11i). Similarly, etoposide 
had no effect on the distribution of unhealthy follicle types within cultured ovaries 
(Fig. 6.11ii).  
 
In order to determine the cell type responsible for the follicles being classified as 
unhealthy, and to determine which cell type was being targeted by etoposide, 
follicles were further classified into 'unhealthy follicle due to an unhealthy oocyte', 
'unhealthy follicle due to unhealthy granulosa cells' or 'unhealthy follicle due to both 
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unhealthy oocyte and granulosa cells'. Nearly all the unhealthy follicles within the 
post-natally treated etoposide ovaries were classified as such due to an unhealthy 
oocyte (Fig. 6.12). There appeared to be a dose-dependent increase in the proportion 














































































































Figure 6.10. Total number (i) and distribution (ii) of follicles within P0 CD1 ovaries 
exposed to etoposide in vitro. No significant effect of etoposide was observed on the 
follicle number within the post-natal ovaries treated with etoposide (p=0.249). There did 
appear to be a dose-dependent reduction in follicle numbers with increasing etoposide dose, 
although this was not significant (i). No significant effect was found on the percentage of any 
of the follicle types (PMF: p=0.250, TRNS: p=0.288, PRIM: p=0.129) except secondary 
follicles, where a significant reduction in the percentage of secondary follicles was observed 
at the high dose (p=0.048), but this was not supported by post-hoc tests (ii). Bars denote 
mean + sem; n=5 for high dose, n=4 for all other groups. Follicle types: PMF: primordial, 















































































































Figure 6.11. Follicle health within P0 ovaries treated with etoposide in vitro. Etoposide 
had no significant effects on the percentage of unhealthy follicles within ovaries (p=0.216). 
There was a slight, dose-dependent increase in the percentage of unhealthy follicles with 
increasing etoposide dose, although this was not significant (i). There appeared to be dose-
dependent trends for an increase in the percentage of unhealthy primordial and transitional 
follicles with increasing dose, but this did not reach significance (PMF: p=0.142, TRNS: 
p=0.415) (ii). Bars denote mean + sem; n=5 for high dose, n=4 for all other groups. Follicle 



















































































































Figure 6.12. Distribution of follicles classified as unhealthy due to an unhealthy 
oocyte, granulosa cells or both. Unhealthy follicles were further classified into damaged 
cell types, with the vast majority of follicles being classified as morphologically unhealthy due 
to an unhealthy oocyte (i). A very small proportion of follicles were classified as unhealthy 







6.4.4. Experiment 4: Newborn ovary cultures with AZTC (F1) 
The first cultures carried out for this work had been where newborn F1 ovaries had 
been cultured with either DMSO or AZTC at 1, 10 or 100 µM concentrations. These 
cultures were then repeated with CD-1 ovaries, to allow a more direct comparison 
with the pre-natal cultures (carried out using CD-1 ovaries, see Chapter 5). None-the-
less, it seems worth including the results from the F1 experiment here, since they 
provide an interesting observation on a topic that is often ignored in reproductive 
biology: inter-strain differences.  
 
At the end of the 6 day culture, no significant effect was observed on the total 
number of follicles within the ovaries. There did appear to be a slight, dose-
dependent reduction in follicle number with increasing AZTC dose, although this 
was not statistically significant (p=0.148) (Fig. 6.13i). When follicles were 
distributed into the different follicle types, there was a significant decrease in the 
percentage of primordial follicles at the high dose when compared with all other 
treatment groups (p=0.0007), as well as a significant increase in the percentage of 
transitional follicles at the high dose (p=0.0006). There was no effect on the 
percentage of primary follicles within treated ovaries (p=0.333) (Fig. 6.13ii).  
 
When follicle health was examined, AZTC had an effect on the proportion of 
follicles within the ovaries that were unhealthy (p=0.0009), where the percentage of 
unhealthy follicles increased significantly at the highest dose when compared with 
controls, low and medium dose treatment groups (Fig. 6.14i). When the distribution 
of unhealthy follicles was examined, a significant increase in the proportion of 
unhealthy transitional follicles was observed within high dose ovaries (p<0.0001). 
Similarly, there were slight increases in the proportions of unhealthy primordial and 
primary follicles but these did not reach statistical significance (primordial: p=0.399, 
primary: p=0.064) (Fig. 6.14ii). 
 
In order to determine the cell type responsible for the follicles being classified as 
unhealthy, and to determine which cell type was being targeted by AZTC, follicles 
were further classified into unhealthy due to the oocyte only, granulosa cells only, or 
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both. The majority of follicles within the AZTC treated embryonic ovaries were 
classified as unhealthy due to an unhealthy oocyte, although there was a slight, non-
significant increase in the proportion of follicles classified as unhealthy due to 
unhealthy granulosa cells (p=0.114). Furthermore, the proportion of follicles 
classified as being unhealthy due to an unhealthy oocyte significantly increased at 































































































Figure 6.13. Total number (i) and distribution (ii) of follicles within F1 AZTC-treated 
ovaries. AZTC had no significant effect on the total follicle number within the F1 exposed 
ovaries compared with controls (p=0.148). A non-significant trend was however observed 
where exposed ovaries appeared to have slightly fewer follicles with increasing dose of 
AZTC (i). A significant decrease in the percentage of primordial follicles (p=0.003), and a 
significant increase in the percentage of transitional follicles was observed at the high dose 
(p=0.0006), but there were no significant differences in the percentage of primary (p=0.180) 
or secondary (p=0.333) follicles between treated and control ovaries (ii). Bars denote mean + 
sem; n=6 for controls, 1 and 10 µM treatment groups, n=7 for the 100 µM treatment group. 
PMF: primordial, TRNS: secondary, PRIM: Primary, SEC: secondary. Means with different 
letters are significantly different (p<0.05). Means with different letters are significantly 

































Figure 6.14. Follicle health within F1 AZTC exposed ovaries. The percentage of 
unhealthy follicles within the high dose ovaries was significantly higher than controls, low and 
medium dose groups (p=0.0009) (i). The percentage of unhealthy transitional follicles in the 
high dose ovaries also increased significantly (p<0.0001), where a slight increase in the 
percentage of unhealthy primary follicles was observed as well, but this did not reach 
statistical significance (p=0.064). There was no effect on the percentage of primordial 
follicles in AZTC-treated F1 ovaries (p=0.399) (ii). Bars denote mean + sem; n=6 for 
controls, 1 and 10 µM treatment groups, n=7 for the 100 µM treatment group. PMF: 
primordial, TRNS: secondary, PRIM: Primary, SEC: secondary. Means with different letters 







































































































Figure 6.15. Distribution of follicles classified as unhealthy due to an unhealthy 
oocyte, granulosa cells or both. Unhealthy follicles were further classified into damaged 
cell types, with the vast majority of follicles being classified as morphologically unhealthy due 
to an unhealthy oocyte. There was a significant increase in the proportion of follicles 
classified as unhealthy due to an unhealthy oocyte (p=0.0006). There was also a slight 
increase in the number of follicles classified as unhealthy due to unhealthy granulosa cells or 
both an unhealthy oocyte and unhealthy granulosa cells at the high dose, although this was 
not significant (Granulosa: p=0.114, Both: p=0.066). Bars denote mean + sem; n=6 for 
controls, 1 and 10 µM treatment groups, n=7 for the 100 µM treatment group. Means with 

















































6.5.1 The expression pattern of Topo IIα within the cultured neonatal mouse 
ovary.  
Immunohistochemical detection of Topo IIα was carried out on cultured newborn 
(P0) ovaries. The expression pattern of Topo IIα in the in vivo mouse ovary had been 
examined previously (Section 5.4.1). Although most germ cells were no longer 
expressing Topo IIα during the first two days of culture, expression was still found in 
a few germ cells at this point. Around the third day of culture Topo IIα expression 
was found in some of the surrounding somatic cells with no more germ cells 
expressing Topo IIα. By the end of culture, expression was found in many granulosa 
cells of growing follicles as well as within the stroma, with no germ cells expressing 
Topo IIα at this point. This was found to correlate quite closely with what was 
observed in the in vivo ovary at the equivalent stages of development and was 
therefore an expected result. Topo IIα expression had previously been shown to 
change from within the germ cells to the surrounding granulosa and stromal cells 
after birth. This did mean, however, that the exposure window of the newborn ovary 
culture (P0) did start before all Topo IIα expression was restricted to the somatic 
cells, and therefore AZTC could still have been directly affecting the oocytes at this 
point, making it difficult to efficiently compare pre- and post-natal AZTC exposure. 
For this reason, the neonatal ovary culture was repeated collecting ovaries at a 
slightly later time-point (P4).  
 
It is worth noting that Topo IIα expression was still found within some germ cells in 
the first few days after birth when Topo II is thought to be involved in meiotic and 
mitotic divisions (Roca, 2009, Nitiss, 2009, Russell et al., 2000, Li et al., 2013) 
whereas these germ cells are undergoing neither. Meiosis has ceased by birth, where 
the germ cells have entered meiotic arrest, but they are not undergoing mitosis either. 
It is possible that this is residual Topo II remaining in the germ cells that are the last 
to enter meiotic arrest, but it also suggests that there might be another role for Topo 





6.5.2. The effect of AZTC on the post-natal ovary in vitro 
AZTC had no significant effects on the total number of follicles within cultured 
newborn (CD-1 P0) ovaries, although there were trends for a dose-dependent 
decrease in the percentage of primordial follicles with increasing AZTC dose, but 
this was not significant. The same trend was observed the P4 cultured ovaries, where 
a non-significant reduction in follicle number was observed in all AZTC-treated 
ovaries. Furthermore, while there was no significant effect on the distribution of 
follicles within treated ovaries in cultured P0 ovaries, a significant decrease in the 
proportion of primordial follicles was observed at the medium dose in P4 cultured 
ovaries. This corresponded with a significant increase in the proportion of 
transitional follicles, but again, only up-to the medium dose.  
 
The pattern of follicle health was also fairly consistent between exposed P0 and P4 
ovaries, where overall, follicles appeared to be more unhealthy at the medium dose 
than at the top dose of AZTC. There was a slight non-significant increase in the 
percentage of unhealthy follicle numbers up-to the medium dose in P0 ovaries, 
reaching significance in the P4 ovaries. The percentage of unhealthy follicles then 
dropped again at the highest dose in both P0 and P4 cultured ovaries. When the 
distribution of unhealthy follicles was analysed, a similar pattern was consistently 
observed in both P0 and P4 ovaries. In P4 ovaries there was a significant rise in the 
proportion of unhealthy primordial and transitional follicles up to the medium dose, 
dropping off at the highest dose. In P0 ovaries, the same trend was observed for both 
primordial and transitional follicles, but only reached significance for the transitional 
follicles. The oocyte appeared to be the primary target for AZTC in both P0 and P4 
cultured ovaries, with very few follicles classified as unhealthy due to unhealthy 
granulosa cells. This result was somewhat surprising, as AZTC was expected to 
inhibit dividing cells, such as granulosa cells, in particular because Topo IIα is 
expressed within the granulosa and stromal cells in the post-natal ovary. Even more 
surprisingly, the effect on oocytes only reached significance in the P4 ovary culture 
but not in the P0 culture, when the P0 culture encompasses the tail-end of Topo IIα 
expression within the oocytes, whereas the P4 ovary culture was chosen to avoid any 
Topo IIα being expressed within the oocytes.  
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6.5.3. How does exposure of the post-natal ovary to AZTC differ from pre-natal 
exposure? 
AZTC had previously been shown to affect the pre-natal ovary, where it resulted in 
an increase in follicle number at lower doses, followed by a reduction at the high 
dose. An increase in the number of unhealthy follicles was also observed both in vivo 
(at the high dose) and in vitro (at low and medium doses only) (Sections 3.4.2 and 
5.4.2, respectively). In the post-natal in vitro ovary, however, the initial increase in 
follicle number was not observed, only a decrease in the number of primordial 
follicles (See Appendix D). The distribution of unhealthy follicles correlated fairly 
closely between pre- and post-natal exposure ovaries, where the medium dose (10 
µM) resulted in a higher proportion of unhealthy follicles than the high dose (100 
µM). This suggests that the effects of AZTC apply to both the pre- and post-natal 
ovary, where it results in a reduction of the size of the follicle pool and increased 
number of atretic follicles. This is further supported by the complete lack of follicles 
at the highest tested doses of AZTC in vitro (200 µM in the embryonic ovary culture, 
and 500 µM in embryonic and neonatal ovary cultures). 
 
6.5.4. Effect of etoposide on the neonatal mouse ovary.  
Etoposide resulted in a dose-dependent reduction in follicle numbers in the cultured 
neonatal ovary, although this was not significant. Similarly, no significant effect was 
found on the proportion of unhealthy follicles within these cultured ovaries. 
Furthermore, somewhat surprisingly, it was the oocyte that was the primary target of 
etoposide. There was also a slight increase in the proportion of oocytes categorised 
as unhealthy due to unhealthy oocytes and granulosa cells, but this was a very small 
proportion of follicles. 
 
The post-natal in vitro ovary did not appear to be as susceptible to ovary damage 
following etoposide exposure, unlike the pre-natal in vitro ovary (Section 5.4.2). The 
embryonic mouse ovary cultured with etoposide had in an increase in the number of 
unhealthy follicles and a significant reduction in the size of the follicle pool. 
Although a slight reduction was observed in the follicle pool of the post-natal ovary, 
this did not occur to the same extent as in the pre-natal ovary, and was not 
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significant. Furthermore, although a slight increase in the proportion of unhealthy 
follicles was recorded in the post-natal ovary, again this was not significant. This 
result was not unexpected, as it had been suggested previously that the post-natal 
ovary is less susceptible to etoposide damage than the pre-natal ovary, although the 
evidence for the reproductive toxicity of etoposide in the adult ovary has been 
conflicting (Oktem and Oktay, 2007, Choo et al., 1985). It is possible that once 
follicles have formed and oocytes are no-longer undergoing meiosis, that they 
become less susceptible to etoposide-induced damage. This could further be 
supported by the fact that Topo IIα is no longer expressed in the oocytes of the post-
natal ovary. Etoposide was, however, expected to elicit effects on granulosa cells 
which are undergoing divisions and expressing Topo IIα during post-natal ovary 
development, but no effect on granulosa cells was observed here. It is possible that 
the doses selected were too low for the post-natal ovary, where the pre-natal ovary 
may be more susceptible to damage at doses lower than what would result in ovary 
damage in the post-natal ovary. Furthermore, the number of ovaries for each 
treatment group was perhaps slightly too low, where the study would most likely 
have benefitted from having at least 6 ovaries per study group as there can be a lot of 
variability in follicle numbers and health between different ovaries, in particular CD-
1 mice which have a very high number of follicles in the ovary compared with other 
mouse strains (Canning et al., 2003). In the future, it would be interesting to repeat 
the study using both P0 and P4 ovaries, including a higher number of ovaries per 
treatment group. It would also be possible to add another treatment group of a higher 
dose of etoposide, 200 µg/ml for example, which is still lower than the recorded 
serum levels following etoposide exposure.  
 
6.5.5. Mechanisms of action of AZTC 
Various different experiments were carried out covering in vivo and in vitro 
exposures of AZTC, as well as pre- and post-natal exposure windows of AZTC and 
etoposide, covering the time that Topo IIα is either expressed within germ cells or 
within the granulosa and stromal cells. This was done to investigate if different 
effects might be observed when AZTC exposure occurred at a time when Topo IIα 
was expressed within germ cells compared with when it was expressed within 
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somatic cells. If AZTC was acting by inhibiting mammalian Topo IIα, we would 
have expected to observe different results between pre- and post-natal exposure 
ovaries. The results between the embryonic, P0 and P4 cultures show fairly similar 
patterns, with a rise in unhealthy follicles up-to the medium dose, and with AZTC 
targeting mainly the oocytes. It is difficult to draw conclusions about the actions of 
AZTC from the data available, since it is still possible that AZTC elicits effects on 
the ovary by an off-target effect that is not necessarily a result of direct mammalian 
Topo II inhibition. On the other hand, considering the similarities between the effects 
of etoposide and AZTC, there could also be effects on the granulosa cells in the post-
natal ovary, which in-turn, result in secondary effects on the oocytes. This will be 
discussed further in Chapter 7.  
 
6.5.6. Inter-strain differences in AZTC-exposure between F1 and CD-1 mouse 
ovaries.  
Initially, ovaries from newborn F1 mice had been used to investigate the effect of 
AZTC on the post-natal ovary. Due to the relatively small litters born to F1 mothers, 
CD-1 mice had then been selected to develop the embryonic ovary culture, due to 
considerably larger litters born to CD-1 mothers. Therefore, the newborn (P0) ovary 
culture was repeated with CD-1 mice to allow direct comparisons of ovarian effects 
of AZTC between the pre- and post-natal ovary. However, the initial use of F1 mice 
in these cultures meant that comparisons could be made between the two strains and 
their responsiveness to AZTC.  
 
At first, F1 and CD-1 control ovaries were compared to investigate if there were any 
underlying differences between the two strains. The main difference was that CD-1 
mice contained considerably more follicles (around 1600) than the F1 ovaries 
(around 1100). Furthermore, the distribution of follicles was different between the 
two species, where CD-1 ovaries had more primordial follicles (around 88%) per 
ovary, compared with the F1 ovaries (around 73%). In turn, F-1 ovaries contained 
slightly more transitional follicles (around 25%) when compared with CD-1 ovaries 
(around 13%), and primary follicles, but only by a relatively small amount (primary 
follicles: around 6% in F1 vs. 4% in CD-1). This suggests that F1 ovaries have a 
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slightly higher rate of follicle recruitment than do CD-1 ovaries. These results were 
consistent with what was expected since CD-1 mice have previously been described 
as having a greater number of follicles within their ovaries than many other strains of 
mice (Canning et al., 2003). 
 
It was then examined whether the two strains differed in the way they were affected 
by AZTC. Several similarities were observed between the strains following neonatal 
ovary exposure to AZTC. The main similarities were that they both had a slight (non-
significant) decrease in total follicle numbers and a dose-dependent decrease in the 
number of primordial follicles (significant in F1 ovaries, not-significant in CD-1 
ovaries). That aside, the results appeared to vary somewhat between the two strains. 
Firstly, while there was a significant dose-dependent reduction in the percentage of 
primordial follicles, correlated with a significant increase in the percentage of 
transitional follicles in the F1 ovaries, AZTC had no effect on the percentage of 
primordial or transitional follicles in CD-1 treated ovaries. When the total numbers 
of each follicle type per ovary were compared however, there were more similarities 
visible, where primordial follicles were reduced in both strains, but only reached 
significance in F1 ovaries. Secondly, in general, the F1 ovary was consistently more 
affected by the top dose of AZTC than were CD-1 ovaries. In CD-1 ovaries, more 
unhealthy follicles were found at the medium dose than at the top dose, with the 
proportion of unhealthy transitional follicles significantly increased at the medium 
dose. In F1 ovaries however, this did not occur until at the high dose. A similar effect 
was observed on total numbers of unhealthy follicles, where there was a significant 
increase at the top dose of AZTC in F1 ovaries, but only a slight non-significant 
increase in the number of unhealthy follicles up-to the medium dose in CD-1 ovaries. 
This effect was again repeated when analysing the proportion of follicles classified 
as unhealthy due to unhealthy oocytes.  
 
These results were unexpected as, despite the differences in total follicle numbers 
and slight differences in the distribution of follicles between the two strains, AZTC 
was expected to affect ovaries in a similar way regardless of the strain. Although 
there were some similarities between the strains, it is possible that due to a smaller 
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pool of follicle to begin with, any effects on F1 ovaries might result in a higher 
statistical significance than in the CD-1 ovary that contains a larger follicle pool. 
That is, the large number of follicles within CD-1 ovaries might in some ways 'mask' 
effects of AZTC if only a proportion of the follicles are affected by the compound. 
Furthermore, even if a relatively small proportion of follicles within F1 ovaries are 
affected and become atretic, other healthy primordial follicles may exit the resting 
pool of follicles to grow, since follicles act by inhibiting each other from entering the 
growing pool (Kalich-Philosoph et al., 2013). The smaller the follicle pool, the more 
likely the quiescent follicles are to grow and undergoing atresia. In CD-1 ovaries on 
the other hand, the effects may not be observed until much later, due to the larger 
pool of primordial follicles to start off with, resulting in increased inhibition of 
follicle activation. Another possibility is that F1 mice were more susceptible to 
ovarian damage by AZTC than CD-1 mice. This could be due to genetic differences 
between the strains. CD-1 mice have previously been shown to have reduced 
sensitivity to estrogen, where there were large variations in ovarian responsiveness to 
gonadotropins between different strains. As a consequence, the ovaries of CD-1 mice 
are far more resistant to endocrine disruptors than other strains of mice (Spearow et 
al., 1999, Spearow et al., 2001). If AZTC is acting by having a non-Topo II (off-
target) effect, or potentially affecting E2 within these ovaries, it would not be 
surprising that CD-1 ovaries were less affected by AZTC. These results raise the 
importance of investigating inter-species strain differences in mice commonly used 






Neonatal P0 and P4 ovaries cultured with AZTC demonstrated consistently similar 
effects, namely a dose-dependent decrease in total follicles, with significant 
decreases in primordial follicle numbers, and an increase in unhealthy follicles up-to 
the medium dose, where AZTC primarily targeted the oocyte. This also corresponded 
closely with effects observed following pre-natal in-vitro AZTC exposure, 
suggesting that perhaps AZTC could be eliciting its effect via an off-target route, 
since Topo IIα is expressed within the germ cells pre-natally, but within the 
granulosa and stromal cells post-natally. Neonatal cultures with etoposide had no 
significant effects on the post-natal ovary, where the results were somewhat 
inconsistent with neonatal AZTC exposure. This makes it difficult to directly 
compare effects of AZTC and etoposide, or to elucidate how AZTC acts on the 
ovary, without further investigation. Finally, when F1 and CD-1 ovaries were 
compared, CD-1 mice were found to have a larger pool of follicles and in slightly 
different ratios to F1 ovaries. The two strains differed in their responses following 
AZTC exposure, where F1 ovaries were affected by AZTC to a much greater extent 
than CD-1 ovaries. This could be due to various reasons that include genetic 
differences between the strains, their susceptibility to damage following exposure to 
gonadotropins and/or ovotoxicants, or the underlying differences in follicle numbers. 
 
 
6.7. Future directions 
In the future, it would be interesting to carry out tests to investigate if AZTC is 
inhibiting Topo II, and if so, by what mechanism. That is, if AZTC inhibits Topo II 
in a way that reduces the level of the protein present within the cell, a Western Blot 
could be carried out following AZTC exposure and AZTC protein levels would be 
expected to decline with increasing AZTC exposure. On the other hand, if AZTC 
acts by blocking or inhibiting the action of the enzyme, then the protein would still 
be expected to be present within the cells but would instead have been rendered 
inactive, in which case the protein levels would not be expected to reduce. The other 
possibility is, of course, that AZTC does not act on mammalian Topo II, in which 
case we would also see no change in protein levels. It would also be useful to carry 
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out further investigations into the effects of AZTC and etoposide exposure during 
meiosis I by repeating the chromosome spreads, or on the meiotic resumption of an 
ovulated and fertilized oocyte. Etoposide has previously been suggested to cause 
defects in chromosome condensation and segregation in mouse oocytes, although 
Topo II has also been suggested to be dispensable for meiotic resumption (Li et al., 
2013). This could potentially outline further whether the effects of AZTC and 
etoposide are more pronounced during meiosis, as so far, they appear to have more 
pronounced effect on the pre-natal ovary than on the post-natal ovary. Finally, 
another study that could be carried out would be to investigate if AZTC and 
etoposide affect steroid production in the growing ovary by carrying out estradiol 









































7.1. Summary of Results 
There is increasing evidence to indicate that a substantial number of both man-made 
and naturally occurring chemicals are disruptive to human and wildlife reproductive 
health. One period that is considered particularly vulnerable is that of pre-natal ovary 
development, during which meiosis I occurs. Current reproductive toxicology testing 
is primarily carried out in vivo, although in the past half a century, a diverse range of 
culture methods have been developed culturing oocytes or whole ovaries at different 
time-points of development. Very few of the established embryonic ovary culture 
systems, however, have been used to investigate potential reproductive toxicants on 
the pre-natal ovary. This aim of this project was to set up and develop such an 
embryonic ovary culture system that would span early meiosis, germ cell nest 
breakdown, follicle formation and growth initiation. The culture system could then 
potentially be used to study the dynamics of early ovary development, as well as to 
assess the reproductive toxicology of man-made and environmental chemicals. 
 
The novel embryonic ovary culture system was developed by adapting, improving 
and bridging pre-existing available culture techniques. The culture system set up here 
supported early meiosis of cultured oocytes, through prophase I, to the formation of 
primordial follicles and finally, initiation of follicle growth to the primary follicle 
stage. Various methodologies were attempted to achieve this, including 
modifications to the culture medium, culture techniques and the inclusion or 
exclusion of the mesonephros prior to culture. The culture method that produced the 
healthiest looking follicles with visible basal lamina, consisted of a 12 day culture on 
an agar block, where ovaries were cultured for 3 days in complex medium, followed 
by 9 days in simple medium, with the mesonephros attached for the duration of 
culture. Histological analysis of cultured ovaries revealed that they were 
morphologically normal and healthy, and that they contained follicles at stages in 
comparable ratios as in vivo ovaries. The presence of basal lamina was further 
examined using a biotin tracer study, which revealed the appropriate establishment of 
basal lamina in most follicles, although the cultured ovaries showed less structural 
organisation than did in vivo ovaries. Finally, chromosome spreads were carried out 
on cultured embryonic ovaries to investigate whether the culture system supported 
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the progression of oocytes through prophase I of meiosis. The chromosome spreads 
revealed that homologous chromosomes in cultured oocyte nuclei were capable of 
progressing through leptotene, zygotene, and fully synapse at the pachytene stage of 
meiosis in an identical manner to in vivo oocyte nuclei. The cultured ovaries were, 
however, slightly delayed when compared with in vivo ovaries.  
 
A novel test compound, a topoisomerase II inhibitor: AZTC, was then used to assess 
the efficacy and validity of the ovarian culture methods. This was done by comparing 
embryonic mouse ovaries that had been cultured with AZTC during prophase of 
meiosis I, with in vivo studies where rat embryos were exposed to AZTC during 
gestation. AZTC was selected as a study compound due to its detrimental effects on 
spermatogenesis in male rats. AZTC targets bacterial Topo II but it was presumed to 
act on mammalian Topo II as well, due to the close homology between bacterial 
Topo II and mammalian Topo II. Topo IIα was expressed within the female germ 
cells pre-natally, but became localised to the granulosa and stroma cells post-natally. 
This occurred both in vivo and in vitro.  
 
Embryonic ovaries cultured with the low and medium dose of AZTC consistently 
demonstrated similar effects to that observed in the in vivo pre-natal AZTC-exposed 
rat ovary. On the other hand, AZTC demonstrated different effects when exposure 
occurred pre-natally vs. post-natally. Furthermore, another Topo II inhibitor, 
etoposide, was used as secondary test compound, to assess the validity and efficacy 
of the embryonic ovary culture. Etoposide-treated embryonic ovaries had a reduction 
in the size of the follicle pool, with primordial and transitional follicles targeted.  
 
The various different experiments carried out on AZTC and etoposide, on both pre-
natal (in vitro and in vivo) and post-natal (in vitro only) are outlined in Table 7.1. 
This therefore allows for numerous comparisons to be made comparing: 
 i) In vivo vs. in vitro 
 ii) Pre- vs. post-natal effects of AZTC 
 iii) Effects of etoposide vs AZTC 





7.2. Advantages and disadvantages of using in vitro testing in 
reproductive toxicology studies. 
The majority of the work presented in this thesis was carried out in vitro. Cultures 
have become a widely used tool in to study the development of follicles in 
reproductive biology and toxicology.  
 
This topic formed the basis of a review written by me, with some of the text below 
reproduced directly from that article (Stefansdottir et al., 2014). In vitro ovary and 
follicle culture models allow for the possibility of varying culture parameters in a 
highly controlled manner, and thus have the potential to allow a more thorough 
evaluation for reproductive toxicity studies than do in vivo studies alone. Considering 
that animals, including humans, are exposed to a very wide range and number of 
compounds and chemical mixtures in their lifetime, it is becoming increasingly 
crucial to develop and improve the in vivo assessments and in vitro culture 
techniques necessary to elucidate the toxic effects of potential ovotoxicants on the 
ovary, to allow for faster screening of potential developmental and/or reproductive 
toxicants. The key point of in vivo studies is to assess the potential toxic risk of a 
drug on the body, when administered at a therapeutic dose. Although this is more 
representative of the 'real life' situation, it can also be difficult for in vivo studies to 
assess how much is reaching the gonads, since compounds can be detoxified, 
activated or eliminated in the body. Calculations to determine the amount of 
compound reaching the gonads are complex and vary between species and life stage. 
The method of exposure also needs careful consideration as subcutaneous injections 
 Pre-natal Post-natal 
 AZTC Etoposide AZTC Etoposide 
 P0 P4 P0 P4 




CD-1 mice  
In vivo Wistar rats      
 
Table 7.1. Outline of all the different experiments carried out on AZTC and etoposide 
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and oral ingestions of the same amount of the same compound will not necessarily 
result in the same ovarian exposure (Doerge et al., 2011, Fisher et al., 2011). Other 
issues reproductive toxicologists face when using in vivo studies include attempting 
to limit the duration of exposure to a single dose of compound, since some 
compounds can, for example, persist in the animal. Exposure of compounds can 
change due to mobilization of maternal body reserves during pregnancy (Herreros et 
al., 2010) or can be passed through breast-milk a long time after the exposure 
window, making it difficult to predict the precise time and duration of exposure 
(Miller et al., 2004, Doerge et al., 2010). In vivo studies often use end-points such as 
pregnancy, implantation and number of offspring, which are parameters that do not 
identify the site of action, the mechanism(s) of toxic damage or the effect on the 
primordial follicle pool. However, female reproductive function requires effective 
communication between the ovary, the neuroendocrine system, the hypothalamic-
pituitary-gonadal (HPG) axis and the reproductive tract, and in vivo studies will be 
able to detect toxic effects on any of these systems, which could result in a secondary 
effect on the gonads. For example, effects on the estrogen-dependent endometrium, 
could subsequently lead to ovary-independent infertility (Suzuki et al., 2002, Zama 
and Uzumcu, 2010). Therefore, one drawback of in vitro studies is that, although 
they can be useful for assessing direct effects on the ovary, they cannot account for 
any indirect action that might modulate hormone-signalling pathways such as the 
HPG axis. Studies carried out in vitro are also unable to take metabolism into 
consideration and care must be taken when examining effects of a compound that has 
no effect until it has been metabolised. Even if a compound has demonstrated 
interference with receptor binding/hormone production in vitro, the same activity 
may not be observed in vivo (Munn and Goumenou, 2013). Despite this, in vitro 
models are a promising area in toxicology, allowing pragmatic and mechanistic 
studies of action of reproductive toxicants and are able to reduce the number of 
animals required for in vivo studies. In vitro systems are proving to be an invaluable 
preliminary method to investigate direct effects of potentially harmful compounds on 
the female reproductive system, especially where appropriate care has been taken to 
administer doses that reflect human exposure levels in at least part of the dose-
response curve design. Crucially, they require relatively little time to yield precise 
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answers, and can cover various, yet specific, stages of ovary and follicle 
development. In vitro studies allow scientists to examine the precise mechanisms of 
action of a reproductive toxicant on the different stages of growth and development, 
as well as to pin-point whether a specific chemical targets the stroma, the oocyte, the 
somatic compartment of the follicle, or the follicle as a whole. Therefore, although in 
vitro cultures are less useful for studying indirect toxic effects on the reproductive 
system, they still do have great potential to provide an important preliminary or 
secondary screening protocol for toxicology testing alongside in vivo studies. The 
combination of in vivo and in vitro work is a powerful one to detect and understand 
mechanisms of damage to the ovary, its follicles and oocytes, and their consequence 
for adult fertility and subsequent generations.  
 
7.3. Comparing in vivo vs. in vitro results of AZTC on the pre-natal 
ovary 
AZTC was developed to target bacterial type II topoisomerases, given the close 
homology between bacterial and mammalian Topo II, it is likely that AZTC will also 
inhibit mammalian homologues that are involved in meiosis. When administered to 
male rats, it resulted in a detrimental effect on spermatogenesis. The main aim of this 
project was therefore to examine the effects of AZTC on the ovary, using both in 
vivo and in vitro studies, to investigate how in vitro cultures might compare with the 
‘real life’ in vivo situation. Despite the differences in species between the two studies 
(rat vs. mouse), the exposure of AZTC occurred during the same crucial time 
windows: entry into meiosis, prophase I of meiosis up-to meiotic arrest, germ cell 
nest breakdown and follicle formation. Histological analysis of AZTC-exposed 
ovaries should therefore reveal any major effects on any of these stages.  
 
Ovaries collected from PND 15 rats exposed to AZTC in utero, consistently 
demonstrated similar results to cultured embryonic ovaries exposed to the low and 
medium doses of AZTC (Fig. 7.1). In both studies, follicle numbers were slightly 
increased (significantly so in vivo). This was due to a rise in primordial follicles 
numbers. Similarly, both in vivo and in vitro ovaries showed a rise in the number of 
unhealthy follicles, where there was an increase in the number of unhealthy 
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primordial follicles. The main difference between the two studies came from the in 
cultured ovaries exposed to the high dose of AZTC. In that instance, there was a 
large, significant drop in the size of the follicle pool, along with a drop in the number 
of primordial follicles, and in the number of unhealthy follicles. This makes it 
difficult to confidently conclude that the in vitro culture correlated with the effects 
observed in vivo. It is possible that the cultured ovaries may be more susceptible to 
ovarian disruption and damage than in vivo, possibly due to the fact that the ovaries 
have been removed from the ovarian bursa and blood supply. The culture 
environment may also not provide the same support as the real life situation. On the 
other hand, it is not known how the in vivo doses compare with the in vitro ones. The 
concentration that is reaching the ovaries in vivo might be considerably lower than 
the in vitro doses and it is therefore possible that the doses reached in vivo are 
roughly equivalent to the low and medium doses in vitro, whereas at doses higher 
than this (100 µM and above), the follicles are destroyed earlier on in culture, 
consistent with what is observed at the top doses tested in vitro in the dose response 
study (200-500 µM). Furthermore, there were some in vivo ovaries exposed to the 
high dose of AZTC in vivo that contained no follicles and appeared very unhealthy. 
Although the source of these ovaries could unfortunately not be confirmed, and they 
were consequently excluded from the study (See Section 3.4.2), it is nevertheless 
possible that this was a result of AZTC exposure. Finally, it must still be borne in 
mind that all the results from the in vivo PND 15 study came from one female, 
making that particular result vulnerable to a possible litter-effect, in particular 
because no effects of AZTC were observed at earlier or later time-points. Bearing 
this in mind, and since the in vivo results consistently correlate with the in vitro 
cultures at low and medium doses of AZTC, it does suggest that AZTC acted on the 
ovary in a similar manner in vivo and in vitro. Consequently, it does suggest that the 
embryonic ovary culture could be a useful tool to determine potential reproductive 
toxicants as a preliminary screening tool. Furthermore, these cultures could be used 
as a way to elucidate if chromosomal sensitivity of oocytes to certain compounds or 
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7.4. Inter-strain and inter-species differences.  
Analysis of biological experiments must always be carried out with caution, as was 
demonstrated during this project, strains of the same species can vary in their 
susceptibility to ovarian disruption following compound exposure. This is, in 
particular, thought to be the case in mouse susceptibility to disruption of E2 levels 
within the ovary, where CD-1 mice are less susceptible than other strains such as F1 
mice. Here, CD-1 mice also showed more resistance to AZTC than did F1 mice (Fig. 
7.2). Inter-strain differences is a frequently ignored subject in science, but the results 
here further demonstrate the importance of improving our understanding and 
awareness of these inter-strain differences when it comes to reproductive toxicology, 
as well as for scientists in general. More efforts should be made to identify and study 
genetic variations between mouse strains, to further understand underlying genetic 
differences, and in reproductive biology, to understand differences in their sensitivity 
to gonadotropins or chemicals, differences in ovarian function as well as their 
vulnerability to disease. Furthermore, it cannot be excluded that some of the 
differences observed when comparing the in vivo and in vitro studies in this project, 
were due to inter-species differences between the mouse and the rat.  
 
This issue also opens up the discussion about the usefulness of the mouse or rat 
model as a way to investigate the reproductive toxicity of drugs on the human. The 
mouse and rat are frequently used models to investigate potential ovotoxicants and 
have been proven to be invaluable tools for reproductive research. The mouse culture 
is also the best available model from which live offspring have been produced from 
cultured primordial follicles (O'Brien et al., 2003). Rodents make a good model due 
to their short time-course, high material availability, the ease by which they can be 
genetically manipulated, but also due to their reproductive similarities to women, 
such as being born with a finite number of follicles. However, it is also important to 
consider differences and limitations in using the rodent model for reproductive 
studies. The mouse is polyovular, has a short estrous cycle and has considerably less 
stromal tissue than the human ovary. Furthermore, there is no certainty that a 
compound will elicit the same response in the human ovary as in the mouse, in 
particular since doses can be difficult to correlate between the two species. 
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Compounds can also not have a typical 'dose-response' curve, where some effects 
may be missed if the relevant dose is not tested. The drug dosage must also be 
appropriately translated from one species to the other (Regan-Shaw et al., 2008). 
Finally, the differences in susceptibility, vulnerability, windows of exposure, 
genetics and many others must be considered. To give one example of this, it has 
now become recognised that rodents and humans do not metabolise xenobiotics in 
the same manner, partly due to the species differences in P450s expression and its 
catalytic activities (Caldwell, 1981, Bogaards et al., 2000). In contrast, there are also 
drawbacks to culturing human ovarian tissue, in that it has limited availability and it 



























































































































































































































































































































































































































































































7.5 Elucidating a possible mechanism of action for AZTC 
The various cultures and in vivo studies carried out throughout the course of the 
project, aimed to not only validate the embryonic ovary culture system but also to 
elucidate how AZTC might be affecting the ovary. From analysing all these studies, 
there are various possibilities to consider (Table 7.1). In some cases, the results 
suggested that AZTC might act directly by inhibiting mammalian Topo II, whereas 
other studies suggested that this was not the case. In the pre-natal ovary culture and 
the in vivo study for example, AZTC resulted in an initial increase in follicle 
numbers, followed by a great drop in follicle numbers in vitro and complete follicle 
disruption at the highest doses tested (200 and 500 µM). While the initial rise in 
follicle number was unexpected, the large drop in follicle number was considered a 
likely outcome, as the exposure window in this study correlated with the time-frame 
at which both Topo II paralogues (α and β) are expressed within the germ cells. It 
may well also have been the case that if the in vivo study had been carried out at 
higher doses, then the same drop might have been observed (Fig. 7.1). This therefore 
suggested that at lower concentrations, there might have been an effect either on 
germ cell nest breakdown or apoptosis, or both, resulting in the observed initial 
increase on follicle numbers. The large drop in follicle numbers following high dose 
exposure in vitro however, could be explained by full inhibition of mammalian Topo 
II, as a result of which most follicles could not undergo meiosis and consequently 
underwent atresia. Surprisingly however, when the nuclei of exposed cultured 
oocytes were examined by meiotic spreads, there were some oocytes that were 
capable of fully synapsing in the presence of AZTC. This suggests either that AZTC 
does not, in fact inhibit mammalian Topo II, or that Topo II is not required for this 
early stage of meiosis.  
 
When the post-natal ovary was cultured in the presence of AZTC, the results were 
even more conflicting (Figure 7.3), since at this stage Topo IIα is only expressed 
within the somatic cells, whereas Topo IIβ expression is still found within the germ 
cells. AZTC appeared to target mainly primordial follicles, where the oocyte was the 
main target of AZTC. Again, this was surprising since the granulosa cells were 
expected to become a target for AZTC if it was, indeed, inhibiting mammalian Topo 
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II. It may, therefore, be that AZTC specifically inhibits Topo IIβ. Overall, it is clear, 
that AZTC does elicit an effect on the ovary, but the exact pathway by which it does 
so cannot be concluded at this point.  
 
For this reason, another drug that is known to target mammalian Topo II was selected 
to be used as a comparison alongside AZTC: etoposide (Chen et al., 1984, Ross et 
al., 1984, Gupta et al., 1987, Fortune and Osheroff, 2000). Furthermore, etoposide 
was thought to be an interesting and relevant drug of choice because it had already 
been prescribed to pregnant women, but its effect on the fertility outcome of the sons 
and daughters born to these women is not yet known. The embryonic ovary culture 
was therefore repeated with etoposide, and the ovaries were examined histologically 
for follicle distributions and health. Although the lower doses of AZTC and 
etoposide did not correlate, there was a significant reduction in size of the follicle 
pool for both compounds, where it was primarily the primordial follicles that were 
targeted in AZTC ovaries but also transitional follicles in etoposide-treated ovaries 
(Figure 7.4). Although the opposite effects were observed for the proportion of 
transitional follicles between compounds, this could also be explained by the large 
drop in primordial follicle numbers, resulting in 'proportionally' more transitional 
follicles per ovary, making it appear as though their numbers have increased. Despite 
the few similarities, the results largely did not appear to correlate, except for the 
controls vs. high dose ovaries. Furthermore, in terms of follicle health, neither 
compound appeared to follow a regular dose-response curve. A post-natal culture 
was also carried out where newborn (CD-1 P0) ovaries were exposed to etoposide in 
vitro, but etoposide had no significant effects on the post-natal cultured ovary, 
making it difficult to compare with AZTC. This therefore does suggest that AZTC 
did not mimic the actions of etoposide, which, in turn, suggests that AZTC may well 
not block the actions of mammalian Topo II, but further studies would be required to 
confirm this. 
 
Overall, there are three main possibilities. Either AZTC does directly inhibit 
mammalian Topo II (on target), or it does not (off-target), or both. If AZTC does 
indeed inhibit mammalian Topo II, then there are four further possibilities within 
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this. Firstly, AZTC might inhibit both or either of the Topo II paralogues, where 
Topo IIα is expressed only within the germ cells pre-natally, and Topo IIβ is 
expressed within the germ cells throughout life. The second possibility, is that AZTC 
also inhibits other types of topoisomerases whose expression and function within the 
mouse ovary has yet to be determined. The third possibility, is that AZTC does 
inhibit Topo II but that Topo II is not required for this early stage of meiosis, 
resulting in the observed few nuclei that were able to progress through to the 
pachytene stage. The fourth and final possibility, is that by inhibiting Topo II, AZTC 
results in a secondary effect on other cell types. For example, it could act on Topo II 
within the granulosa cells in the post-natal cultures, which then might affect the 
signalling loop between granulosa cells and oocytes, consequently resulting in an 
effect on the oocytes.  
 
If, on the other hand, AZTC does not inhibit mammalian Topo II, it might instead act 
by a completely different, off-target pathway. If this is the case, as outlined before 
(Section 5.5.5), AZTC might inhibit Hsp90, a protein involved in cell cycle 
regulation, cellular homeostasis and steroid hormone signalling, that bears similar 
topology to the mammalian Topo II molecule (Dunbrack et al., 1997, Prodromou et 
al., 1997). This would be a particular pathway of interest since an antitumour drug 
that inhibits Hsp90 has previously been shown to also inhibit mammalian Topo II 
(Gadelle et al., 2006). If this is the case, it could account for many of the effects 
observed on the ovary, such as altered E2 levels or cellular homeostasis or an effect 
on regulation of the cell cycle. E2 protects oocytes from programmed cell death and 
has been suggested to play a role in follicle formation (Billig et al., 1993, Britt et al., 
2004). An alteration in E2 levels in the developing ovary would therefore likely 
result in altered germ cell nest breakdown (Billig et al., 1993), potentially explaining 
the observed initial increase in the observed number of primordial follicles. Some 
compounds, including chemotherapy agents have previously been shown to affect E2 
production in the cultured ovary (Oktem and Oktay, 2007), which consequently can 
affect the primordial follicle pool. Due to the role of E2 in preventing oocytes and 
granulosa cells from undergoing programmed cell death, disruption of E2 production 
could induce premature follicle growth and over time, the consequent depletion of 
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the primordial follicle pool. It would be interesting to investigate if, in fact, the 
reduction in follicle numbers observed here, in particular, the number of primordial 
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7.6. Future Work 
In the future, I think that the main priority should be to expand on the embryonic 
ovary culture system. The work presented here showed promising results where this 
culture system could be a useful tool for reproductive toxicology testing. It would be 
interesting to try carrying out longer cultures, since at the end of the 12 day culture 
period the ovaries still appeared very healthy, some consisting of a relatively large 
number of follicles. If some secondary and even pre-antral follicles were to begin to 
form, it could then be disaggregated and individual follicles could potentially be 
cultured to the antral stage, to be ovulated and fertilised in vitro. If successful, then 
this would mean that the culture system could cover the entire meiotic division in the 
female. It would also be interesting to test and assess the efficacy of the culture 
system further by using compounds with known effects on early meiosis or the pre-
natal ovary, such as B[a]P or DMBA for example (Mattison and Thorgeirsson, 1979, 
Borman et al., 2000, Matikainen et al., 2002, Igawa et al., 2009). Ultimately, the 
culture system could be attempted using human embryonic ovary tissue; if 
successful, this could be a very important tool to determine potential ovarian 
toxicants.  
 
Since the mechanism of action of AZTC was not elucidated during the course of the 
project, the next step would be to carry this investigation further. Western blot 
analysis on exposed cultured ovaries could demonstrate whether Topo II levels 
decreased in the presence of AZTC, and carrying out an immunostain for γH2AX on 
AZTC-treated ovaries could also demonstrate if AZTC results in a similar increase in 
DSBs as was observed with etoposide. Furthermore, another experiment that could 
be carried out, is to do estradiol assays on the culture medium following culture with 
AZTC, to examine if there is in fact a difference in E2 levels following AZTC 
exposure. Finally, it would be interesting to investigate whether AZTC does have an 
effect on meiosis or not, by repeating the chromosome spreads to produce a higher 
yield of oocytes, or by carrying out immunohistochemistry for diplotene markers on 
exposed ovaries. Ideally, the in vivo study could then be repeated but with AZTC-
exposure occurring post-natally, to investigate how our post-natal ovary cultures 




ABERCROMBIE, M. 1946. Estimation of nuclear population from microtome sections. The 
Anatomical Record, 94, 239-247. 
ADAMS, I. R. & MCLAREN, A. 2002. Sexually dimorphic development of mouse primordial 
germ cells: switching from oogenesis to spermatogenesis. Development, 129, 1155-
1164. 
ADHIKARI, D., ZHENG, W., SHEN, Y., GORRE, N., HAMALAINEN, T., COONEY, A. J., 
HUHTANEIMI, I., LAN, Z. J. & LIU, K. 2010. Tsc/mTORC signaling in oocytes governs 
the quiescence and activation of primordial follicles. . Human Molecular Genetics, 
19, 397-410. 
AERTS, J. M. J. & BOLS, P. E. J. 2010. Ovarian Follicular Dynamics: A Review with Emphasis 
on the Bovine Species. Part I: Folliculogenesis and Pre-antral Follicle Development. 
Reproduction in Domestic Animals, 45, 171-179. 
AKAMITSU, N., ADACHI, N., HIRAI, H., HOSSAIN, M. S., HAMAMOTO, H., KOBAYASHI, M., 
ARATANI, Y., KOYAMA, H. & SEKIMIZU, K. 2003. Enforced cytokinesis without 
complete nuclear division in embryonic cells depleting the activity of DNA 
topoisomerase II alpha. Genes to Cells, 8, 393-40. 
ALBERTINI, D. F., COMBELLES, C. M., BENECCHI, E. & CARABTSOS, M. J. 2001. Cellular basis 
for paracrine regulationo f ovarian follicle development. Reproduction, 121, 647-53. 
ALT, S., MITCHENALL, L. A., MAXWELL, A. & HEIDE, L. 2011. Inhibition of DNA gyrase and 
DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by 
aminocoumarin antibiotics. Journal of Antimicrobial Chemotherapy, 66, 2061-9. 
ANDERSON, E. & ALBERTINI, D. F. 1976. Gap junctions between the oocyte and companion 
follicle cells in the mammalian ovary. Journal of Cell Biology, 71, 680-6. 
ANDERSON, L. D. & HIRSHFIELD, A. N. 1992. An overview of follicular development in the 
ovary: from embryo to the fertilized ovum in vitro. Maryland Medical State Journal 
41, 614-620. 
ANDERSON, R. A., FULTON, N., COWAN, G., COUTTS, S. & SAUNDERS, P. T. K. 2007. 
Conserved and divergent patterns of gene expression in female and male germ cells 
during development of the human fetal gonad. BMC Developmental Biology, 7, 136-
145. 
ANDERSON, R. A., MCILWAIN, L., COUTTS, S., KINNELL, H. L., FOWLER, P. A. & CHILDS, A. J. 
2014. Activation of the aryl hydrocarbon receptor by a component of cigarette 
smoke reduces germ cell proliferation in the human fetal ovary. Molecular Human 
Reproduction, 20, 42-48. 
ANDERSON, R. D. & BERGER, N. A. 1994. Mutagenicity and carcinogenicity of 
topoisomerase-interactive agents. Mutation Research, 309, 109-142. 
ANGENARD, G., MUCZYNSKI, V., COFFIGNY, H., DUQUENNE, C., FRYDMAN, R., HABERT, R., 
LIVERA, G. & ROUILLER-FABRE, V. 2011a. In vitro effects of uranium on human fetal 
cells. Reproductive Toxicology, 31, 470-6. 
ANGENARD, G., MUCZYNSKI, V., COFFIGNY, H., DUQUENNE, C., FRYDMAN, R., HABERT, R., 
LIVERA, G. & ROUILLER-FABRE, V. 2011b. In vitro effects of Uranium on human fetal 
germ cells. Reproductive Toxicology, 31, 470-476. 
BAGULEY, B. C. & FERGUSON, L. R. 1998. Mutagenic properties of topoisomerase-targeted 
drugs. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1400, 
213-222. 
BAILLET, A. & MANDON-PEPIN, B. 2012. Mammalian ovary differentiation - A focus on 
female meiosis. Molecular and Cellular Endocrinology, 356, 417-433. 
222 
 
BAKER, T. G. 1963. A quantitative and cytological study of germ cells in human ovaries. . 
Proceedings of the Royal Sociaty of London B. Biological Sciences. , 158. 
BALTUS, A. E., MENKE, D. B., HU, Y. C., GOODHEART, M. L., CARPENTER, A. E., DE ROOIJ, D. 
G. & PAGE, D. C. 2006. In germ cells of mouse embryonic ovaries, the decision to 
enter meiosis precedes premeiotic DNA replication. Nature Genetics, 12, 1430-
1434. 
BARLOW, D. P. & BARTOLOMEI, M. S. 2014. Genomic Imprinting in Mammals. Cold Spring 
Harbor Perspectives in Biology, 6a, a018382. 
BELLINGHAM, M., FIANDANESE, N., BYERS, A., COTINOT, C., EVANS, N. P., POCAR, P., 
AMEZAGA, M. R., LEA, R. G., SINCLAIR, K. D., RHIND, S. M. & FOWLER, P. A. 2012. 
Effects of Exposure to Environmental Chemicals During Pregnancy on the 
Development of the Male and Female Reproductive Axes. Reproduction in Domestic 
Animals, 47, 15-22. 
BEN-AHARON, I., BAR-JOSEPH, H., TZARFATY, G., KUCHINSKY, L., RIZEL, S., STEMMER, S. M. 
& SHALGI, R. 2010. Doxorubicin-induced ovarian toxicity. Reproductive Biology and 
Endocrinology, 8, 20. 
BENDEL-STENZEL, M. R., GOMPERTS, M., ANDERSON, R., HEASMAN, J. & WYLIE, C. 2000. 
The role of cadherins during primordial germ cell migration and early gonad 
formation in the mouse. Mechanisms of Development, 91, 143-152. 
BENDSEN, E., BYSKOV, A. G., ANDERSEN, C. Y. & WESTERGAARD, L. G. 2006. Number of 
germ cells and somatic cells in human fetal ovaries during the first weeks after sex 
differentiation. . Human Reproduction, 21, 30-35. 
BERNAL, A. J. & JIRTLE, R. L. 2010. Epigenomic disruption: the effects of early 
developmental exposures. Birth Defects Research. Part A, Clinical and Molecular 
Teratology, 88. 
BERTHOIS, Y., KATZENELLENBOGEN, J. A. & KATZENELLENBOGEN, B. S. 1986. Phenol red in 
tissue culture media is a weak estrogen: Implications concernign the study of 
estrogen-responsive cells in culture. Proceedings of the National Academy of 
Sciences (USA), 83, 2496-2500. 
BILLIG, H., FURUTA, I. & HSUEH, A. J. 1993. Estrogens inhibit and androgens enhance 
ovarian granulosa cell apoptosis. Endocrinology, 133, 2204-2012. 
BIRKLETT, J. W. 2003. Scope of the problem. Endocrine Disruptors in Wastewater and 
Sludge Treatment Processes. Lewis Publishers Boca Raton, Florida. 
BLANDAU, R. J., WARRICK, E. & RUMERY, R. E. 1965. In vitro cultivation of fetal mouse 
ovaries. Fertility and Sterility, 16, 705-715. 
BOGAARDS, J. J., BERTRAND, M., JACKSON, O., OUDSHOORN, M. J., WEAVER, R. J., VAN 
BLADEREN, P. J. & WALTHER, B. 2000. Determining the best animal model for 
human cytochrome P450 activities a comparison of mouse, rat, rabbit, dog, 
micropig, monkey and man. Xenobiotica, 20, 1131-52. 
BONASIO, R., TU, S. & REINBERG, D. 2010. Molecular signals of epigenetic states. Science, 
330, 612-6. 
BORMAN, S. M., CHRISTIAN, P. J., SIPES, G. & HOYER, P. B. 2000. Ovotoxicity in female 
fischer rats and B6 mice induced by low-dose exposure to three polycyclic aromatic 
hydrocarbons: comparison through calculation of an ovotoxic index. Toxicology and 
Applied Pharmacology, 167, 191-8. 
BOWLES, J. & KOOPMAN, P. 2007a. Retinoic acid, meiosis and germ cell fate in mammals. 
Development, 134, 3401-3411. 
BOWLES, J. & KOOPMAN, P. 2007b. Retinoic acid, meiosis and germ cell fate in mammals. 
Development, 134, 3401-3411. 
223 
 
BRIENO-ENRIQUEZ, M. A., REIG-VIADER, R., CABERO, L., TORAN, N., MARTINEZ, F., ROIG, I. 
& GARCIA CALDES, M. 2012. Gene expression is altered after bisphenol A exposure 
in human fetal oocytes in vitro. Molecular Human Reproduction, 18, 171-83. 
BRIENO-ENRIQUEZ, M. A., ROBLES, P., GARCIA-CRUZ, R., ROIG, I., CABERO, L., MARTINEZ, F. 
& GARCIA CALDES, M. 2010. A new culture technique that allows in vitro meiotic 
prophase development of fetal human oocytes. Human Reproduction, 25, 74-84. 
BRISTOL-GOULD, S. K., KREEGER, P. K., SELKIRK, C. G., KILEN, S. M., COOK, R. W., KIPP, J. L., 
SHEA, L. D., MAYO, K. E. & WOODRUFF, T. K. 2006. Postnatal regulation of germ 
cells by activing: the establishment of the initial follicle pool. Developmental 
Biology, 298, 132-48. 
BRITT, K. L., SAUNDERS, P. K., MCPHERSON, S. J., MISSO, M. L., SIMPSON, E. R. & FINDLAY, J. 
K. 2004. Estrogen actions on follicle formation and early follicle development. 
Biology of Reproduction, 71, 1712-23. 
BROUILLETTE, J., RIVARD, K., LIZOTTE, E. & FISET, C. 2004. Sex and strain differences in adult 
mouse cardiac repolarization: importance of androgens. Cardiovascular Research, 
65, 148-57. 
BUEHR, M., GU, S. & MCLAREN, A. 1993. Mesonephric contribution to testis differentiation 
in the fetal mouse. Development, 117, 273-81. 
BYSKOV, A. G., GUOLIANG, X. & ANDERSEN, C. Y. 1997. The cortex-medulla oocyte growth 
pattern is organized during fetal life: an in-vitro study of the mouse ovary. 
Molecular Human Reproduction, 3, 795-800. 
CALDWELL, J. 1981. The current status of attempts to predict species differences in drug 
metabolism. Drug Metabolism Reviews, 12, 221-37. 
CAN, A. & SEMIZ, O. 2000. Diethylstilbestrol (DES) induced cell cycle delay and meiotic 
spindle disruption in mouse oocytes during in vitro maturation. Molecular Human 
Reproduction, 6, 154-62. 
CANIPARI, R. 2000. Oocyte-granulosa cell interactions. Human Reproduction Update, 6, 279-
289. 
CANNING, J., TAKAI, Y. & TILLY, J. 2003. Evidence for Genetic Modifiers of Ovarian Follicular 
Endowment and Development from Studies of Five Inbred Mouse Strains. 
Endocrinology, 144, 9-12. 
CAPRANICO, G., TINELLI, S., AUSTIN, C. A., FISHER, M. L. & ZUNINO, F. 1992. Different 
patterns of gene expression of topoisomerase II isoforms in differentiated tissues 
during murine development. Biochimica et Biophysica Acta (BBA), 1132, 43-8. 
CARBATOS, M. H., ELVIN, J., MATZUK, M. M. & ALBERTINI, D. F. 1998. Characterization of 
oocyte and follicle development in growth differentiation factor-9 deficient mice. 
Developmental Biology, 2, 373-84. 
CARPENTER, A. J. & PORTER, A. C. 2004. Construction, characterization and 
complementation of a conditional-lethal DNA topoisomerase IIalpha mutant human 
cell line. Molecular Biology of the Cell, 15, 5700-11. 
CASTRILLION, D. H., MIAO, L., KOLLIPARA, R. & HORNER, J. W. 2003. Suppression of ovarian 
follicle activation in mice by the transcription factor Foxo3a. Science, 301, 215-8. 
CHASSOT, A. A., RANC, F., GREGOIRE, E. P., ROEPERS-GAJADIEN, H. L., TAKETO, M. M., 
CAMERINO, G., DE ROOIJ, D. G., SCHEDL, A. & CHABOISSIER, M. C. 2008. Activation 
of the beta=catenin signaling by Rspo1 controls differentiation of the mammalian 
ovary. . Human Molecular Genetics, 17, 1264-1277. 
CHEN, G. L., YANG, L., ROWE, T. C., HALLIGAN, B. D., TEWEY, K. M. & LIU, L. F. 1984. Non-
intercalative antitumour drugs interfere with the breakage reunion reaction of 
mammalian DNA topoisomerase II. Biological Chemistry, 259, 13560-66. 
224 
 
CHEN, L., WERT, S. E., HEDRIZ, E. M., RUSSELL, P. T., CANNON, M. & LARSEN, W. J. 1990. 
Hyaluronic acid synthesis and gap junction endocytosis are necessary for normal 
expansion of the cumulus mass. Molecular Reproduction and Development, 26, 
236-47. 
CHEN, Y., JEFFERSON, W. N., NEWBOLD, R. & PADILLA-BANKS, E. 2007. Estradiol, 
Progesterone and Genistein Inhibit Oocyte Nest Breakdown and Primordial Follicle 
Assembly in the Neonatal Mouse in vitro and in vivo. Endocrinology, 148, 3580-
3590. 
CHILDS, A. J., KINNELL, H. L. & ANDERSON, R. A. 2012. LIN28 is selectively expressed by 
primordial and pre-meiotic germ cells in the human fetal ovary. Stem Cells and 
Development, 21, 2343-2349. 
CHILDS, A. J., KINNELL, H. L., COLLINS, C. S., HOGG, K., ROESMARY, A. L., BAYNE, S., GREEN, 
J., MCNEILLY, A. S. & ANDERSON, R. 2010. BMP Signaling in the Human Fetal Ovary 
is Developmentally Regulated and Promotes Primordial Germ Cell Apoptosis. Stem 
Cells, 28, 1368-78. 
CHOO, Y. C., CHAN, S. Y., WONG, L. C. & MA, H. K. 1985. Ovarian dysfunction in patients 
with gestational trophoblastic neoplasia treated with short intensive courses of 
etoposide (VP-16-213). Cancer, 55, 2348-52. 
CIMAFRANCA, M. A., DAVILA, J., EKMAN, G. C., ANDREWS, R. N., NEESE, S. L., PERETZ, J., 
WOODLING, K. A., HELFERICH, W. G., SARKAR, J., FLAWS, J. A., SCHANTZ, S. L., 
DOERGE, D. R. & COOKE, P. S. 2010. Acute and Chronic Effects of oral Genistein 
Administration in Neonatal Mice. Biology of Reproduction, 83, 114-121. 
CORTVRINDT, R. & SMITZ, J. 2002. Follicle culture in reproductive toxicology: a tool for in 
vivo testing of ovarian function? Human Reproduction Update, 8, 243-254. 
CRAIG, J., ORISAKA, M., WANG, H., ORISAKA, S., THOMPSON, W., ZHU, C., KOTSUJI, F. & 
TSANG, B. K. 2007. Gonadotropin and intra-ovarian signals regulating follicle 
development and atresia: the delicate balance between life and death. Frontiers in 
Biosciences, 12, 3628-39. 
CRAIG, Z. R., LESLIE, T. C., HATFIELD, K. P., GUPTA, R. K. & FLAWS, J. A. 2010. Mono-hydroxy 
methoxychlor alters the levels of key sex steroids and steroidogenic enzymes in 
cultured mouse antral follicles. Toxicology and Applied Pharmacology, 249, 107-
113. 
CRISPONI, L., DEIANA, M., LOI, A., CHIAPPE, F., UDA, M., AMATI, P., BISCEGLIA, L., ZELANTE, 
L., NAGARAJA, R., PORCU, S., RISTALDI, M. S., MARZELLA, R., ROCCHI, M., 
NICOLINO, M., LIENHARDT-ROUSSIE, A., NIVELON, A., VERLOES, A., SCHLESSINGER, 
D., GASPARINI, P., BONNEAU, D., CAO, A. & PILIA, G. 2001. The putative forkhead 
transcription factor FOXL2 is mutated in blepharaphimosis/ptosis/epicanthus 
inversus syndrome. Nature Genetics, 27, 159-166. 
DABOUSSI, F., DUMAY, A., DELACÔTE, F. & LOPEZ, B. S. 2002. DNA double-strand break 
repair signalling: The case of RAD51 post-translational regulation. Cellular 
Signalling, 14, 969-975. 
DAMELIN, M. & BESTOR, B. H. 2007. The decatenation checkpoint. British Journal of Cancer, 
96, 201-205. 
DAVILA, J. C., RODRIGUEZ, R. J., MELCHERT, R. B. & ACOSTA, D. 1998. Predictive value of in 
vitro model systems in toxicology. Annual Review of Pharmacology and Toxicology, 
38, 63-96. 
DE BAERE, E., BEYSEN, D., OLEY, C., LORENZ, B., COCQUET, J., DE SUTTER, P., DEVRIENDT, K., 
DIXON, M., FELLOUS, M., FRYNS, J.-P., GARZA, A., JONSRUD, C., KOIVISTO, P. A., 
KRAUSE, A., LEROY, B. P., MEIRE, F., PLOMP, A., VAN MALDERGEM, L., DE PAEPE, A., 
VEITIA, R. & MESSIAEN, L. 2003. FOXL2 and BPES: Mutational Hotspots, Phenotypic 
225 
 
Variability, and Revision of the Genotype-Phenotype Correlation. The American 
Journal of Human Genetics, 72, 478-487. 
DE CUEVAS, M., LILLY, M. A. & SPRADLING, A. C. 1997. Germline cyst formation in 
drosophila. Annual Review of Genetics, 21, 405-428. 
DE FELICI, M. 2000. Regulation of primordial germ cell development in the mouse. The 
International Journal of Developmental Biology, 44, 575-80. 
DE FELICI, M., DOLCI, S. & SIRACUSA, G. 1989. Fetal germ cells establish cell coupling with 
follicle cells in vitro. Cell Differentiation and Development, 28, 65-9. 
DE FELICI, M., LOBASCIO, A. M. & KLINGER, F. G. 2008. Cell death in fetal oocytes: many 
players for multiple pathways. Autophagy, 4, 240-2. 
DE VOS, A. & VAN STEIRTEGHEM, A. 2000. Zona hardening, zona drilling and assisted 
hatching: New achievements in assisted reproduction. Cells Tissues Organs, 166, 
220-227. 
DE VOS, M., DEVROEY, P. & FAUSER, B. C. J. M. 2010. Primary ovarian insufficiency. The 
Lancet, 376, 911-921. 
DESMEULES, P. & DEVINE, P. J. 2006. Characterization of a rat in vitro ovarian culture 
system to study the ovarian toxicant 4-vinycyclohexene diepoxide. . Toxicology and 
Applied Pharmacology, 184, 107-15. 
DEVINE, J. P., SIPES, G., SKINNER, M. K. & HOYER, P. B. 2002a. Characterization of a rat in 
vitro ovarian culture system to study to ovarian toxicant 4-vinylcyclohexene 
diepoxide. Toxicology and Applied Pharmacology, 184, 107-115. 
DEVINE, J. P., SIPES, I. G. & HOYER, P. B. 2004. Initiation of delayed ovotoxicity by in vitro 
and in vivo exposures of rat ovaries to 4-vinylcyclohexene diepoxide. . Reproductive 
Toxicology, 19, 71-77. 
DEVINE, P. J., RAJAPAKSA, K. S. & HOYER, P. B. 2002b. In vitro ovarian tissue and organ 
culture: a review. Front. Biosci. , 1, 1979-89. 
DOERGE, D. R., TWADDLE, N. C., VANLANDINGHAM, M. & FISHER, J. W. 2011. 
Pharmacokinetics of Bisphenol A in neonatal and adult CD-1 mice: Inter-species 
comparisons with Sprague-Dawley rats and rhesus monkeys. Toxicology Letters, 
207, 298-305. 
DOERGE, D. R., VANLANDINGHAM, M., TWADDLE, N. C. & DELCLOS, K. B. 2010. Lactational 
transfer of bisphenol A in Sprague–Dawley rats. Toxicology Letters, 199, 372-376. 
DONAHOE, P. K., ITO, Y. & HENDREN, H. 1977. A graded organ culture assay for the 
detection of mullerian inhibiting substance. Journal of Surgical Research, 23, 141-8. 
DONG, H. S., LI, L., SONG, Z. H., TANG, J., XU, B., ZHAI, X. W., SUN, L. L., ZHANG, P., LI, Z. B., 
PAN, Q. J., SHI, Q. H. & SHEN, W. 2009. Premeiotic fetal murine germ cells cultured 
in vitro form typical oocyte-like cells but do not progress through meiosis. 
Theriogenology, 72, 219-231. 
DONG, J. W., ALBERTINI, D. F., NISHIM, KUMAR, T. R., LU, N. F. & MATZUK, M. M. 1996. 
Growth differentiation factor-9 is required during early ovarian folliculogenesis. 
Nature, 383, 531-35. 
DUNBRACK, R. L. J., GERLOFF, D. L., BOWER, M., CHEN, C., LICHTARGE, O. & COHEN, F. E. 
1997. Meeting review: the second meeting on the critical assessment of techniques 
for protein structure prediction (CASP2). Asilomar, California. , R27-42. 
DURLINGER, A. L. L., GRUIJTERS, M. J. H., KRAMER, P., KARELS, B., INGRAHAM, H. A., 
NACHTIGAL, M. W., UILENBROEK, J. T. J., GROOTEGOED, J. A. & THEMMEN, A. P. N. 
2002. Anti-Mullerian hormone inhibits initiation of primordial follicle growth in the 
mouse ovary. Endocrinology, 143, 1076-84. 
DURLINGER, A. L. L., KRAMER, P., KARELS, B., DE JONG, F. H., UILENBROEK, J. T. J., 
GROOTEGOED, J. A. & THEMMEN, A. P. N. 1999. Control of primordial follicle 
226 
 
recruitment by anti-Mullerian hormone in the mouse ovary. Endocrinology, 140, 
5789-96. 
EDINGER, A. L. & THOMPSON, C. B. 2004. Death by design: apoptosis, necrosis and 
autophagy. Current Opinion in Cell Biology, 16, 663-9. 
EICHENLAUB-RITTER, U. 1996. Parental age-related aneuploidy in human germ cells and 
offspring: a story of past and present. . Environmental and Molecular Mutagenesis, 
28, 211-236. 
EICHENLAUB-RITTER, U. 1998. Genetics of oocyte ageing. Maturitas, 30. 
EICHENLAUB-RITTER, U., VOGT, E., CUKURCAM, S., SUN, F., PACHHIEROTTI, F. & PARRY, J. 
2008. Exposure of mouse oocytes to bisphenol A causes meiotic arrest but not 
aneuploidy. . Mutation Research, 12, 82-92. 
ELKIN, N. D., PINER, J. A. & SHARPE, R. M. 2010. Toxicant-induced leakage of germ cell 
specific proteins from seminiferous tubules in the rat: relationship to blood-testis 
barrier integrity and prospects for biomonitoring. Toxicological Sciences, 117, 439-
48. 
ELVIN, J., YAN, C., WANG, P., NISHIMORI, K. & MATZUK, M. M. 1999. Molecular 
characterization of the follicle defects in the growth differentiation factor 9 
deficient ovary. . Molecular Endocrinology, 13, 1018-34. 
EPPIG, J. J. 1979. A comparison between oocyte growth in coculture with granulosa cells 
and oocytes with granulosa cell-oocyte junctional contact maintained in vitro. J Exp 
Zool, 209, 345-53. 
EPPIG, J. J. 2001. Oocyte control of ovarian follicular development and function in 
mammals. Reproduction, 122, 829-38. 
EPPIG, J. J. & O'BRIEN, M. J. 1996. Development in vitro of mouse oocytes from primordial 
follicles. . Biology of Reproduction, 54, 197-207. 
EPPIG, J. J. & SCHROEDER, A. C. 1989. Capacity of mouse oocytes from preantral follicles to 
undergo embryogenesis and development to live young after growth, maturation 
and fertilization in vitro. . Biology of Reproduction, 41, 268-276. 
ESPEY, L. L. 1980. Ovulation as an inflammatory reaction: a hypothesis. Biology of 
Reproduction, 22, 73-106. 
FAMILIARI, G., CAGGIATI, A., NOTTOLA, S. A., ERMINI, M., DI BENEDETTO, M. R. & MOTTA, 
P. M. 1993. Ultrastructure of human ovarian primordial follicles after combination 
chemotherapy for Hdogkin's disease. Human Reproduction, 8, 2080-7. 
FARHI, J., FISCH, B., GAROR, R., PELED, Y., PINKAS, H. & ABIR, R. 2011. Neurotrophin 4 
enhances in vitro follicular assembly in human fetal ovaries. Fertility and Sterility, 
95, 1267-71. 
FARINI, D., LA SALA, G., TEDESCO, M. & DE FELICI, M. 2007. Chemoattractant action and 
molecular signaling pathways of Kit ligand on mouse primordial germ cells. 
Developmental Biology, 306, 572-583. 
FISHER, B., SHERMAN, B., ROCKETTE, H., REDMOND, C., MARGOLESE, R. & FISHER, E. R. 
1979. 1-phenylalanine mustard (L-PAM) in the management of premenopausal 
patients with primary breast cancer: lack of association of disease free survival with 
depression of ovarian function. National Surgical Adjuvant Project for Breast and 
Bowel Cancers. Cancer  44, 847-57. 
FISHER, J. W., TWADDLE, N. C., VANLANDINGHAM, M. & DOERGE, D. R. 2011. 
Pharmacokinetic modeling: Prediction and evaluation of route dependent 
dosimetry of bisphenol A in monkeys with extrapolation to humans. Toxicology and 
Applied Pharmacology, 257, 122-136. 
FORTUNE, J. E. 1994. Ovarian follicular growth and development in mammals. Biology of 
Reproduction, 50, 225-32. 
227 
 
FORTUNE, J. M. & OSHEROFF, N. 2000. Topoisomerase II as a target for anticancer drugs: 
when enzymes stop being nice. Progress in Nucleic Acid Research and Molecular 
Biology, 64, 221-53. 
FOWLER, P. A., DORA, N. J., MCFERRAN, H., AMEZAGA, M. R., MILLER, D. W., LEA, R. G., 
CASH, P., MCNEILLY, A. S., EVANS, N., COTINOT, C., SHARPE, R. M. & RHIND, S. M. 
2008. In utero exposure to low doses of environmental pollutants disrupts fetal 
ovarian development in sheep. Molecular Human Reproduction, 14, 269-80. 
FRAGOULI, E., WELLS, D. & DELHANTY, J. D. A. 2011. Chromosome abnormalities in the 
human oocyte. . Cytogenetic and Genome Research, 133, 107-118. 
FULTON, N., MARTINS DA SILVA, S. J., BAYNE, R. A. L. & ANDERSON, R. A. 2005. Germ cell 
proliferation and apoptosis in the developing human ovary. . Journal of Clinical 
Endocrinology and Metabolism, 90, 4664-4670. 
GADELLE, D., GRAILLE, M. & FORTERRE, P. 2006. The HSP90 and DNA topoisomerase VI 
inhibitor radicicol also inhibits human type II DNA topoisomerase. . Biochemical 
Pharmacology, 72, 1207-16. 
GEOFFROY-SIRAUDIN, C., PERRARD, M.-H., GHALAMOUN-SLAIMI, R., ALI, S., CHASPOUL, F., 
LANTEAUME, A., ACHARD, V., GALLICE, P., DURAND, P. & GUICHAOUA, M.-R. 2012. 
Ex-vivo assessment of chronic toxicity of low levels of cadmium on testicular 
meiotic cells. Toxicology and Applied Pharmacology, 262, 238-246. 
GEOFFROY-SIRAUDIN, C., PERRARD, M. H., CHASPOUL, F., LANTEAUME, A., GALLICE, P., 
DURAND, P. & GUICHAOUA, M. R. 2010. Validation of a Rat Seminiferous Tubule 
Culture Model as a Suitable System for Studying Toxicant Impact on Meiosis Effect 
of Hexavalent Chromium Toxicological Sciences, 116, 286-96. 
GILCHRIST, R. B., RITTER, L. J. & ARMSTRONG, D. T. 2004. Oocyte somatic cell interactions 
during follicle development in mammals. . Animal Reproduction 82, 431-446. 
GODIN, I., WYLIE, C. & HEASMAN, J. 1990. Genital ridges exert long-range effects on mouse 
primordial germ cell numbers and direction of migration in culture. Development, 
108, 357-63. 
GONDOS, B. 1987. Comparative studies of normal and neoplastic ovarian germ cells: I. 
Ultastructure of oogonia and intercellular bridges in the fetal ovary. International 
Journal of Gyneacological Pathology, 6, 114-123. 
GU, W., TEKUR, S., REINBOLD, R., EPPIG, J. J., CHOI, Y. C., ZHENG, J. Z., MURRAY, M. T. & 
HECHT, N. B. 1998. Mammalian male and female germ cells express a germ cell-
specific Y-Box protein, MSY2. Biology of Reproduction, 59, 1266-74. 
GUPTA, R. K., MILLER, K. P., BABUS, J. K. & FLAWS, J. A. 2006. Methoxychlor inhibits growth 
and induces atresia of antral follicles through an oxidative stress pathway. . 
Toxicological Sciences, 93, 382-9. 
GUPTA, R. S., BROMKE, A., BRYANT, D. W., GUPTA, R. K., SING, B. & MCCALLA, D. R. 1987. 
Etoposide (VP16) and teniposide (VM26): novel anticancer drugs, strongly 
mutagenic in mammalian but not prokaryotic test systems. Mutagenesis, 2, 179-86. 
HAJKOVA, P., ANCELIN, K., WALDMANN, T., LACOSTE, N., LANGE, U. C., CESARI, F., LEE, C., 
ALMOUZNI, G., SCHNEIDER, R. & SURANI, M. A. 2008. Chromatin dynamics during 
epigenetic reprogramming in the mouse germ line. Nature, 452, 877-881. 
HAJKOVA, P., ERHARDT, S., LANE, N., HAAF, T., EL-MAARRI, O., REIK, W., WALTER, J. & 
SURANI, M. A. 2002. Epigenetic reprogramming in mouse primordial germ cells. 
Mechanisms of Development, 117, 15-23. 
HAN, J. Y., NAVA-OCAMPO, A. A., KIM, T. J., SHIM, J. Y. & PARK, C. T. 2005. Pregnancy 
outcome after prenatal exposure to bleomycin, etoposide and cisplatin for 




HANDE, K. R. 1998. Etoposide: Four Decades of Development of a topoisomerase II 
inhibitor. European Journal of Cancer, 34, 1514-1521. 
HANDE, K. R., WEDLUND, P. J., NOONE, R. M., WILKINSON, G. R., GRECO, F. A. & WOLFF, S. 
N. 1984. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to 
cancer patients. Cancer Research, 44, 379-82. 
HARTSHORNE, G. M., BARLOW, A. L., CHILD, T. J., BARLOW, D. H. & HULTEN, M. A. 1999. 
Immunocytogenetic detection of normal and abnormal oocytes in human fetal 
ovarian tissue in culture. Human Reproduction, 14, 172-182. 
HARTSHORNE, G. M., LYRAKOU, S., HAMODA, H., OLOTO, E. & GHAFARI, F. 2009. Oogenesis 
and cell death in human prenatal ovaries: what are the criteria for oocyte 
selection? Molecular Human Reproduction, 15, 805-819. 
HAYASHI, M., MCGEE, E. A., MIN, G., KLEIN, C., ROSE, U. M., VAN DUIN, M. & HSUEH, A. J. 
1999. Recombinant growth differentiation factor-9 (GDF9) enhances growth and 
differentiation of cultured early ovarian follicles. Endocrinology, 140, 1236-44. 
HECK, M. M. S., HITTELMAN, A. N. & EAMSHAW, W. C. 1988. Differential expression of DNA 
topoisomerase I and II during the eukaryotic cell cycle. Proceedings of the National 
Academy of Sciences (USA), 85, 1086-90. 
HENDERSON, S. A. & EDWARDS, R. G. 1968. Chiasma frequency and maternal age in 
mammals. Nature, 218, 22-8. 
HENGSTLER, J. G., HEIMERDINGER, C. K., SCHIFFER, I. B., GEBHARD, S., SAGEMULLER, J., 
TANNER, B., HERMANN, M. B. & OESCH, F. 2002. Dietary topoisomerase II poisons: 
Contribution of soy products to infant leukemia? EXCLI journal, 1, 8-14. 
HENNET, M. L. & COMBELLES, C. M. 2012. The antral follicle: a microenvironment for 
oocyte differentiation. The International Journal of Developmental Biology, 56, 819-
831. 
HERREROS, M. A., GONZALEZ-BULNES, A., INIGO-NUNEZ, S., LETELIER, C., CONTRERAS-
SOLIS, I., ROS-RODRIGUEZ, J. M. & ENCINAS, T. 2010. Pregnancy-associated changes 
in plasma concentration of the endocrine disruptor di(2-ethylhexyl) phthalate in a 
sheep model Theriogenology, 73, 141-6. 
HIRAO, Y., NAGAI, T., KUBO, M., MIYANO, T., MIYAKE, M. & KATO, S. 1994. In vitro growth 
and maturation of pig oocytes. Journal of Reproduction and Fertility, 100, 333-339. 
HIRSHFIELD, A. N. 1991. Development of follicles in the mammalian ovary. International 
Review of Cytology, 124, 43-101. 
HOYER, P. B. (ed.) 2010. Ovarian Toxicology, Second Edition: CRC Press. Taylor & Francis 
Group. 
HU, C. L., COWAN, R. G., HARMAN, R. M., PORTER, D. A. & QUIRK, S. M. 2001. Apoptosis of 
bovine granulosa cells after serum withdrawal is mediated by Fas antigen (CD95) 
and Fas ligand. . Biology of Reproduction, 64, 518-526. 
HU, Y., SUN, J., WANG, J., WANG, L., BAI, Y., YU, M., LIAN, Z., ZHANG, S. & HUA, J. 2012. 
Characterization of female germ-like cells derived from mouse embryonic stem 
cells through expression of GFP under the control of Figla promoter. Journal of 
Cellular Biochemistry, 113, 1111-1121. 
HUNT, P. A., KOEHLER, K. E., SUSIARJO, M., HODGES, C. A., ILAGAN, A. & VOIGT, R. C. 2003. 
Bisphenol A exposure causes meiotic aneuploidy in the female mouse. Current 
Biology, 13. 
HUNT, P. A., LAWSON, C., GIESKE, M., MURDOCH, B., SMITH, H., MARRE, A., HASSOLT, T. & 
VANDEVOORT, C. A. 2012. Bisphenol A alters early oogenesis and follicle formation 
in the fetal ovary of the rhesus monkey. . Proceedings of the National Academy of 
Sciences, 109, 17525-17530. 
229 
 
HUSSEIN, M. R. 2005. Apoptosis in the ovary: molecular mechanisms. Human Reproduction 
Update, 11, 162-178. 
ICH 1993. Detection of Toxicity to Reproduction for Medicinal Products and Toxicity to Male 
Fertility S5 (R2). ICH Harmonised Tripartite Guideline. 
IGAWA, Y., KEATING, A. F., RAJAPAKSA, K. S., SIPES, I. G. & HOYER, P. B. 2009. Evaluation of 
ovotoxicity induced by 7, 12-dimethylbenz[a]anthracene and its 3,4-diol metabolite 
utilizing a rat in vitro ovarian culture system. Toxicology and Applied Pharmacology, 
234, 361-369. 
IGUCHI, T., FUKEZAWA, Y., UESUGI, Y. & TAKSUGI, N. 1990. Polyovular follicles in mouse 
ovaries exposed neonatally to diethylstilbestrol in vivo and in vitro. Biology of 
Reproduction, 43, 478-484. 
IGUCHI, T., KAMIYA, K., UESUGI, Y., SAYAMA, K. & TAKASUGI, N. 1991. In vitro fertilization 
of oocytes from polyovular follicles in mouse ovaries exposed neonatally to 
diethylstilbestrol. In vivo, 5, 359-363. 
INADA, H., CHIHARA, K., YAMASHITA, A., MIYAWAKI, I., FUKUDA, C., TATEISHI, Y., 
KUNIMATSU, T., KIMURA, J., FUNABASHI, H. & MIYANO, T. 2012. Evaluation of 
ovarian toxicity of mono-(2-ethylhexyl) phthalate (MEHP) using cultured rat ovarian 
follicles. . Journal of Toxicological Sciences, 37, 483-490. 
JACKSON, M. R. 1998. Priorities in the development of alternative methodologies in the 
pharmaceutical industry. . Archives of Toxicology, 20 (suppl), 61-70. 
JEFFERSON, E., PADILLA-BANKS, E. & NEWBOLD, R. 2007. Disruption of the female 
reproductive system by the phytoestrogen genistein. . Reproductive Toxicology, 23. 
JENSEN, J. R., MORBECK, D. E. & CODDINGTON, C. C. 2011. Fertility Preservation. May Clinic 
Proceedings, 86, 45-49. 
JIN, S. Y., LEI, L., SHIKANOV, A., SHEA, L. D. & WOODRUFF, K. 2010. A novel two-step 
strategy for in vitro culture of early stage ovarian follicles in the mouse. . Fertility 
and Sterility, 93, 2633-2639. 
JOHNSON, J., CANNING, J., KANEKO, T., PRU, J. K. & TILLY, J. L. 2004. Germline stem cells 
and follicular renewal in the postnatal mammalian ovary. Nature, 428, 145-150. 
JOHNSON, M. D., PHUA, H. H., BENNETT, S. C., SPENCE, J. M. & FARR, C. J. 2009. Studying 
vertebrate topoisomerase 2 function using a conditional knockout system in DT40 
cells. Nucleic Acids Research, 37, e98. 
JOYCE, I. M., PENDOLA, F. L., WIGGLESWORTH, K. & EPPIG, J. J. 1999. Oocyte regulation of 
kit ligand expression in mouse ovarian follicles. Developmental Biology, 214, 342-
53. 
JOYCE, J. M., CLARK, A. T., PENOLA, F. L. & EPPIG, J. J. 2000. Comparison of GDF9 and oocyte 
regulation kit ligand expression in mouse ovarian follicles. Biology of Reproduction, 
63, 1699-1675. 
JURKOWSKA, R. Z. & JELTSCH, A. 2013. Genomic Imprinting—The Struggle of the Genders at 
the Molecular Level. Angewandte Chemie International Edition, 52, 13524-13536. 
KAIPA, A., HSU, S. Y. & HSUEH, A. J. 1997. Expression and function of a pro-apoptotic Bcl-2 
family member Bcl-XL/Bcl-2 associated death promoter (BAD) in rat ovary. 
Endocrinology, 138, 5497-5504. 
KALICH-PHILOSOPH, L., RONESS, H., CARMELY, A., FISHEL-BARTAL, M., LIGUMSKY, H., 
PAGLIN, S., WOLF, I., KANETY, H., SREDNI, B. & MEIROW, D. 2013. 
Cyclophosphamide triggers follicle activation and 'burnout'; AS101 Prevents Follicle 
Loss and Preserves Fertility. . Science Translational Medicine, 5, 185ra62. 
KALLIO, M. & LAHDETIE, J. 1996. Fragmentation of centromeric DNA and prevention of 
homologous chromosome separation in male meiosis in vivo by the topoisomerase 
II inhibitor etoposide. Mutagenesis, 11, 435-443. 
230 
 
KALLIO, M. & LÄHDETIE, J. 1997. Effects of the DNA topoisomerase II inhibitor merbarone in 
male mouse meiotic divisions in vivo: Cell cycle arrest and induction of aneuploidy. 
Environmental and Molecular Mutagenesis, 29, 16-27. 
KAMPRANIS, S. C., BATES, A. D. & MAXWELL, A. 1999. A model for the mechanism of strand 
passage by DNA gyrase. Proceedings of the National Academy of Sciences, 96, 8414-
8419. 
KARAVAN, J. R. & PEPLING, M. 2012. Effects of estrogenic compounds on neonatal oocyte 
development. Reproductive Toxicology, 34, 51-56. 
KIM, H., NAKAJIMA, T., HAYASHI, S., CHAMBON, P., WATANABE, H., IGUCHI, T. & SATO, T. 
2009. Effects of Diethylstilbestrol on programmed cell death and induction of 
polyovular follicles in neonatal mouse ovaries. Biology of Reproduction, 81, 1002-
1009. 
KIMURA, K., SAIJO, M., UI, M. & ENOMOTO, T. 1994. Growth state-and cell cycle-depenent 
luctuation in the expression of two forms of DNA topoisomerase II and possible 
specific modification of the higher molecular weight form in the M phase. Journal 
of Biological Chemistry, 269, 1173-6. 
KLINGER, H. & FELICI, M. 2002. In vitro development of growing oocytes from fetal mouse 
oocytes: stage-specific regulation by stem cell factor and granulosa cells. 
Developmental Biology, 244, 85-95. 
KLUETZ, P. G. & EDELMAN, M. J. 2008. Successful treatment of small cell lung cancer during 
pregnancy. Lung Cancer, 61, 129-30. 
KNIGHT, P. G. & GLISTER, C. 2006. TGF-beta superfamily members and ovarian follicle 
development. Reproduction, 2, 191-206. 
KURIYAMA, K., KITAMURA, T., YOKOI, R., HAYASHI, M., KOBAYASHI, K., KURODA, J. & TSUJI, 
H. 2005. Evaluation of Testicular Toxicity and Sperm Morphology in Rats Treated 
with Methyl Methanesulphonate (MMS). Journal of Reproduction and 
Development, 51, 657-67. 
KYPRIANOU, N., ENGLISH, H. F., DAVIDSON, N. E. & ISAACS, J. T. 1991. Programmed cell 
death during regression of the MCF-7 human breast cancer following estrogen 
ablation. Cancer Research, 51, 162-166. 
LEE, W. S., OTSUKA, F., MOORE, R. K. & SHIMASAKI, S. 2001. Effect of bone morphogenetic 
protein-7 on folliculogenesis and ovulation in the rat. Biology of Reproduction, 4, 
994-999. 
LI, Z., YU, C., WANG, Z. W., ZHANG, Y. L., LIU, X. M., ZHOU, D., SUN, Q. Y. & FAN, H. Y. 2013. 
DNA topoisomerase II is dispensable for oocyte meiotic resumption but is essential 
for meiotic chromosome condensation and separation in mice. Biology of 
Reproduction, 89, 118. 
LIN, Y., GILL, M. E., KOUBOVA, J. & PAGE, D. C. 2008. Germ cell-intrinsic and -extrinsic 
factors govern meiotic initiation in mouse embryos. Science, 322, 1685-7. 
LIU, C., DUAN, W., LI, R., XU, S., ZHANG, L., CHEN, C., HE, M., LU, Y., WU, H., PI, H., LUO, X., 
ZHANG, Y., ZHONG, M., YU, Z. & ZHOU, Z. 2013. Exposure to bisphenol A disrupts 
meiotic progression during spermatogenesis in adult rats through estrogen-like 
activity. Cell Death and Disease, 4, e676. 
LIU, C. F., BINGHAM, N., PARKER, K. & YAO, H. H. 2009a. Sex specific roles of beta-catenin in 
mouse gonadal development. . Human Molecular Genetics, 18, 405-417. 
LIU, H., LUO, L., QIAN, Y., FU, Y., SUI, X., GENG, Y., HUANG, D., GAO, S. & ZHANG, R. 2009b. 
Foxo3a is involved in the apoptosis of naked oocytes and oocytes of primordial 
follicles from neonatal rat ovaries. Biochemical and Biophysical Research 
Communications, 381, 722-727. 
231 
 
LOBASCIO, A. M., KLINGER, F. G., SCALDAFERRI, M. L., FARINI, D. & DE FELICI, M. 2007. 
Analysis of programmed cell death in mouse fetal oocytes. Reproduction, 134, 241-
52. 
LYU, Y. L. & WANG, J. C. 2003. Aberrant lamination in the cerebral cortex of mouse embryos 
lacking DNA topoisomerase IIβ. Proceedings of the National Academy of Sciences, 
100, 7123-7128. 
MACKIE, E. J., RADFORD, M. & SHALET, S. M. 1996. Gonadal function following 
chemotherapy for childhood Hodgkin's disease. Medical and Pediatric Oncology, 
27, 74-8. 
MAILHES, J. B. & MARCHETTI, F. 1994. Chemically-induced aneuploidy in mammalian 
oocytes. Mutation Research/Genetic Toxicology, 320, 87-111. 
MARCHETTI, F., PEARSON, F. S., BISHOP, J. B. & WYROBEK, A. J. 2006. Etoposide induces 
chromosomal abnormalities in mouse spermatocytes and stem cell spermatogonia. 
Human Reproduction, 21, 888-95. 
MARTINOVITCH, P. N. 1937. Development in vitro of the mammalian gonad. . Nature, 139-
413. 
MARTINOVITCH, P. N. 1938. The development in vitro of the mammalian gonad. Ovary and 
ovogenesis. . Proceedings of the Royal Society (Biology). , 125, 232-249. 
MATIKAINEN, T. M., MORIYAMA, T., MORITA, Y., PREREZ, G. I., KORSMEYER, S. J., SHERR, D. 
H. & TILLY, J. 2002. Ligand Activation of the Aromatic Hydrocarbon Receptor 
Transcription Factor Drives Bax-Dependent Apoptosis in Developing Fetal Ovarian 
Germ Cells. Endocrinology, 143, 615-620. 
MATTISON, D. R. & THORGEIRSSON, S. S. 1979. Ovarian aryl hydrocarbon hydroxylase 
activity and primordial oocyte toxicity of polycyclic aromatic hydrocarbons in mice. 
Cancer Research, 39, 3471-5. 
MCGEE, E. A. & HSUEH, A. J. 2000. Initial and cyclic recruitment of ovarian follicles. 
Endocrine Reviews, 21, 200-14. 
MCGRATH, S. A., ESQUELA, A. F. & LEE, S. J. 1995. Oocyte-specific expression of 
growth/differentiation factor-9. Molecular Endocrinology, 9, 131-136. 
MCLAREN, A. & BUEHR, M. 1990. Development of mouse germ cells in cultures of fetal 
gonads. Cell Differentiation and Development, 31, 185-95. 
MCLAUGHLIN, M. & TELFER, E. E. 2010. Oocyte development in bovine primordial follicles is 
promoted by activin and FSH within a two-step serum-free culture system. 
Reproduction, 139, 971-978. 
MCNATTY, K. P., SMITH, P., HUDSON, N. L., HEATH, D. A., TISDALL, D. J., WS, O. & BRAW-
TAL, R. 1995. Development of the sheep ovary during fetal and early neonatal life 
and the effect of fecundity genes. Journal of Reproduction and Fertility. 
Supplement., 49, 123-35. 
MEIROW, D., BIEDERMAN, H., ANDERSON, R. A. & WALLACE, W. H. 2010. Toxicity of 
chemotherapy and radiation on female reproduction. . Clinical Obstetrics and 
Gyneacology, 53, 727-739. 
MEIROW, D., LEWIS, H., NUGENT, D. & EPSTEIN, M. 1999. Subclinical depletion of 
primordial follicular reserve in mice treated with cyclophosphamide: clinical 
importance and proposed accurate investigative tool. Human Reproduction, 14, 
1903-7. 
MILLER, K. P., BORGEEST, C., GREENFELD, C., TOMIX, D. & FLAWS, J. A. 2004. In utero 
effects of chemicals on reproductive tissues in females. . Toxicology and Applied 
Pharmacology, 198, 111-131. 
232 
 
MILLER, K. P., GUPTA, R. K., GREENFELD, C., BABUS, J. K. & FLAWS, J. A. 2005. Methoxychlor 
directly affects ovarian antral follicle growth and atresia through Bcl-2 and Bax 
mediated pathways. . Toxicological Sciences, 88, 213-221. 
MITCHELL, P. A. & BURGHARDT, R. C. 1986. The ontogeny of nexuses (gap junctions) in the 
ovary of the fetal mosue. The Anatomical Record, 214, 283-8. 
MOCHIDA, N., AKATANI-HASEGAWA, A., SAKA, K., OGINO, M., HOSODA, Y., WADA, R., 
SAWAI, H. & SHIBAHARA, H. 2013. Live births from isolated primary/early 
secondary follicles following a multistep culture without organ culture in mice. . 
Reproduction, 146, 37-47. 
MONIRUZZAMAN, M. & MIYANO, T. 2010. Growth of primordial oocytes in neonatal and 
adult mammals. The Journal of Reproduction and Development, 56, 559-66. 
MONTECUCCO, A. & BIAMONTI, G. 2007. Cellular response to etoposide treatement. 
Cancer Letters, 252, 9-18. 
MORA, J. M., FENWICK, M. A., CASTLE, L., BAITHUN, M., RYDER, T. A., MARGARET, M., 
CARZANIGA, R., FRANKS, S. & HARDY, K. 2012. Characterization and Significance of 
Adhesion and Junction-Related Proteins in Mouse Ovarian Follicles. Biology of 
Reproduction, 86, 153, 1-14. 
MORGAN, S., ANDERSON, R. A., GGOURLEY, C., WALLACE, W. H. & SPEARS, N. 2012. How do 
chematherapeutic agents damage the ovary? Human Reproduction, 18, 525-535. 
MORGAN, S., LOPES, F., GOURLEY, C., ANDERSON, R. A. & SPEARS, N. 2013. Cisplatin and 
doxorubicin induce distinct mechanisms of ovarial follicle loss; imatinib provides 
selective protection only against cisplatin. . PloS One, 8, 43-48. 
MORITA, Y., MANGANARO, T. F., TAO, X. J., MARTIMBEAU, S., DONAHOE, P. K. & TILLY, J. 
1999. Requirement for Phosphatidylinositol-3′-Kinase in Cytokine-Mediated Germ 
Cell Survival during Fetal Oogenesis in the Mouse. Endocrinology, 140, 941-949. 
MORK, L., TANG, H., BATCHVAROV, I. & CAPEL, B. 2012. Mouse germ cell clusters form by 
aggregation as well as clonal divisions. Mechanisms of Development, 128, 591-596. 
MOTOHASHI, H., SANKAI, T., NARIAI, K., SATO, K. & KADA, H. 2009. Effects of in vitro culture 
of mouse fetal gonads on subsequent ovarian development in vivo and oocyte 
maturation in vitro. . Human Cell, 22, 43-48. 
MOTTA, P. M., MAKABE, S., NAGURO, T. & CORRER, S. 1994. Oocyte follicle cells association 
during development of human ovarian follicle. A study by high resolution scanning 
and transmission electron microscopy. Archives of Histology and Cytology, 57, 369-
94. 
MU, X., WEN, J., GUO, M., WANG, J., LI, G., WANG, Z., WANG, Y., TENG, Z., CUI, Y. & XIA, G. 
2012. Retinoic Acid Derived from the Fetal Ovary Initiates Meiosis in Mouse Germ 
Cells. Journal of Cellular Phyisology, 228, 627-639. 
MU, X., WEN, J., GUO, M., WANG, J., LI, G., WANG, Z., WANG, Y., TENG, Z., CUI, Y. & XIA, G. 
2013. Retinoic acid derived from the fetal ovary initiaties meiosis in mouse germ 
cells. Journal of Cellular Physiology, 228, 627-639. 
MUNN, S. & GOUMENOU, M. 2013. Key scientific issues relevant to the identification and 
characterisation of endocrine disrupting substances. JRC Scientific and policy 
reports. 
MURRAY, A., MOLINEK, M. D., BAKER, S. J., KOJIMA, F. N., SMITH, M. F., HILLIER, S. G. & 
SPEARS, N. 2001. Role of ascorbic acid in promoting follicle integrity and survival in 
intact mouse ovarian follicles in vitro. Reproduction, 121, 89-96. 
MYERS, M., MORGAN, F. H., LIEW, S. H., ZERAFA, N., GAMAGE, T. U., SARRAJ, M., COOK, M., 
KAPIC, I., SUTHERLAND, A., SCOTT, C. L., STRASSER, A., FINDLAY, J. K., KERR, J. B. & 
HUTT, K. J. 2014. PUMA regulates germ cell loss and primordial follicle endowment 
in mice. Reproduction, 148, 211-9. 
233 
 
MYLLYMAKI, S. H., T., VAINIO, M., TOPPARI, J. & PARANKO, J. 2005. In vitro effects of 
diethylstilbestrol, genistein, 4-tert-butylphenol and 4-tert-octylpyhenol on 
steroidogenic activity of isolated immature rat ovarian follicles. Toxicology and 
Applied Pharmacology, 204. 
NAGAO, T., YOSHIMURA, S., SAITO, Y., NAKAGOMI, M., USUMI, K. & ONO, H. 2001. 
Reproductive effects in male and female rats of neonatal exposure to genistein. . 
Reproductive Toxicology, 15, 399-411. 
NEWBOLD, R., HANSON, R. B., JEFFERSON, W. N., BULLOCK, B. C., HASEMAN, J. & 
MCLACHLAN, J. A. 2000. Proliferative lesions and reproductive tract tumors in male 
descendants of mice exposed developmentally to diethylstilbestrol. . 
Carcinogenesis, 21, 1355-1363. 
NILSSON, E. E., KEZELE, P. & SKINNER, M. K. 2002. Leukemia inhibitory factor (LIF) promotes 
the primordial to primary follicle transition in rat ovaries. Molecular and Cellular 
Endocrinology, 188, 65-73. 
NILSSON, E. E. & SKINNER, M. K. 2003. Bone morphogenetic protein-4 acts as an ovarian 
follicle survival factor and promotes primordial follicle development. Biology of 
Reproduction, 4, 1265-72. 
NILSSON, E. E. & SKINNER, M. K. 2004. Kit ligand and basic fibroblast growth factor 
interactions in the induction of ovarian primordial to primary follicle transition. 
Molecular and Cellular Endocrinology, 214, 19-25. 
NITISS, J. L. 2009. DNA topoisomerase II and its growing repertoire of biological functions. 
Nature Reviews Cancer, 9, 327-37. 
O'BRIEN, M. J., PENDOLA, F. L. & EPPIG, J. J. 2003. A revised protocol for in vitro 
development of mouse oocytes from primordial follicles dramatically improves 
their developmental competence. Biology of Reproduction, 1682-1686. 
OBATA, Y. M., KONO, T. & HATADA, I. 2002. Maturation of mouse fetal germ cells in vitro. 
Nature, 418, 497-498. 
OBLAK, M., KOTNIK, M. & SOLMAJER, T. 2007. Discovery and development of ATPase 
inhibitors of DNA gyrase as antibacterial agents. Current Medicinal Chemistry, 14, 
2033-47. 
OHINATA, Y., PAYER, B., O'CARROLL, D., ANCELIN, K., ONO, Y., SANO, M., BARTON, S. C., 
OBUKHANYCH, T., NUSSENZWEIG, M., TARAKHOVSKY, A., SAITOU, M. & SURANI, M. 
A. 2005. Blimp1 is a critical determinant of the germ cell lineage in mice. Nature, 
436, 207-213. 
OKHUBO, Y., SHIRAYOSHI, Y. & NAKATSUJI, N. 1996. Autonomous regulation of proliferation 
and growth arrest in mouse primordial germ cells studies by mixed and clonal 
cultures. Experimental Cell Research, 222, 291-7. 
OKTAY, K., BRIGGS, D. & GOSDEN, R. G. 1997. Ontogeny of follicle-stimulating hormone 
receptor gene expression in isolated human ovarian follicles. The Journal of Clinical 
Endocrinology and Metabolism, 11, 3748-3751. 
OKTEM, O. & OKTAY, K. 2007. Quantitative assessment of the impact of chemotherapy on 
ovarian follicle reserve and stromal function. Cancer, 110, 2222-9. 
OKTEM, O. & URMAN, B. 2010. Understanding follicle growth in vivo. Human Reproduction, 
25, 2944-2954. 
OLLINGER, R., REICHMANN, J. & ADAMS, I. R. 2010. Meiosis and retrotransposon silencing 
during germ cell development in mice. Differentiation, 19, 147-158. 
ORISAKA, M., TAJIMA, K., TSANG, B. K. & KOTSUJI, F. 2009. Oocyte-granulosa-theca cell 




OSTREA, E. M., MANTARING, J. B. & SILVESTRE, M. A. 2004. Drugs that affect the fetus and 
newborn infant via the placenta or breastmilk. Pediatric Clinics of North America, 
51, 539-79. 
OTSUKA, F., YAMAMOTO, S., ERICKSON, G. F. & SHIMASAKI, S. 2001. Bone morphogenetic 
protein-15 inhibits follicle-stimulating hormone (FSH) action by suppressing FSH 
receptor expression. Journal of Biological Chemistry, 276, 11387-92. 
OTSUKA, F., YAO, Z., LEE, T., YAMAMOTO, S., ERICKSON, G. F. & SHIMASAKI, S. 2000. Bone 
morphogenetic protein 15. Identification of target cells and biological functions. 
Journal of Biological Chemistry, 275, 523-39, 528. 
PAILHOUX, E., VIGIER, B., CHAIFFAUX, S., SERVEL, N., TAOURIT, S., FURET, J. P., FELLOUS, M., 
GROSCLAUDE, F., CRIBIU, E. P., COTINOT, C. & VAIMAN, D. 2001. A 11.7-kb deletion 
triggers intersexuality and polledness in goats. . Nature Genetics, 29, 453-458. 
PARK, O. K. & MAYO, K. E. 1991. Transient expression of progesterone receptor messenger 
RNA in ovarian granulosa cells after the preovulatory luteinizing hormone surge. 
Molecular Endocrinology, 5, 967-978. 
PARMA, P., RADI, O., VIDA, L., CHABOISSIER, M. C., DELLAMBRA, E., VALENTINI, S., GUERRA, 
L., SCHEDL, A. & CAMERINO, G. 2006. R-spondin1 is essential in sex determination, 
skin differentiation and malignancy. Nature Genetics, 38, 1304-1309. 
PARROTT, J. A. & SKINNER, M. K. 1999. Kit-Ligand/Stem Cell Factor Induces Primordial 
Follicle Development and Initiates Folliculogenesis. . Endocrinology, 140, 339-351. 
PEPLING, M. & SPRADLING, A. C. 1998. Female mouse germ cells form synchronously 
dividing cysts. Development, 125, 3323-3328. 
PEPLING, M. & SPRADLING, A. C. 2001. Mouse Ovarian Germ Cell Cysts Undergo 
Programmed Breakdown to Form Primordial Follicles. . Developmental Biology, 234, 
339-351. 
PEPLING, M., SUNDMAN, E. A., PATTERSON, N. L., GEPHARDT, G. W., MEDICO, J. L. & 
WILSON, K. I. 2010. Differences in oocyte development and estradiol sensitivity 
among mouse strains. Reproduction, 139, 349-57. 
PERILLO, B., SASSO, A., ABBONDANZA, C. & PALUMBO, G. 2000. 17beta-estradiol inhibits 
apoptosis in MCF-7 cells, indluding bcl-2 expression via two estrogen-responsive 
elements present in the coding sequence. Molecular and Cellular Biology, 20, 2890-
901. 
PESCE, M., FARRACE, M. G., PIACENTINI, M., DOLCI, S. & DE FELICI, M. 1993. Stem cell factor 
and Leukemia inhibitory factor promote primordial germ cell survival by 
suppressing programmed cell death (apoptosis). Development, 118, 1089-94. 
PETERS, H. 1969. Follicle growth in the immature mouse ovary. Acta Endocrinologica, 62, 
98-116. 
PETERS, H. 1970. Migration of gonocytes into the mammalian gonad and their 
differentiation. Philosophical Transactions of the Royal Society of London B, 259, 91-
101. 
PETERS, H. & CRONE, M. 1967. DNA synthesis of oocytes of mammals. Archives d'Anatomie 
Microscopique et de Morphologie Experimentale, 56, 160-70. 
PETRO, E. M. L., LEROY, J. L. M. R., VAN CRUCHTEN, S. J. M., COVACI, A., JORSSEN, E. P. A. & 
BOLS, P. E. J. 2012. Endocrine disruptors and female fertility: focus on (bovine) 
ovarian follicular physiology. . Theriogenology, 78, 1887-900. 
PICTON, H. M., DANFOUR, M. A., HARRIS, S. E., CHAMBERS, E. L. & HUNTRISS, J. 2003. 
Growth and maturation of oocytes in vitro. Reproduction Supplement, 61, 445-62. 
PLACHOT, M. 2001. Chromosomal abnormalities in oocytes. Molecular and Cellular 
Endocrinology, 183(suppl.1), s59-s63. 
235 
 
PRODROMOU, C., ROE, S. M., O'BRIEN, R., LADBURY, J. E., PIPER, P. W. & PEARL, L. H. 1997. 
Identification and Structural Characterization of the ATP/ADP-Binding Site in the 
Hsp90 Molecular Chaperone. Cell, 90, 65-75. 
PROPPER, C. R. 2005. The Study of Encirone-Disrupting Compounds: Past Approaches and 
New Directions. Intergative and Comparative Biology, 45, 194-200. 
QU, X., ZHOU, Z., SUN, Q., LUBY-PHELPS, K., CHENG, P., HOGAN, R. N., GILPIN, C. & LEVINE, 
B. 2007. Autophagy gene-dependent clearance of apoptotic cells during embryonic 
development. Cell  128, 931-946. 
RAHMAN, M. F., YANFUL, E. K. & JASIM, S. Y. 2009. Endocrine disrupting compounds (EDCs) 
and pharmaceuticals and personal care products (PPCPs) in the aquatic 
environment: implications for the drinking water industry and the global 
environmental health. Journal of Water and Health, 7, 224-243. 
RAJAH, R., GLASER, E. M. & HIRSHFIELD, A. N. 1992. The Changing Architecture of the 
Neonatal Rat Ovary During Histogenesis. Developmental Dynamics, 194, 177-192. 
RALPH, J. H., WILMUT, I. & TELFER, E. E. 1995. In vitro growth of bovine preantral follicles 
and the influence of FSH on follicular and oocyte diameters. . Journal of 
Reproduction and Fertility Abstract Series., 15, 6. 
REGAN-SHAW, S., NIHAL, M. & AHMAD, N. 2008. Dose translation from animal to human 
studies revisited. 22, 2. 
RHIND, S. M., EVANS, N. P., BELLINGHAM, M., SHARPE, R. M., COTINOT, C., MANDON-
PEPIN, B., LOUP, B., SINCLAIR, K. D., LEA, R. G., POCAR, P., FISCHER, B., VAN DER 
ZALM, E., HART, K., SCHMIDT, J.-S., AMEZAGA, M. R. & FOWLER, P. A. 2010. Effects 
of environmental pollutants on the reproduction and welfare of ruminants. animal, 
4, 1227-1239. 
RICHARDS, J. S. 1994. Hormonal control of gene expression in the ovary. Endocrine Reviews, 
15, 725-51. 
RICHARDS, J. S., RUSSELL, D. L., ROBKER, R. L., DAJEE, M. & ALLISTON, T. N. 1998. Molecular 
mechanisms of ovulation and luteinization. Molecular and Cellular Endocrinology, 
145, 47-54. 
RIVERA, O. E., VARAYOUD, J., RODRIGUEZ, H. A., MUNOZ-DE-TORO, M. & LUQUE, E. H. 
2011. Neonatal exposure to bisphenol A or diethylstilbestrol alters the ovarian 
follicular dynamics in the lamb. . Reproductive Toxicology, 32, 304-312. 
ROBKER, R. L. & RICHARDS, J. S. 1998a. Hormonal control of the cell cyle in ovarian cells: 
proliferation versus differentiation. Biology of Reproduction, 59, 476-82. 
ROBKER, R. L. & RICHARDS, J. S. 1998b. Hormone-Induced Proliferation and Differentiation 
of Granulosa Cells: A Coordinated Balance of the Cell Cycle Regulators Cyclin D2 and 
p27Kip1. Molecular Endocrinology, 12, 924-940. 
ROCA, J. 2009. Topoisomerase II: a fitted mechanism for the chromatin landscape. Nucleic 
Acids Research, 37, 721-30. 
ROCA, J., ISHIDA, R., BERGER, J. M., ANDOH, T. & WANG, J. C. 1994. Antitumor 
bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in 
the form of a closed protein clamp. Proceedings of the National Academy of 
Sciences, 91, 1781-1785. 
RODRIGUEZ, P., LIMBACK, D., MCGINNIS, L. K., PLANCHA, C. E. & ALBERTINI, D. F. 2009. 
Multiple mechanisms of germ cell loss in the perinatal mouse ovary. . Reproduction, 
137, 709-720. 
ROSS, W., ROWE, T., GLISSON, B., YALOWICH, J. & LIU, L. 1984. Role of topoisomerase II in 
mediating epidophyllotoxin-induced DNA cleavage. Cancer Research, 44, 5857-60. 
ROY, S. K. & TREACY, B. J. 1993. Isolation and long term culture of human pre-antral 
follicles. Fertility and Sterility, 59, 783-790. 
236 
 
RUSSELL, L. B., HUNSICKER, P. R., HACK, A. M. & ASHLEY, T. 2000. Effect of the 
topoisomerase-II inhibitor etoposide on meiotic recombination in male mice 
Mutation Research, 464, 201-12. 
RUSSELL, L. B., HUNSICKER, P. R., JOHNSON, D. K. & SHELBY, M. D. 1998. Unlike other 
chemicals, etoposide (a topoisomerase-II inhibitor) produces peak mutagenicity in 
primary spermatocytes of the mouse. Mutation Research/Fundamental and 
Molecular Mechanisms of Mutagenesis, 400, 279-286. 
SARRAJ, M. & DRUMMOND, A. E. 2012. Mammalian foetal ovarian development: 
consequences for health and disease. Reproduction, 143, 151-163. 
SAWADA, H. & SHIMOHAMA, S. 2000. Neuroprotective effects of estradiol in 
mesencephalic dopaminergic neurons. Neuroscience and biobehavioural reviews, 
24, 143-147. 
SCHINDLER, R., NILSSON, E. E. & SKINNER, M. K. 2010. Induction of ovarian primordial 
follicle assembly by connective tissue growth factor CTGF. PLoS One, 5, e12979. 
SHARPE, R. M. & IRVINE, D. 2004. How strong is the evidence of a link between 
environmental chemicals and adverse effects on human reproductive health? 
British Medical Journal, 328, 447-51. 
SHEN, W., ZHANG, D., QING, T., CHENG, J., BAI, Z., YUQIANG, S., DING, M. & DENG, H. 2006. 
Live offpsing produced by mouse oocyes derived from premeiotic fetal germ cells. 
Biology of Reproduction, 75, 615-623. 
SHIMASAKI, S., ZACHOW, R. J., LI, D., KIM, H., IEMURA, S.-I., UENO, N., SAMPATH, K., 
CHANG, R. J. & ERICKSON, G. F. 1999. A functional bone morphogenetic protein 
system in the ovary. Proceedings of the National Academy of Sciences, 96, 7282-
7287. 
SIEPERMANN, M., KOSCIELNIAK, E., DANTONELLO, T., KLEE, D., BOOS, J., KREFELD, B., 
BORKHARDT, A., HOEHN, T., ASEA, A. & WESSALOWSKI, R. 2012. Oral low-dose 
chemotherapy: successful treatment of an alveolar rhabdomyosarcoma during 
pregnancy. Pediatric Blood & Cancer, 58, 104-6. 
SMITH, P., WILHELM, D. & RODGERS, R. J. 2014. Development of the mammalian ovary. 
Journal of Endocrinology, 221, R145-64. 
SOLEIMANI, R., HEYTENS, E., DARZYNKIEWICZ, Z. & OKTAY, K. 2011. Mechanisms of 
chemotherapy induced human ovarian aging: double strand DNA breaks and 
microvascular compromise. . Aging, 3, 782-93. 
SONMEZER, M. & OKTAY, K. 2004. Fertility preservation in female patients. Human 
Reproduction Update, 10, 251-66. 
SPEAROW, J. L., DOEMENY, P., SERA, R., LEFFLER, R. & BARKLEY, M. 1999. Genetic variation 
in susceptibility to endocrine disruption by estrogen in mice. Science, 285, 1259. 
SPEAROW, J. L., O'HENLEY, P., DOEMENY, P., SERA, R., LEFFLER, R., SOFOS, T. & BARKLEY, M. 
2001. Genetic variation in physiological sensitivity to estrogen in mice. APMIS, 109, 
356-64. 
SPEARS, N., BOLAND, N. I., MURRAY, A. & GOSDEN, R. G. 1994. Mouse oocytes derived from 
in vitro grown primary ovarian follicles are fertile. . Human Reproduction, 9, 527-
532. 
SROMMENGER, B., BARTELS, M. D., KURT, K., LAYER, F., ROHDE, S. M., BOYE, K., WESTH, H., 
WITTE, W., DE LENCASTRE, H. & NUBEL, U. 2014. Evolution of methicillin-resistant 
staphylococcus aureus towards increasing resistance. Journal of Antimicrobial 
Chemotherapy, 69, 616-22. 
STEFANSDOTTIR, A., FOWLER, P. A., POWLES-GLOVER, N., ANDERSON, R. A. & SPEARS, N. 




SU, Y., WU, X., O'BRIEN, M. J., PENDOLA, F. L., DENEGRE, J. N., MATZUK, M. M. & EPPIG, J. J. 
2004. Synergistic roles of BMP15 and GDF0 in the development and function of the 
oocyte-cumulus cell complex in mice: genetic evidence for an oocyte-granulosa cell 
regulatory loop. . Developmental Biology, 276, 64-73. 
SUH, E.-K., YANG, A., KETTENBACH, A., BAMBERGER, C., MICHAELIS, A. H., ZHU, Z., ELVIN, J. 
A., BRONSON, R. T., CRUM, C. P. & MCKEON, F. 2006. p63 protects the female germ 
line during meiotic arrest. Nature, 444, 624-628. 
SUN, F., BETZENDAHL, I., SHEN, Y., CORTVRINDT, R., SMITZ, J. & EICHENLAUB-RITTER, U. 
2004. Pre-antral follicle culture as a novel in vitro assay in reproductive toxicology 
testing in mammalian oocytes. . Mutagenesis, 19, 13-25. 
SURANI, M. A., BARTON, S. C. & NORRIS, M. L. 1984. Development of reconstituted mouse 
eggs suggests imprinting of the genome during gametogenesis. Nature, 308, 548-
50. 
SUSIARJO, M., HASSOLD, T. J., FREEMAN, E. & HUNT, P. A. 2007. Bisphenol A exposure in 
utero disrupts early oogenesis in the mouse. PLoS Genetics, 3, e5. 
SUZUKI, A., SUGIHARA, A., UCHIDA, K., SATO, T., OHTA, Y. & KATSU, Y. 2002. Developmental 
effects of perinatal exposure to bisphenol A and diethylstilbestrol on reproductive 
organs in female mice. . Reproductive Toxicology, 16, 107-16. 
TAIPALE, M., JAROSZ, D. F. & LINDQUIST, S. 2010. HSP90 at the hub of protein homeostasis: 
emerging mechanistic insights. . Nature Reviews Molecular Cell Biology, 11, 515-28. 
TARSOUNAS, M., MORITA, T., PEARLMAN, R. E. & MOENS, P. B. 1999. RAD51 and DMC1 
form mixed complexes associated with mouse meiotic chromosome cores and 
synaptonemal complexes. . Journal of Cell Biology, 147, 207-20. 
TATENO, H. & KAMIGUCHI, Y. 2001a. Meiotic stage-dependent induction of chromosome 
aberrations in chinese hamster primary oocytes exposed to topoisomerase II 
inhibitor etoposide. Mutation Research, 476, 139-48. 
TATENO, H. & KAMIGUCHI, Y. 2001b. Meiotic stage-dependent induction of chromosome 
aberrations in Chinese hamster primary oocytes exposed to topoisomerase II 
inhibitor etoposide. Mutation Research/Fundamental and Molecular Mechanisms 
of Mutagenesis, 476, 139-148. 
TAUCHMANOVA, L., SELLERI, C., ROSA, G. D., PAGANOL, L., ORIO, F., LOMBARDI, G., 
ROTOLI, B. & COLAO, A. 2002. High prevalence of endocrine dysfunction in long-
term survivors after allogeneic bone marrow transplantation for hematologic 
diseases. Cancer, 95, 1076-84. 
TAVENDALE, S. J., MACKAY, S. & SMITH, R. A. 1992. Oocyte numbers are reduced in 
developing mouse ovaries cultured in testis-conditioned medium. Journal of 
Anatomy, 180, 289-96. 
TELFER, E. E., MCLAUGHLIN, M., DING, C. & THONG, K. J. 2008. A two-step serum-free 
culture system supports development of human oocytes from primordial follicles in 
the presence of activin. Human Reproduction, 23, 1151-8. 
THOMAS, F. H. & VANDERHYDEN, B. C. 2006. Oocyte-granulosa cell interactions during 
mouse follicular development: regulation of kit ligand expression and its role in 
oocyte growth. . Reproductive Biology and Endocrinology, 4, 19. 
THOMAS, J., WOODRUFF, K., TEI, L. & TINGEN, C. 2010. Strain differences in Follicle 
Development and Gene Expression in Mice. Northwestern Undergraduate Research 
Journal, 6, 11-15. 
TILLY, J. 2001. Commuting the death sentence: how oocytes strive to survive. Nature 
Reviews, Molecular Cell Biology. 
238 
 
TILLY, J. & TILLY, K. I. 1995. Inhibitors of oxidative stress mimic the ability of follicle-
stimulating hormone to suppress apoptosis in cultured rat ovarian follicles. 
Endocrinology, 136, 242-52. 
TILLY, J. L., TILLY, K. I., KENTON, M. L. & JOHNSON, A. L. 1995. Expression of members of the 
bcl-2 gene family in the immature rat ovary: equine chorionic gonadotropin-
mediated inhibition of granulosa cell apoptosis is associated with decreased bax 
and constitutive bcl-2 and bcl-x long messenger ribonucleic acid levels. . 
Endocrinology, 136, 232-241. 
TINGEN, C., KIM, A. & WOODRUFF, T. K. 2009. The primordial pool of follicles and nest 
breakdown in mammalian ovaries. Molecular Human Reproduction, 15, 795-803. 
TSE-DINH, Y. C. 2007. Exploring DNA topoisomerases as targets of novel therapeutic agents 
in the treatment of infectious diseases. Infectious Disorders - Drug Targets, 7, 3-9. 
UPADHYAY, S., LUCIANI, J. M. & ZAMBONI, L. 1979. The role of the mesonephros in the 
development of indifferent gonads and ovaries of the mouse. Annales de Biologie 
Animale, Biochimie, Biophysique, 19, 1179-1196. 
UPADHYAY, S., LUCIANI, J. M. & ZAMBONI, L. 1981. The role of the mesonephros in the 
development of the mouse testis and its excurrent pathways. Development and 
Function of Reproductive Organs. Excerpta Medica, Amsterdam. , 18-27. 
VAN NASSAUW, L., TAO, L. & HARRISON, F. 1999. Distribution of apoptosis-related proteins 
in the quail ovary during folliculogenesis: BCL-2, BAX and CPP32. . Acta 
Histochemica, 101, 103-112. 
VITT, U. A., MCGEE, E. A., HAYASHI, M. & HSUEH, A. J. 2000. In vivo treatment with GDF-9 
stimulates primordial to primary follicle progression and theca marker CYP17 in 
ovaries of immature rats. . Endocrinology, 10, 3814-3820. 
VOGT, E., KIRSCH-VOLDERS, M., PARRY, J. & EICHENLAUB-RITTER, U. 2008. Spindle 
formation chromosome segregation and the spindle checkpoint in mammalian 
oocytes and susceptibility to meiotic error. Mutation Research, 651, 14-29. 
WALKIN, L., HERRICK, S. E., SUMMERS, A., BRENCHLEY, P. E., HOFF, C. M., KORSTANJE, R. & 
MARGETTS, P. J. 2013. The role of mouse strain differences in the susceptibility to 
fibrosis: a systematic review. Fibrogenesis & Tissue Repair, 6, 18. 
WALLACE, W. H., SHALET, S. M., CROWNE, E. C., MORRIS-JONES, P. H., GATTAMANENI, H. R. 
& PRICE, D. A. 1989. Gonadal dysfunction due to cis-platinum. Medical and 
Pediatric Oncology, 17, 409-13. 
WAN, X., ZHU, Y., MA, X., ZHU, J., ZHENG, Y., HOU, J., WANG, F., LIU, Z. & ZHANG, T. 2010. 
Effect of DEHP and its metabolite MEHP on in vitro rat follicular development. . Wei 
Sheng Yan Jiu, 39, 268-270, 274. 
WANDINGER, S. K., RICHTER, K. & BUCHNER, J. 2008. The Hsp90 chaperone machinery. 
Journal of Biological Chemistry, 283, 18473-77. 
WANG, S., YANG, S., LAI, Z., DING, T., SHEN, W., SHI, L., JIANG, J., MA, L., TIAN, Y., DU, X., 
LUO, A. & WANG, S. 2013. Effects of culture and transplantation on follicle 
activation and early follicular growth in neonatal mouse ovaries. Cell and Tissue 
Research, 354, 609-621. 
WARTENBERG, H. 1981. Differentiation and development of the testes. Raven Press, New 
York., 39-79. 
WEN, J., ZHANG, H., LI, G., MAO, G., CHEN, X., WANG, J., GUO, M., MU, X., OUYANG, H., 
ZHANG, M. & XIA, G. 2009. PAR6, A Potential Marker for the Germ Cells Selected to 
Form Primordial Follicles in Mouse Ovary. PLoS One, 4, e7372. 
WHITE, Y. A., WOODS, D. C., TAKAI, Y., ISHIHARA, O., SEKI, H. & TILLY, J. 2012. Oocyte 
formation by mitotically active germ cells purified from ovaries of reproductive-age 
women. Nature Medicine, 18, 413-21. 
239 
 
WOESSNER, R. D., MATTERN, M. R., MIRABELLI, C. K., JOHNSON, R. K. & DRAKE, F. H. 1991. 
Proliferation and cell cycle dependent differences in expression of the 170 
kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell 
Growth & Differentiation, 2, 209-14. 
WOODRUFF, T. K. & WALKER, C. L. 2008. Fetal and early postnatal environmental exposures 
and reproductive health effects in the female. Fertility and Sterility 89, e47-e51. 
XU, J., OSUGA, Y., YANO, T., MORITA, Y., TANG, X., FUJIWARA, T., TAKAI, Y., MATSUMI, H., 
KOGA, K., TAKETANI, Y. & TSUTSUMI, O. 2002. Bisphenol A induces apoptosis and 
G2-M arrest of ovarian granulosa cells. . Biochemical and Biophysical Research 
Communications, 292, 456-62. 
XU, M., WEST-FARRELL, E., STOUFFER, R. L., SHEA, L. D., WOODRUFF, T. K. & ZELINSKI, M. B. 
2009. Encapsulated Three-Dimensional Culture Supports Development of 
Nonhuman Primate Secondary Follicles. Biology of Reproduction, 81, 587-594. 
XUYING, W., JIANGBO, Z., YUPING, Z., XILI, M. A., ZHEN, L., FEI, W., GUIFEN, X. & TIANBAO, 
Z. 2011. A novel method for toxicology: in vitro culture system of a rat preantral 
follicle. Toxicology and Industrial health, 27, 637-645. 
YANG, F., ECKARDT, S., LEU, N. A., MCLAUGHLIN, K. J. & WANG, P. J. 2008a. Mouse TEX15 is 
essential for DNA double-strand break repair and chromosomal synapsis during 
male meiosis. . Journal of Cell Biology, 180, 673-679. 
YANG, F., GELL, K., VAN DER HEIJDEN, G. W., ECKARDT, S., LEU, N. A., PAGE, D. C., 
BENAVENTE, R., HER, C., HOOG, C., MCLAUGHLIN, K. J. & WANG, P. J. 2008b. 
Meiotic failur in male mice lacking an X-linked factor. Genes and development, 22, 
682-91. 
YANG, X., LI, W., PRESCOTT, E. D., BURDEN, S. J. & WANG, J. C. 2000. DNA Topoisomerase 
IIβ and Neural Development. Science, 287, 131-134. 
YOUNG, J. C., MOAREFI, I. & HARTL, F. Y. 2001. Hsp90: a specialised but essential protein-
folding tool. Journal of Cell Biology, 154, 267-73. 
YU, M., WANG, J., LIU, W., QIN, J., ZHOU, Q., WANG, Y., HUANG, H., CHEN, W. & MA, C. 
2014. Effects of tamoxifen on the sex determination gene and the activation of sex 
reversal in the developing gonad of mice. Toxicology, 321, 89-95. 
YU, N. & ROY, S. K. 1999. Development of Primordial and Prenatal Follicles from 
Undifferentiated Somatic 
Cells and Oocytes in the Hamster Prenatal Ovary In Vitro: Effect of Insulin. Biology of 
Reproduction, 61, 1558-67. 
ZACHOS, N. C., BILLIAR, R. B., ALBRECHT, E. D. & PEPE, G. J. 2002. Developmental regulation 
of baboon fetal ovarian maturation by estrogen. Biology of Reproduction, 67, 1148-
1156. 
ZAMA, A. M. & UZUMCU, M. 2010. Epigenetic effects of endocrine-disrupting chemicals on 
female reproduction: An ovarian perspective. Frontiers in Neuroendocrinology, 31, 
420-439. 
ZHANG, Y. L., YU, C., JI, S. Y., LI, X. M., ZHANG, Y. P., ZHANG, D., ZHOU, D. & FAN, H. Y. 2013. 
TOP2β Is Essential for Ovarian Follicles That Are Hypersensitive to 
Chemotherapeutic Drugs. Molecular Endocrinology, 27, 1678-1691. 
ZHANG, Z., LIAN, G., ZHANG, X., ZHANG, G., CHAO, H., LI, L., SUN, X., MIN, L., PAN, Q., SHI, 
Q., SUN, Q., DE FELICI, M. & SHEN, W. 2012. Growth of Mouse Oocytes to Maturity 
from Premeiotic Germ Cells In Vitro. PLoS One, 7, e41771. 
ZHOU, W., LIU, J., LIAO, L. & HAN, S. 2008. Effects of bisphenol A on steroid hormone 
production in rat ovarian theca-interstitial and granulosa cells. . Molecular and 
Cellular Endocrinology, 283, 12-18. 
240 
 
ZICKLER, D. 2006. From early homologue recognition to synaptonemal complex formation. 
Chromosoma, 115, 158-174. 
ZOU, K., YUAN, Z., YANG, Z., LUO, H., SUN, K., ZHOU, L., XIANG, J., SHI, L., YU, Q., ZHANG, Y., 
HOU, R. & WU, J. 2009. Production of offspring from a germline stem cell line 








Appendix A. Publication 
260 
 










Group # Study design Animal # Dose of AZTC 
1 
Ovaries collected on day 15 pp 1,2,5,6 Control 
Ovaries collected at 13+ weeks 343,344, 346, 




Ovaries collected on day 15 pp 8,9,10 Low dose 





Ovaries collected on day 15 pp 14,16,17 High dose 





Ovaries collected at 12 dpc - Control 
Ovaries collected at 17 dpc - Control 
Ovaries collected at 21 dpc - Control 
Ovaries collected on day 0 pp - Control 
Ovaries collected on day 5 pp 22,23,28 Control 
5 
Ovaries collected at 12 dpc - High dose 
Ovaries collected at 17 dpc - High dose 
Ovaries collected at 21 dpc - High dose 
Ovaries collected on day 0 pp - High dose 





















































































































































































































































































































































































































































Appendix E. Effects of etoposide on the neonatal (P0) CD-1 












































































































































Appendix F. Effect of AZTC on newborn (P0) F1 ovaries in vitro.  
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